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Abstract

This work expounds on some of the current computational tools and programs available
and the best practices associated with their use. A high-level introduction, intended for both
novices and the semi-experienced, focusing on the more common programs used in scientific
literature is the scope of this topic. Both classical and quantum techniques are described.
Classical methodologies include Molecular Dynamics, Monte Carlo, energy minimization
methods, molecular docking, low-mode, and homology modeling. Quantum chemistry
techniques are also discussed encompassing Hartree-Fock, Post-Hartree-Fock theories, and
Density Functional Theory along with associated basis sets.
Along with established methodologies, novel theoretical methods are introduced for
furthering the application of computational modeling. Constituent partitioning consensus
docking makes use of disparate docking methodologies to elucidate physical characteristics of
protein binding sites. This opus also advances the function of virtual target screening,
implementing robust algorithmic treatment of the protocol and improving the accuracy and scope
of target identification and binding site description. The introduction focuses on theoretical
approaches while subsequent chapters encompass the execution of these techniques in practical
applications of drug discovery.

xii

1 Introduction
This chapter expounds on some of the current computational tools and programs
available and the best practices associated with their use. A high-level introduction focusing on
the more common programs used in scientific literature is the scope of this topic. Additionally,
the chapter concentrates on biochemistry and protein dynamics and does not include references
to solid state modeling.
Proteins might be best characterized on the molecular scale as incredible, awe-inspiring,
and deceptively simple wriggling balls of snot and frustration. Many rarely exist in
conformations that allow catalysis (1–6), yet all life depends on their function which, in turn,
depends almost entirely on a stochastic 3D morphology dictated purely by quantum effects
leading to minute energetic biases toward an overall statistically ephemeral structure. As such,
exploring the properties of these entities is an insane task.
Yet, in the face of such lunacy, we attempt the equally absurd approach of molecular
modeling that makes use of all theoretical methods and computational techniques to model or
mimic the behavior of these infinitely complex molecules. It studies molecular systems ranging
from small chemical systems to large biological molecules requiring the aid of computers to
process the vast quantities of data and intricate algorithms. While the assumption that our reality
can be readily explained by microscale deterministic events is a reasonable one, modeling these
events and extrapolating their outcomes to describe bulk properties and predict macroscale
quantities is an arduous undertaking with consistently meager results. From experience, much of
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the failings of computational models appears to be from thinking only one program or algorithm
is needed for any particular task at hand. Just as those large-scale properties we wish to elucidate
are not as conveniently simple as most might like, nor too is the modeling and practices needed
to surmount such Brobdingnagian tasks.

1.1 Preparation and Best Practices for Modeling
First and foremost, when developing a computational model, preparation is key.
Molecular modeling is highly dependent on experimental data for initial structure. Therefore,
proper identification of the specific protein and/or ligand is crucial before moving forward. As
always, this necessitates an extensive scientific literature search including the complete name
(along with all know aliases), sequence (full biological assembly and individual domains), and
origins of protein/ligand (species, tissue, cellular compartment, metabolic pathway), binding sites
(orthosteric, known allosteric, and any potential alternate sites). For ligands, chemical structure,
chirality, tautomerization, and protonation states of the ligand should be accounted for. The more
information, the better.

1.1.1 Protein Structure Selection
For protein structures, an exhaustive wwPDB (Worldwide Protein Data Bank (7), portal
sites through RCSB (8), ePDB, and jPDB) search for the specified protein under all known
aliases, all possible isozymes, and/or interspecies homologs is required. If no structure exists,
molecular modeling is severely limited (see section 1.3.8 Homology Modeling and Protein
Folding for more details). X-ray diffraction studies are preferable for a starting point due to finer
structural detail and better approximation of resolution. NMR (Nuclear Magnetic Resonance) is
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generally more useful as an addendum to X-ray diffraction by providing information about
protein loop and side chain motion (9). Additionally, NMR is currently the only way to study
intrinsically disordered proteins, which are estimated to comprise 40–50% of the human
proteome (10,11). Lately, cryo-electron microscopy (cryo-EM) has made significant
technological leaps and will likely replace X-ray crystallography as the standard for structure
determination in the near future. However, at the time of this publication, most cryo-EM
structures do not have comparable resolution to X-ray diffraction and are only amenable to
studies of mesoscopic scales. This technique is indispensable for understanding protein-protein
interactions and complexes, but currently not able to replace a fine-tuned crystallographic study
(12,13).

1.1.2 X-Ray Crystal Structure Resolution
Optimal crystallographic resolution of a structure for modeling purposes is less than 2Å.
For structural resolution between 2Å and 3Å, significant uncertainties exist in the crystal
structure and further computational refinement and control studies are necessary (outlined later
in this chapter). Without proper refinement and controls, substantial error will likely persist
throughout a modeling study because of possible inaccuracies in initial protein structure, such as
indeterminate protonation states and disordered loop conformations (14). Protonation states are
designated by inference any way since hydrogen atoms are not localized even at these
resolutions. For structural resolutions beyond approximately 3.5Å, errors in the crystal structure
tend to be too large for proper computational refinement. At this point, electron density is far too
poor for localizing even internal residues leading to domain regions becoming unstable and any
information on loop structures is typically completely lost (15).
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1.1.3 Co-Factors, Ligand and Sequence Verification, and Biological Assembly
Many other factors aside from structural resolution must be examined before any
modeling or experimentation is performed, e.g. verification of sequence (including allotypes,
isozymes and possible mutants) and ligand binding (holo and/or apo structures) of target protein.
If a PDB entry is missing less than 2-3 residues owing to a lack of structural resolution or
intended methodological exclusion, homology modeling software packages, such as
Schrödinger's Prime (16) and YASARA (17,18) or the web-based SWISS-MODEL (19,20), can
be used to estimate possible initial configurations of known sequences. If any of the missing
residues comprise part of the active site or exceed 2-3 missing residues, quantum mechanical
modeling and refinement (Sections 1.3.4 Quantum Chemistry, 1.3.5 Quantum Mechanical
Molecular Modeling, and 1.3.8 Homology Modeling and Protein Folding) may be necessary.
Another common oversight is a failure to identify potential crystal artifacts that may unnaturally
influence the crystallographic structure. Crystal packing can cause unphysical dimerization or
induced folding not seen in nature. There may also exist possible dependencies on dimerization
for protein function. An extensive review of literature for understanding the biological
environment, pathways, and potential binding partners is vital to determine the biological
assembly of a target protein. Protein complexes can form alternate folding or binding pockets
relevant for study, but their addition will obviously complicate any modeling. Great care is
needed for optimization of computational costs versus model detail.
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1.1.4 Model Optimization
For computation, there is always a compromise between accuracy and speed/cost of
calculation. Minimizing the size and complexity of a system, using the fewest calculations
possible, and specializing a model to a specific task with the greatest number of assumptions, all
while maintaining a sufficient level of accuracy is a discussion of high priority. Three general
categories arise when discussing optimization. A simulation or model can be completed quickly,
cheaply (in terms of hardware or financial resources), or accurately. Realistically, prioritization
can only be done on two of three categories at best.
Speed is largely determined by size and complexity of a system and the dynamics to be
studied. Algorithm selection and level of applied theory is helpful here. For example, Molecular
Dynamics (MD) simulation is faster than quantum mechanical simulation. System simplification
or focusing on only the most pertinent kinetics can also reduce simulation time so long as other
assumptions are reasonably held. Cost is generally the simplest way to solve an optimization
problem. A bigger computer with better hardware is an effective solution for most research.
Faster algorithms can also be implemented, but many require significant manpower and costly
research to optimize and some software applications under a commercial license are simply more
costly than others. Accuracy is the most difficult of the three to address. This is where proper
statistical methodology can help optimize sample size or extrapolate a data set (see section 1.4.3
Best Practices in Statistics for details). When it comes to determination of physical quantities,
however, universal constraints and uncertainty limit precise determination of any physical
measurements. For thermodynamic quantities, such as binding affinity, the trade-off between
precision and dissipation is the thermodynamic uncertainty relation. This relation shows that a
more precise output requires a higher thermodynamic cost independent of the time used to
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produce the output (21). Therefore, no experiment can have a true free energy resolution of an
affinity lower than kBT. For structural determination, low electron density around hydrogen
atoms restrict hydrogen atom resolution as well as the need for extremely high energy X-rays to
reach resolutions lower than 1Å.
It should also be noted that crystal structures can be notoriously inaccurate as a result of
the extreme conditions necessary to crystallize a protein that are far from biologically relevant
(e.g. low temperatures, high/low pH, large salt concentrations, crystal artifacts caused by proteinprotein interactions of crystal mates, the fact that solid crystals do not exist in living cells, etc.)
(22). It is for these reasons that crystallography is also highly dependent on computational
modeling for verifying aspects of crystallographic data. System equilibration should always be
standard under MD simulation before further modeling (see section 1.3.3.3 Equilibration). This
mutual dependence on theory and experimentation requires close collaboration with both areas of
study.

1.1.5 Visual Interfaces and User Environments
Programs that are primarily for 3D viewing are considered visual interfaces and user
environment programs provide a platform for interfacing with other programs. These are not
considered molecular modeling software in and of themselves, simply a way to view or access
other modeling software output.
The molecular visualization system, PyMOL (23), is open-source software released under
the Python license. The program was initially developed by DeLano Scientific LLC, a private
software company dedicated to making accessible tools specifically for scientific and educational
uses, and is currently commercialized by Schrödinger, Inc. PyMOL can produce high-quality 3D
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images of small molecules and biological macromolecules and is able to solve Poisson–
Boltzmann equations for electrostatics visualization. However, the program is not intended for
molecular modeling.
VMD (Visual Molecular Dynamics) is another popular molecular modeling and
visualization computer program used primarily as an interface for many third-party, open source
molecular modeling applications (24). VMD was first developed as a tool to view and analyze
the results of molecular dynamics simulations. More recently, it now includes an extensive tool
set for working with more rigorous applications such as volumetric data, sequence data, and
arbitrary graphics objects. Development of several external plug-ins and an increasing set of
features and tools make it one of the most commonly used software packages in computational
chemistry, biology, and biochemistry.
In addition to PyMOL, Schrödinger, Inc. also develops another graphical user interface
called Maestro (25), but it is more akin to VMD as a single common user environment providing
a platform for fully-integrated molecular modeling, visualization, and analysis. Another similar
and popular proprietary software that serves as both a visualization program and platform for a
range of modeling and simulation applications is MOE (Molecular Operating Environment) (26).
Another common interface for computational chemistry is Avagadro (27), a molecular
builder and editor based on Open Babel. It is designed for cross-platform use in computational
chemistry, molecular modeling, bioinformatics, materials science, and related areas and utilizes a
plug-in architecture to extend its capabilities.

7

1.2 Selection of Molecular Mechanics Force Fields
The force terms and integrated classical constraints, such as bonding interactions, bond
angles, vibrational spring constants, dihedral angles, partial charges, etc., make up a force field
file for specific molecules. The force field files are built from a set of potential energy equations
and their derivatives combined with the parameters used to describe pairwise interactions
between unique particles or atoms. There are essentially three main types of force fields with
varying atomic resolution. All atom force fields are the most common, where each atom is
enumerated with a parameter set. United atom force fields provide parameters for all atoms
except non-polar hydrogens, which are folded into the parameter set for the larger bonded atom
creating a more course grained model. Lastly, there are fully course grained parameter sets where
several atoms are grouped together as an abstract representation of a single particle.
The parameters related to these force fields rely heavily on the accuracy and availability
of experimental data for individual molecules and bulk effects. Tuning parameters is usually
semi-empirical, application-specific, and is where differences between force fields are most
apparent. For example, OPLS was originally tuned to reproduce certain bulk properties of
liquids, whereas CHARMM was tuned mainly for macro-molecules, such as proteins and nucleic
acids. Therefore, it can be argued that certain force fields may be better or worse for specific
applications. OPLS might be more suited for liquid studies, CHARMM for proteins, and
AMBER for DNA simulations. However, even with these disparate approaches, no substantial
difference has been observed between the force fields like AMBER, CHARMM, OPLS,
GROMOS, etc., used in computational biophysics (28). The more immediate and substantial
sources of error come from model design, implementation, and data interpretation.
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1.2.1 Force Field Energy Components
The main components of a force field are bond distances and bond angles, described by
harmonic spring potentials due to near ideal stretching behavior and slight fluctuations around
equilibrium values observed at temperatures generally used for molecular simulations. These
parameters can be constrained to fixed values to save computational effort with some loss of
accuracy. A so-called improper dihedral term accounts for out of plane bending to help keep
certain atom groups, such as aromatic rings and amides, planar. The dihedral potential is
characterized by a cosine expansion whose amplitude describes the barrier height between the
low energy conformations. Long range interactions specifically enumerated in the force field file
are only counted for atoms three or more bonds apart, consisting of Coulomb and Lennard-Jones
two-body interaction terms. The Lennard-Jones potential is a combination of attractive van der
Waals forces and empirical repulsive forces due to Pauli repulsion.

General Classical MM Hamiltonian
ETotal =E Bond + E Angle + E Imp Dih + E Dihedral + ECoulomb + E VdW

(Eq. 1)

EBond =∑ K Bond ( r ij − r o )2

(Eq. 2)

E Angle = ∑ K θ ( θijk −θ o )2

(Eq. 3)

E Imp Dih =∑ K ζ ( ζ ijkl − ζ o )2

(Eq. 4)

Where,

ij

i< j

i< j< k

ijkl

ijk

ijkl
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N

E Dihedral =∑ K n cos (ω)n
n=0

1
≈∑ [ K 1(1+ cos(ω))+ K 2 (1−cos(2 ω))+ K 3 (1+cos (3 ω))+ K 4 ]
ijkl 2

ECoulomb =∑
i< j

EVdW =∑ 4 ϵ o
i<j

qiq j
4 π ϵo r ij

(Eq. 6)

[( ) ( ) ]
σ ij
r ij
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σ
− ij
r ij

(Eq. 5)
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(Eq. 7)

The OPLS potential function (and some formulations of AMBER) is given as the first
few terms of a Fourier series of the Ryckaert-Bellemans function. OPLS parameters were
originally the exact AMBER parameters for bonded interactions, but the two formulations have
slowly diverged over the years. OPLS was originally known as OPLSA (A meaning AMBER).
An alternate dihedral formulation is used for some force fields (CHARMM in particular) and is
ultimately equivalent but has the advantage of faster convergence.

E Dihedral=∑ K ijkl [ 1+ cos ( n ω − ωo ) ]
ijkl

(Eq. 8)

1.2.2 Generalized Force Fields
Generalized force fields are a combination of databases, tables, and programs to access
topology information and assign atom types, connectivity, and charges based on fragments for
automatically constructing force fields for any molecule. They are largely used for initially
generating files for further parameter refinement. However, more recent implementations have
10

had significant initial accuracy for generating molecules with well-studied atom types and
connectivity. The most commonly cited generalized force fields are the AMBER (29–31),
CHARMM (32,33), OLPS (34–36), and MMFF (37) formats. They each have multiple revised
versions continually updated as research advances and are optimized under different models with
various datasets and refinement procedures.
Selection of a force field file format is mostly dependent on the software being used for
modeling (See Table 1) and does not have an overall effect on the quality of a model, but a
generalized force field can influence accuracy due to what type of systems and conditions for
which a generalized force field has been optimized. Some examples are Gromos43A1, OPLSAA, and CHARMM27 being known to be in best accordance with NMR data concerning helical
structures while others tend to overpopulate the alpha-region (38). Each vary in the treatment of
solvent models, depending on which one they are optimized with. With respect to MD simulation
of biomolecules, many force fields have trouble undergoing transitions to non-native
conformational states beyond 100 ns simulation time (39). They also differ in ability to form
certain secondary structures, such as hairpins. CHARMM27 and OPLS-AA are particularly poor
at this (40). However, later implementations of OLPS, OPLS2005 and OPLS3, have made
significant strides in overcoming these issues, becoming one of the better generalized force fields
to date.
CHARMM has a large contributing user-base and many versions and variations of the
force field exist. The main generalized force fields are CHARMM22 and CHARMM27. For
protein simulation, they are equivalent, but for nucleic acids, CHARMM27 is optimal.
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AMBER force fields are very diverse and optimized for very specific simulations. As of
2018, ff14SB is the current iteration for protein, lipid14 is used for lipids, and ff99 for nucleic
acids.
The OPLS-AA, OPLS-2005, and the most recent OPLS3 are generalized force fields
optimized to fit the experimental properties of liquids, such as heat of vaporization and density,
in addition to fitting gas-phase torsional profiles. OPLS force fields were optimized with TIP3P
and TIP4P water models.
The Merck Molecular Force Field (MMFF), derived from computational simulation, is
not optimized for one use, such as simulating proteins or small molecules, but tries to perform
well for a wide range of calculations on small to medium-sized organic molecules. GROMOS is
a parameter set used in the MD software GROMACS and is a united atom force field initially
optimized with respect to the condensed phase properties of alkanes (41).

1.2.3 Customized Parameterization of Force Fields
Parameters for force fields are constructed in a semi-empirical manner, combining
experimental data and small molecule electronic structure calculations. Correcting values for
force field parameters with experimental data improves accuracy due to the inclusion of bulk
phase properties and phenomena that small-scale ab initio modeling methods cannot simulate.
Much of the parameterization is done with iterative quantum and classical simulations, using
experimental quantities for verification.
Lower complexity parameters with stiff degrees of freedom, like bond stretching and
angle bending, are the easiest to fit, often experimental vibrational spectra and structural data are
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sufficient, with some electronic structure calculations on smaller molecular fragments for
refinement.
Lennard-Jones parameterization is usually done by finding values that reproduce bulk
properties, such as density and enthalpies of phase change, in iterative simulations of small
molecules and molecular fragments. Initial parameters can be quickly tabulated from van der
Waals radii and energetics extracted from critical point data and experimental crystal packing.
Partial charges are then assigned based on ab initio calculations of the electron density
surrounding small molecular fragments using Mulliken populations (used by CHARMM) or
electrostatic potential derived point charges such as Restrained Electrostatic Potential Fit, RESP
(used by AMBER and OPLS). Additionally, if a molecule has several relevant conformers (such
as rotations around a torsional angle), or external polarization factors exist (like solvent or
protein interactions), separate electron densities need to be computed for each conformer. The
electron density can then be rendered into discrete atomic partial charges by various methods to
reproduce the electrostatic potential around the molecule.
FFinally, to account for any remaining energetic contributions needed for agreement with
electronic structure calculations not already captured by van der Waals and partial charge
interactions, torsional potentials, proper and improper, are used to adjust the energies of rotation
around bonds.

To generate these parameters, quantum simulations should be employed with perturbation
(MP2), restricted Hartree-Fock (RHF), or hybrid methods between Hartree-Fock and density
functional theory (DFT). Basis sets chosen for the geometry optimization should not be coarsegrained and are at least 6-31G, and often require going up to 6-311G**, and may include diffuse
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functions depending on the size and charge complexity of the molecule in question. Quantum
mechanical calculation is also required for experimental parameterization of small molecules to
verify accuracy of a force field. If a generalized force field is shown to be insufficient or
inaccurate, a new force field parameterization may have to be generated through extensive QM
simulation (Section 1.3.4 Quantum Chemistry). If a protein exhibits significant quantum
interactions (i.e. “behaves poorly” in a classical system), a new force field may have to be
generated as well.

Table 1. Software that implements particular force fields.
Force Field
Program

AMBER CHARMM

OPLS

OPLS2005

OPLS3

MMFF

AMBER

Yes

Yes

Yes

No

No

No

CHARMM

Yes

Yes

Yes

No

No

Yes

GROMACS

Yes

Yes

Yes

No

No

No

NAMD

Yes

Yes

Yes

No

No

No

Schrödinger

No

No

Yes

Yes

Yes

Yes

No

No

YASARA
Yes
No
No
No
Force fields are most recent implementations as of this publication.

1.2.4 More Complex Models
Metal coordination, ligand reactions, heme groups, and many other common interactions
are very difficult to account for in molecular modeling and are often neglected, resulting in
significant decrease in model accuracy. Attempts to overcome or simplify these issues have
resulted in more complex force fields with varying degrees of success.
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One significant problem with classical force fields is that they are not able to account for
induced polarization (rearrangement of charge distribution in a molecule) caused by adjacent
interacting molecules. Intra-molecular polarization (polarization of atoms in the same molecule
due to conformational rearrangements) should be largely accounted for through proper force
field parameterization. Many methods have been conceived for incorporating this effect into
classical force fields with two common approaches: perturbation of atomic partial charges or
creation of inducible dipoles on each atom. For each conformation of the molecule, the partial
charge or induced dipole on each atom must be solved iteratively. The iteration typically reaches
a self-consistent state where the electric field due to the charges or dipoles is consistent with the
induced response in the molecule (42). Unfortunately, this added iteration during each step of a
simulation greatly increases the computational cost when using polarizable force fields, making
them expensive to simulate and limiting their use. Despite this difficulty, with future increases in
computing power and the need for higher accuracy in simulations, polarizable force fields are
beginning to be explored further (43). The CHARMM-based Drude force field (44) and the
fragment-based molecular orbital method, Xpol (45), are some examples of current polarizable
force field implementations being researched.
Another severe issue with classical force fields is their inability to model chemical
reactions due to the dependence on having all bonds explicitly defined. Reactive force fields
attempt to replace explicit bonds in favor of bond orders, which can allow for continuous bond
formation and breaking. ReaxFF is a bond order-based force field developed at the California
Institute of Technology (46). ReaxFF attempts generalization but the more complex
parameterization often relegates it to limited context and specific simulations (47). It has been
parameterized and tested for many hydrocarbon reactions and high-energy materials, as well as
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some more specialized problem such as metal catalyzed nanotube formation and alkoxysilane
gelation, and oxygen interactions with non-idealized silica surfaces. ReaxFF relies on high
accuracy DFT based on Minnesota Functionals (48).
A number of other force fields have been developed to better capture specific behavior in
atomic systems. These methods all aim to improve agreement with quantum mechanical behavior
and hence increase quantitative accuracy, but are beyond the scope of this chapter.

1.3 Modeling Methods, Algorithms, and Techniques
Organization of the following techniques are based on a general first pass through
molecular modeling. It should be noted that research is rarely linear and often requires multiple
iterations to refine a model. As such, this section may refer ahead to other subsections or pass
over certain subjects to be elaborated on in more depth later.

1.3.1 Protein and Ligand Preparation
Artifacts, assumptions, and omissions from various structure determination methods are
ubiquitous and must be accounted for prior to simulation. Preparation of protein/ligand is
required for any program and each software application has its own proprietary method of
indexing molecules, chains, residues, and atoms. Some programs use model building scripts or
“wizards” to assist in these tasks like the Schrödinger program, Protein Prep Wizard. Some of the
more common concerns are side chain modifications, hydrogen treatment, and poor initial atom
placements. For X-ray structures, replacing the sulfur atom in methionine with selenium is a
regular practice to assist in structure elucidation. Selenomethionines do occur naturally, but
converting them back to methionine is needed if done artificially. Treatment of hydrogens is a
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particular difficulty in structure determination due to their small size, overwhelming abundance,
and rapid motion. Scripts for insertion, deletion, and reordering of hydrogens help account for
differential protonation states, insufficient electron densities, and unintentional spatial overlap.
Since PDB entries are frequently a single structure averaged from an ensemble of conformational
data, this positional averaging regularly leads to overlapping atoms that do not naturally exist in
such a high energy state (49). Careful energy minimization should be used to slowly push a
system to a less volatile state.

1.3.1.1 Determination of Protonation States. As mentioned previously, hydrogens are a
pervasive nuisance in structural determination causing very few crystal structures to possess
atomic resolutions accurate enough to assume the protonation state of a protein. Conditions
required for crystallization also often require non-physiological pHs leading to unphysical
protonation of side chains. Empirically-based programs, like PROPKA (50), can estimate the
initial protonation state of side chains. Other physics-based methods exist for finer pKa
estimations using classical Poisson-Boltzmann or quantum mechanical free energy calculations.
Since proteins are dynamic entities, protonation states can change throughout simulation due to
conformational shifts inducing local environmental changes on side chains. Key residues,
histidine for instance, that are susceptible to alternate protonation states (i.e., tautomeric states)
should be identified, and iterative and/or separate simulations are recommended.

1.3.2 Energy Minimization
Energy minimization is often crucial on prepared protein structures and ligands and
should be done individually so as to not bias conformations towards initial structures. This
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allows for any algorithm to rely on its intended function and helps to limit false model
convergence. Energy minimization is necessary to alleviate overlapping atoms, close contacts, or
unrealistic constraints imposed by structural resolving methods. Use of constrained energy
minimization, with successive relaxation of these constraints, is useful in this context in order to
prevent unrealistic divergence from the crystal structure during the relief of close contacts.

1.3.2.1 Energy, Entropy, Free Energy, and Enthalpy. The concept of energy itself is
ambiguous and does not physically exist. Energy is simply the sum of all possible forces, kinetic
(T) and potential (U), in a system and is useful for understanding and modeling more
complicated systems. This is also known as the Hamiltonian definition where the energy term is
H. For modeling dynamics, the principle of least action is implemented through the Lagrangian,
L.
H=T +U

Hamiltonian

(Eq. 9)

L=T −U

Lagrangian

(Eq. 10)

Which forces are deemed relevant for inclusion into any heuristic, ad-hoc definition of
energy is largely arbitrary, based only on what may be important to a researcher at the time. This
almost always leads to confusion when energetics are employed to explain certain observations
or predict other quantities. For biochemistry, focusing on thermodynamic quantifications of
energy tends to be most useful with the Grand Canonical Ensemble to represent the possible
states of a mechanical system of particles.
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U=TS − PV + μ N

(Eq. 11)

Where U is the total internal energy of a system with the components TS, temperature (T) and
entropy (S), representing the amount of heat in a system, PV, pressure (P) and volume (V),
denoting the work done by or on the system, and μN, chemical potential of a single molecule (μ)
and number of molecules (N), inferring the total potential for work to be done by or be extracted
from the system. Each of the multiplied constituents in the equation demarcate a specific
subdivision of potential and kinetic forces in a system.
Expansive and contracting motions are defined by work, PV. This term does not hold
much practical use for biochemistry and is rarely implemented since most experiments are
carried out under constant pressure.
The more valuable terms are heat and total chemical potential in a system. Heat is a
measure of unavailable energy in a system locked up in conformational or structural modes. This
term is a composite of the average relative kinetic energy of a system, otherwise known as
temperature, and the possible number of states accessible to the system, or entropy, at a given
temperature. Entropy is nearly impossible to measure directly but is an extremely valuable term
describing how energy is stored in a system.
The last term, μN, is arguably the most important. It expresses the amount of work a
system could perform or free energy. Most calculations attempt to derive or predict values
associated with free energy since it can elucidate phenomena that can or cannot occur in a system
given a particular state. Unfortunately, free energy is difficult to extricate from other energy
terms. Empirically, enthalpy, the total chemical energy and heat contained in a system, is an
easier value to measure. For example, the enthalpy of formation is the total energy required to
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create all bonds and configurations in a molecule. By measuring the heat (TS) lost and work
(PV) done when all bonds are broken, the free energy of a bond can be deduced from the
remaining energy.
Theoretical calculations of free energy are just as challenging. Many procedures rely on
perturbatory methods on equilibrated systems. For understanding potential effects on protein
binding with differing ligand, alchemical transmutation is advantageous where the atoms in a
ligand are transformed into different elements or molecular moieties. Any change in the
equilibrated system’s energy must be caused by the new functional group. For conformational or
positional effects, umbrella sampling methods allow for free energy determination by fixing a
predefined reaction coordinate in various states and measuring the associated energy changes.
Thermodynamic integration and Metropolis Monte Carlo methods, which are not based on
perturbation, are also available for more specialized systems utilizing clever exploitation of
various thermodynamic quantities. Each system requires a novel approach for free energy
determination, so no algorithm can be made to automatically setup a system for ascertaining this
measure. Forming an appropriate hypothesis and testing environment for extracting explicit
energetic terms demands rigorous attention and consideration of all assumptions and constraints.
Again, discussing energy alone is meaningless, so any use of energy terminology must include
specific definitions of the quantities examined.

1.3.2.2 Energy Minimization Algorithms. Many computational methods exist, but the
Newton-Raphson method is one of the most accurate and commonly used algorithms. Based on a
Taylor series expansion of the potential energy surface at the current geometry, it is the most
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computationally expensive per step of all the methods utilized to perform energy minimization.
However, it usually requires the fewest steps to reach the minimum (51).
For rapid estimation, the steepest descent algorithm relies on approximations instead of
requiring explicit calculation of numerous second derivatives. The second derivative is assumed
to be a constant making it much faster per step than the Newton-Raphson method. This
computational gain is unfortunately offset by its inefficiency, and more steps are generally
required to find the minimum if it can be found at all (52).
The conjugate gradient method is a decent compromise between speed and accuracy.
Similar to steepest descent, the search first takes place in the direction of the largest gradient. In
contrast to steepest descent, the conjugate gradient method remembers the direction of the
previous search to help avoid some of the persistent oscillating behavior that often plagues the
steepest descent as it moves toward the minimum. This gives a greater likelihood to find a
minimum with far fewer iterations. For larger molecules, the expense of the Newton-Raphson
method becomes even more pronounced, leading to a much higher computational cost than other
methods. Despite the smallest amount of CPU time per step of the three methods, steepest
descent requires many more steps to find a minimum due its overall inefficiency. As such, the
conjugate gradient method is the most commonly used method for energy minimization of large
molecules (53). The Truncated Newtonian Conjugate Gradient (TNCG) adaptation of the original
conjugate gradient method is a far faster variant implemented in most energy minimization codes
(54).
These energy minimization methods do not incorporate any dynamics and seek only to
lower local potential energy. Biomolecules have evolved to rely on thermal vibrations to
maintain an optimal structural equilibrium. Multiple minimization runs will drop a structure into
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a local energy well further than thermal kinetics would allow. This over-minimization is
analogous to freezing and is not physiologically relevant to biomolecules (55). For exploring
global energetic minimums, other minimization protocols, such as simulated annealing (Section
1.3.3.2 Simulated Annealing), can be used to overcome the locality problem in a molecule’s
potential energy surface.

1.3.2.3 MM/GBSA. The procedure haphazardly named Molecular Mechanics energies
combined with Poisson–Boltzmann (MM/PBSA) or Generalized Born (MM/GBSA) and Surface
Area continuum solvation is essentially a minimization procedure designed to estimate free
energies of binding. By analyzing multiple conformations, normally through MD or MC
simulation, free energy estimations are obtained from energy minimizations on the receptor,
ligand, and complex individually and combined with the following equation,

Δ Gbind =ΔG complex−Δ Greceptor −Δ Gligand

(Eq. 12)

While MD is not necessarily required for a large conformational search set (56–59), it is
highly recommended in order to capture dynamic processes and for statistical validation of the
approach (60). MM/GBSA also requires knowledge of the solvent and electrostatic environment
around the target system.
To account for solvation effects when the atomic details of the solvent are not relevant, a
continuum approximation can be used to reproduce thermodynamic properties of the system. By
rolling a coarse-grained solvent molecule over the target system, the solvent accessible surface
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area is traced out and calculated allowing estimation of the free energy required to move a
molecule from an aqueous solvent to a non-polar one.
Electrostatics can be handled by solving the Poisson-Boltzmann equation. Though
computationally demanding to solve, it gives good estimates of the electrostatic component of
the solvation free energy. The overall quality of the approximation relies on the solvent behavior
being reasonably close to a dielectric continuum. For bulk water, this is a very good estimate; for
interface waters or where molecular granularity is important, such as water bridges, this
approximation breaks down quickly. An alternative algorithm for estimating electrostatics is the
Generalized Born (GB) method, a fast, highly accurate, approximate solution to the PoissonBoltzmann equation (61).
MM/PBSA and MM/GBSA are useful for improving the results of virtual screening and
docking and the approaches can reproduce and rationalize a number of experimental findings.
However, owing to the numerous and nested approximations and assumptions, performance
varies strongly with the tested system and can be difficult to correlate free energies with
experimental values. Additionally, many attempts to improve accuracy with a more refined
method such as quantum calculations, polarizable force fields, or improved solvation models
have actually deteriorated results (62–64).
GB was originally developed by Clark Still (65), and then incorporated into the
MM/GBSA method, being later adopted by many other software platforms including
GROMACS, NAMD, and Schrödinger (66–68).

1.3.2.4 Low Frequency Normal Mode Analysis. S Since protein function is almost
entirely predicated on dynamic motions, analytical methods pursuant to the understanding and
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categorization of protein flexibility can yield significant insight into the biological and
evolutionary purpose of a protein. Normal mode analyses (NMA) look to classify and rank
collective protein motions into independent (i.e. normal) harmonic oscillatory behavior (i.e.
modes). A normal mode is a concerted motion of many atoms where the center of mass does not
move and all atoms pass through their associated equilibrium positions at the same time. Normal
modes are also directly related to vibrational spectroscopy (e.g. IR). NMA methods apply a great
deal of assumptions that sharply hinder the method’s general use and requires explicit
equilibration of the initial system (see section 3.3.3 Equilibration). NMA assumes that all
pairwise forces behave like springs for short displacements, all motion vectors are linear, and all
fluctuations are in a ground state harmonic energy well with force constraints able to be
approximated as the second derivative of the energy multiplied by the displacement in a specific
direction. The assumptions allow the system to be expressed as a Hessian (2 nd derivative) matrix
where the normal modes are eigenvectors of the matrix. Closed forms for the second derivatives
are rarely available, so they are calculated numerically.
The general procedure for NMA is initial structure energy minimization and subsequent
Hessian generation followed by diagonalization of the Hessian to solve for the eigenvectors and
eigenvalues. Eigenvalues correspond to amplitude of a motion. Low eigenvalues are associated
with low force constants or low frequencies. Eigenvectors denote the directions of movement
and are valuable for visualizing the collective movements. These quantities can also be extracted
from an MD simulation with concomitant expense in computational time (69). It is not known
which modes are relevant for protein function but extensive surveys of structural databases have
shown that structural transitions of many proteins can be explained by just a few of the lowestfrequency normal modes (70). Therefore, most NMA is only concerned with low frequency
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vibrations (5-10 lowest eigenvalues), commonly abbreviated as low-mode (71). Low-modes are
similar to atomic normal modes constructed from crystallographic models and can be beneficial
in extracting information on protein function from poor resolution X-ray or NMR structures and
homology models since they require little resolution to reproduce functional rearrangements,
even as low as 30Å resolution(72,73).

1.3.3 Molecular Dynamics and Monte Carlo
Molecular Dynamics (MD) is a classical simulation of the motion of molecules by
solving Newton’s equations of motion for a virtual system with respect to time, temperature, and
pressure. Monte Carlo (MC) methods are a broad class of computational algorithms that obtain
numerical results by repeated random sampling. The fundamental concept in MC is to employ
randomness for solving problems that are likely deterministic in principle. MC generates states
according to Boltzmann probabilities where MD attempts to reproduce the dynamics of a system.
A Markov chain procedure is used to determine a new system state from a previous one. This
new state is accepted at random, using certain criteria such as a Bennett acceptance ratio, to keep
the system stochastic.

1.3.3.1 MC vs MD. MC is usually superior for conformational sampling as large energy
barriers, often several kBT, exist for torsional rotations. This tends to cause poor state sampling in
MD simulations due to molecules being trapped in a few low energy conformations. In contrast,
the random moves in a MC simulation can easily produce barrier crossings if the energy window
for accepted moves is sufficient. Unfortunately, this strength of MC can also be a difficulty for
the procedure and cause for error (74). Choosing an energy window depends on the size of a
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system and the conformational behavior being studied. Leaving the energy window near k BT will
likely not produce any significant state changes but is helpful in elucidating local degenerate
structures. Larger windows, above 100 kcal/mol, will generate a very diverse set of states, but for
proteins this is often useless unfolding behavior. Biomolecule energy windows around 5 or 6
kcal/mol are ideal since that is near the thermal energy contained in bulk water at body
temperature (75).
MD becomes favorable for liquid simulations where molecular collisions exchange
energy between molecules, enabling barrier crossings, and thus improving the ability of MD to
sample system conformations. MD may also be more costly in terms of computation, but in MC
simulations, there exists a high chance of selecting random moves where atoms or molecules
overlap, especially for rotations of nematic molecules with long tails such as phospholipids or
liquid crystals. This results in a large number of rejected moves and subsequent decrease in
sampling efficiency. For larger systems, this issue often negates the lower computing time of
MC, frequently making MD faster overall. Despite this, the ability of MC to make unphysical
moves can compensate for this slow down in some cases, breaking through energy barriers that
may take MD an inordinate amount of time to sample. Moreover, MD handles collective motions
in general better than MC, though recent methods such as Hybrid Monte Carlo and
Configurational Bias Monte Carlo have been developed to improve the performance of MC
simulations in these areas (76). MacroModel (77), MCPRO (78), and the open-source FEASST
(79) are some software programs available for MC molecular modeling simulation. While many
systems can use either method to achieve the same result, some applications can only use one
method. Determining transport properties, such as viscosity coefficients, is only possible with
MD, since MC lacks any objective definition of time. On the other hand, MC can be used for
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simulations with varying numbers of particles, a procedure known as Grand Canonical Monte
Carlo, by defining moves for the destruction and creation of particles. For the most part, the
avoidance of dynamics relegates MC to the study of static quantities only (80).

Table 2. Table of available MD Software
Program

Replica Simulated Free Energy Implicit
GPU
Exchange Annealing Perturbation Solvent Accelerated

AMBER

Yes

Yes

Yes

Yes

Yes

CHARMM

Yes

Yes

Yes

Yes

Yes

Desmond

Yes

Yes

Yes

No

Yes

GROMACS

Yes

No

No

Yes

Yes

NAMD
Yes
No
No
Yes
Yes
Indicates if a particular program has a preexisting algorithm or interface for a certain
procedure requiring minimal effort for system setup.
1.3.3.2 Simulated Annealing. One of the advantages of MC compared to MD is the
method’s ability to surmount energy barriers (81,82). Simulated annealing (SA) can confer some
of this capacity to stochastic dynamics for overcoming large energy wells. In terms of molecular
systems, SA is the process in which a molecule is heated progressively to 600+ K with a very
small time step (less than 1 femtosecond) for a very short length of time (about 10 picoseconds).
This can “kick” a molecule out of possibly artificial energy wells and unreasonable
conformations. The temperature is then gradually lowered back down to more relevant
temperatures. The rapid heating opens up more possible states for a systems, but the entropy
incurred by this process often yields even more unreasonable conformations. A well-planned
annealing schedule is important for slowly lowering the system into the global minimum. Many
SA runs tend to be required for this followed by energy minimization once more after the
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annealing is finished to allow the structure to properly settle into the local energy well. This
stepwise process gives a relatively quick assay of stereoisomer conformations, optimal dihedrals,
bond lengths, and molecular geometries.

1.3.3.3 Equilibration. The discipline of statistical mechanics is intrinsic to all
computational modeling with the axiomatic concept of equilibrium at its core. A system at
internal thermodynamic equilibrium observes no macroscopic change even when microscopic
thermodynamic variables fluctuate. Therefore, any collective shifts in the average
thermodynamic quantities can only be due to external influences imposed on the system. Without
this global assumption of equilibrium, determination of cause and effect for an isolated variable
cannot be verified. For this reason, great care should be taken to ensure a system has
convergence around appropriate constants (Section 1.3.3.5 Trajectory Analysis for
Equilibration). A system should eventually evolve into a state that is independent of any history
and simulation time. This is referred to as equilibration. If it does not, the system cannot be
adequately described by computational modeling and demands further examination of initial
assumptions and conditions used to build and/or simulate the dynamics of a system (83).
It is important to note that thermodynamic equilibrium is not the same as dynamic
equilibrium. Thermodynamic equilibrium is achieved when thermodynamic quantification of a
system is stable and is no longer influenced by its initial configuration. The thermodynamic
quantities, such as pressure, temperature, and volume, are not changing above thermal
fluctuation and the potential energy of the system is minimized for a local energy well. This does
not mean that total energy is constant. Often, the total energy of the system appears constant for
short timescales since all systems equilibrate thermodynamically into some local energy well and
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will oscillate within it until a thermal fluctuation kicks the system out into another energy well.
Dynamic equilibrium is achieved when the system reaches its global structural energetic
minimum.

1.3.3.4 Common Setup Parameters for MD Simulation. MD simulations use a periodic
boundary box to spatially constrain the simulated system. Many enclosure geometries exist,
though cubic boxes are often a better choice for simplicity, but an orthorhombic box can take
more advantage of the shape of a protein or ligand to minimize box volume. Decreasing box
volume reduces the number of solvent molecules needed to encase the solute and thereby lower
the number of calculations entailed for the simulation. These two geometries are also almost
always compatible with any MD software. Proper periodic boundary conditions can be
established by allowing at least 5-10 Å of buffer from the solute to the box boundary. This is
where MD commonly has issues with unrealistically imposed high solute concentrations as
bordering boxes can affect each other through long range electrostatics. Ensuring interface
waters, solvent affected by the solute, do not touch each other by increasing the distance of the
solute from the box boundary will greatly reduce this self-interaction. Bulk solvent occurs when
the dissolved solute no longer influences the solvent. Distinct metrics should be asserted to test
for bulk properties in the solvent to prove adequate buffering. For a constant temperature and
pressure, density is entirely dictated by the intermolecular forces described in the force field file
making it a simple and sufficient indicator of force field accuracy. A protein touching its periodic
image is completely unphysical, akin to shaking your own hand through a mirror. The choice of a
solvent model is another influential decision on an MD simulation. Water is the most common
solvent and the most difficult to simulate classically. The GROMOS force field is optimized with
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the Simple Point Charge (SPC) and SPC/E model. OPLS and CHARMM are optimized with
TIP3P and TIP4P. Multi-site models may be necessary if protein or ligand displays a dependence
on water or has coordinated waters. Many other solvent models exist, such as chloroform or
octanol, but may not be available for some MD model builders.

Table 3. Overview of molecular timescales for general atomic and protein movements.
Approx. Number
of Atoms

Distance
Amplitudes

Average Timescales

Bond Stretching and Angle Bending

2–3

0.001 – 0.1 Å

1 – 5 femtoseconds

Side chain and dihedral motions

6 – 20

0.1 – 2 Å

1 – 10 picoseconds

50 – 1000

1 – 100 Å

10 – 100 nanoseconds

100 – 10000

10 – 100 Å

0.1 – 5 microseconds

1000 – 100000

10 – 500 Å

1 – 1000+ microseconds

Motion of Interest

Loop and Collective Protein Motion
Protein Domain Motion
Protein Folding

Estimating an acceptable runtime for achieving equilibrium is not trivial. The time span
simulated should match the kinetics of the natural process, implying that an initial understanding
of the system is necessary. For many small (~<50 residues) stable proteins with accurate
crystallographic data (~<2Å resolution with no missing or unresolved residues), the minimum
time required is at least 10-20 ns. This is, again, a minimum and larger systems (10,000+ atoms)
with greater degrees of freedom require longer simulations (Often 100-1,000 ns). Table 3 has a
synopsis of some basic kinetics for protein systems (84). For simulations longer than 100ns,
special care must be taken to refine force fields to adequately reproduce known structures since
most generalized force fields do not possess the required precision and systems start to deviate
significantly past this scale (39).
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Classical MD simulations follow an approximate O(N 2) rule. The “big O” notation is a
function of time complexity for the upper bound of an algorithm where, in this case, N is defined
as the number of atoms. This means that if the number of atoms in a system doubles, then the
computation time quadruples. On average, with 4 CPU cores and a 30,000 atom system,
computation time is about 0.5 nanoseconds simulated per day. This makes GPU acceleration
almost mandatory for MD, reaching hundreds of nanosecond per day for an equivalently sized
system. As such, nearly all current MD programs are optimized for running on GPUs.
The thermodynamic ensemble applied to simulation is commensurate to the scale of the
phenomena being studied. The adiabatic Microcanonical (NVE - constant number, volume, and
energy) ensemble is implemented when the total energy of a system must be conserved and is
useful for simulating chemical processes, even though simulation time and temperature are not
well defined under this constraint scheme. QM simulations are usually run in a Microcanonical
ensemble. The isothermic, isochoric Canonical (NVT - constant number, volume, and
temperature) and the isothermal, isobaric Grand Canonical ensemble (NPT - Constant number,
pressure, and temperature) are closer to experimental configurations, though it is not a minor task
obtaining a Canonical distribution of conformations and velocities. Dependency on system size,
thermostat choice, thermostat parameters, time step, and integrator is the subject of many articles
in the field. For MD simulation, the differences between NPT and NVT are usually quite small
(85–87). Therefore, NPT is a better choice as this method corresponds most closely to laboratory
conditions with a flask open to ambient temperature and pressure. However, if the simulated
system is very large and NPT is presenting difficulties with equilibration, especially if the system
exhibits significant dispersion effects, leading to unstable density reduction, then NVT may be a
better ensemble choice. In the simulation of biological membranes, isotropic pressure control is
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not appropriate. For lipid bilayers, pressure control occurs under constant membrane area
(NPAT) or constant surface tension, gamma (NPγT).
For defining a thermostat and barostat, the Nose-Hoover thermostat for NPT simulation
is recommended. Temperature choice should be based on the experimental methods being used
to correlate simulations. Biological temperature (310 K) or room temperature (298 K) are the
most common temperatures for protein systems. The Parrinello-Rahman barostat is advised when
Nose-Hoover thermostat is used, which works by changing the box shape (i.e. volume) to affect
the simulation pressure. Martyna-Tuckerman-Klein (MTK or MTTK) is an extension of the
Parrinello-Rahman barostat and is often preferred for protein simulations.
With regard to simulation timesteps and integrators, the Reversible rEference System
Propagator Algorithm (RESPA) is favored since it is one of the more stable and empirically
validated integration schema. The Verlet algorithm is another common and stable integrator,
recommended for NVE simulations. A timestep of 2 femtoseconds (fs) is advised for rigid bonds,
1 fs for flexible. Raising the timestep can reduce computational loads, but is broadly discouraged
as it usually causes severe artifacts at best and simulation explosion at worst.
Long-range electrostatics are the most computationally expensive calculations in an MD
simulation with Particle Mesh Ewald (PME) (88,89) being one of the more common and
effective correction methods. The reaction field (RF) (90) method is another solution that yields
the same accuracy as PME, but with slightly less computational costs (91,92). Imposing cutoffs
can greatly reduce computation time but at a cost of potentially inducing significant error over
the course of a simulation. A 20Å cutoff is advocated but is usually not feasible due to size and
system constraints. For proteins, a minimum of 13Å is recommended, though cutoffs down to 9Å
can still be adequate. Small molecules can get away with even smaller cutoffs. Potential and
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force tapering are also applicable for amending short- and long-range electrostatics but are not as
effective in error reduction as having longer cutoffs (93).
Positional constraints may also need to be imposed on a system to help approximate
larger structural restrictions or simulation conditions. Restriction of motion is correlated to the
thermal energy of the solvent. The thermal energy contained in bulk water at 298K is about 5
kcal/mol. Rigid restriction is any energy value much greater than this, thermal restriction is near
this value, and loose restrictions are for energies much less than solvent’s thermal energy. Any
bias imposed on the system drastically affects the physical relevance of the simulation.
Therefore, constraints should be carefully reviewed and correlated to known systems.

1.3.3.5 Trajectory Analysis for Equilibration. Equilibration is the primary goal in MD
simulations. Without it, no other quantity can be confidently determined. Many different general
principle components can be analyzed to establish that system equilibrium was achieved. The
more popular ones are Root Mean Square Displacement (RMSD), Root Mean Square
Fluctuations (RMSF), and Radius of gyration (R g). RMSD is the most prevalent analysis for
measuring equilibration. It quantifies the difference in inter-atomic position over time and can
help to catch possible conformational shifts in proteins. Root Mean Square Fluctuation (RMSF)
is essentially the RMSD per residue averaged over the length of the simulation. X-ray
crystallography uses a metric called B-factors related to RMSD and RMSF.

2

2

B=8 π ⟨ RMSD ⟩ ⇒ RMSD=
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√ √

B
B
≈
2
79
8π

(Eq. 13)

This equation roughly shows that an atom with a B-factor around 80 will be localized in a
sphere with a radius of 1Å about half the time. Analysis of individual residue B-factors identifies
the most flexible regions of the protein. For a successful simulation, secondary structures in
proteins must be maintained and core residues should not move beyond thermal fluctuation (~
+/- 1Å). Radius of gyration (Rg) calculates the centroid of protein and average intra-atomic
distance to that centroid. This is useful in measuring density shifts but is generally only
meaningful for globular proteins since many geometries can have identical centroid positioning.
Alpha carbon distance maps are another good tool for large oscillatory behavior. A principle
component analysis on multiple alpha carbon distance maps can be correlated to RSMF. Normal
mode calculations (Section 1.3.2.4 Low Frequency Normal Mode Analysis) may be useful for
verifying oscillatory behavior but, since normal mode calculations require all interactions to be
constant, this method has limited use.
These metrics supplicate a comprehensive review to identify if and when equilibrium was
achieved. Analyzed properties such as RMSD should converge or asymptote/plateau to a
reasonable average value (A good RMSD cutoff is near the PDB resolution). Multiple plateaus
may exist for longer run times. Final analyses should only be performed on the equilibrated
frames and no pre-equilibration frames should be included into production. Production runs
should be at least 5 – 10 times longer than the equilibration times to properly investigate the
local energetic minima. Finally, conclusions should be consistent with the time scales of the
simulation (See Table 3).
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1.3.4 Quantum Chemistry
Energy minimization, MD, and MC are all deterministic classical methods that do not
treat electrons and nuclei as separate entities nor account for uncertainty in their motions. As
such, these methods cannot describe high resolution details of atomic interactions. This is most
evident in the inability to characterize chemical reactions, but also leads to artifacts and poor
replication of physical phenomena. Since all physical interactions are governed by quantum
mechanics (QM), discretization of fundamental quantities described by probabilities as opposed
to continuous functions with definite precision, classical interpretations are often inadequate.
QM methods are needed to elucidate and quantify many chemical phenomena, such as reaction
paths, spectroscopy, and the prediction of many atomic and molecular properties. QM
computation is vital throughout many disciplines, not just in the more directly related sciences of
physics, chemistry, and engineering, but also in biology with respect to drug discovery and
molecular biochemistry.
As described previously (Section 1.2 Selection of Molecular Mechanics Force Fields),
quantum mechanical (QM) computation is needed for the creation of force fields in classical
simulation, but is also commonly required to further refine the initial geometry of a system.
Some classical iteration is still needed before running QM simulations as they are also extremely
dependent on the initial configuration of the system. All previous preparation steps (protonation
state analysis, MD, minimization, etc.) are advised and may have to be done iteratively until
sufficient convergence. Even though QM simulation is far more accurate than classical methods,
it possesses extreme computational cost. The total computational time is dependent on the level
of theory and accuracy desired. QM calculations (for DFT) follow an approximate O(N3) rule.
This means that if a simulation of 100 atoms takes a week to run on one core, then a simulation
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of 300 atoms will take approximately 27 weeks to complete (3 x number of atoms = 27 x
simulation time). Proteins are very large molecules (thousands to hundreds of thousands of
atoms) and are therefore often impractical to run simulations with greater than 300 atoms without
incredible computational resources. If a relatively small 3,000 atom protein were run using the
same configuration described previously, it would take about 520 years to finish the QM
simulation on the same number of cores. This example is greatly simplified as for ab initio
calculations, N actually stands for the number of basis functions, not the number of atoms. Each
atom can have as many or more basis functions then the number of electrons, so larger elements
contribute even more computational cost to the final simulation.
It is worthwhile to note that QM geometry optimization is fundamentally different from
MD simulation. MD simulates the motion of molecules with respect to time subject to initial
velocities,

temperature, ensemble pressure with solvent, and other approximated meso to

macroscopic effects. This permits the MD time evolved trajectories of the system to have some
physical interpretation. Geometry optimization, by contrast, works much the same way as
classical energy minimization by reducing the forces acting on each atom in a system. The
pathway with which it achieves this lower energy state lacks any physical meaning. Optimization
algorithms are path independent and can yield the same energy minimized structures.

1.3.4.1 Quantum Calculation Methods. Solutions to the Schrödinger equation that
describes the wave function of a quantum system are rarely amenable to analytical means due to
N-body coupling interactions. As such, numerous numerical and approximative methods have
been developed to describe the evolution of atomic systems on quantum scale.
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One of the first and more successful approximative schemes created soon after the
discovery of the Schrödinger equation is the Hartree-Fock (HF) method that uses a selfconsistent field (SCF) to estimate charge distributions. HF imposes many strict assumptions that
often preclude its unitary use, the worst being a complete disregard for Coulomb correlation (the
instantaneous correlation among the electrons arising from their mutual Coulombic repulsion)
leading to the inability of HF to describe London dispersion forces. These forces are critical to
most macroscopic phenomena for both atoms and molecules. Consequently, other methods are
employed to bolster the accuracy in describing many electron systems after initial non-relativistic
HF calculation, known collectively as post-HF methods (94). These methods attempt to include
some level of estimating electron correlation to the multi-electron wave function. Some methods
attempt to expand the wave functions into a linear combination of Slater determinants. The
coupled cluster (CC) method, especially CCSD(T), is considered a gold-standard for quantum
chemistry. However, this accuracy comes at a very high computational cost, limiting CC methods
to relatively smaller systems compared to other methods (95–97). Configuration Interaction (CI)
is a linear variational method that confers a unique ability to generalize its formalism to many
disparate system configurations from excited states, open-shell systems, and to systems far from
their equilibrium geometries (98,99). By contrast, traditional single-reference perturbation
theories and CC approaches generally assume that the reference conﬁguration is dominant, and
tend to fail when that is not the case. The major downside to CI is that truncation of CI space is
necessary for it to be computationally tractable and causes the method to have inconsistent
energy behavior with increasing distances and no longer scales correctly with an increasing
number of electrons. Other post-HF methods are perturbative, such as Møller-Plesset (MP)
perturbation (100), and are relatively cheaper to compute than others if kept at a lower level of
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theory while retaining reasonable accuracy. The simpler and less computationally expensive
MP2 method gives superior results compared to CI when the size of the system increases. Unlike
CC and CI methods, MP perturbation suffers from convergence and accuracy issues that higher
levels of theory don’t seem to be able to solve (101).
An alternative to HF that can produce properties of a molecular system based solely on
electron density is Density Functional Theory (DFT). DFT was not originally considered a viable
alternative to HF methods until recent advancements sufficiently improved the accuracy of the
exchange and correlation interactions. It still has issues describing some important molecular
properties, such as van der Waals forces and excited states, but the simplicity and computational
efficiency of the method provides a good balance between accuracy and computational cost. The
method scales as O(N3) or better, enabling calculations with thousands of electrons. DFT uses
functionals to calculate electron densities and probability distributions. Most of the more popular
functionals include some HF input to determine exchange interaction energies. The choice of a
functional to incorporate into a QM calculation is determined by which functional performs best
for a given system. As an example, B3LYP is the standard but gives significant and consistent
error and MO6-2X (102) is more accurate for molecules containing atoms smaller than argon but
yields substantial error for transition metals, whereas MO6 has been validated as a preferred
choice for organometallic compounds (103,104). Many review articles exist discussing
benchmarks and optimization of system configurations with the appropriate functional. With
over half a century of research behind the theory, DFT is now a very well-established technique
with its capabilities and limitations reasonably understood and an abundance of efficient
implementations available.
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1.3.4.2 Basis Sets. QM simulations are highly dependent on the level of theory used. The
theory is further decomposed into the required functional and basis set. In quantum chemistry, a
basis set usually refers to the set of single particle functions used to build up molecular orbitals.
The term gets confused sometimes by theorists who might also refer to sets of Slater
determinants as N-electron basis sets, which is something else entirely (105). Atomic orbitals
represented by atom-centered Gaussian functions (GTO) are the prevailing basis set. Some older
programs use Slater functions (STO) which have the correct short-range and long-range behavior
but GTOs are much easier to compute through the Gaussian product theorem. The Pople basis
sets are the most popular with split-valence double-zeta basis set is called 6-31G as its flagbearer (106). STO-3G is a deprecated minimal basis set in which each atomic orbital is
represented by only 3 Gaussians that attempt to mimic the behavior of a Slater function.
For further set refinement, polarization functions can be added demarcated by an asterisk
for a function that covers only heavy (non-hydrogen) atoms or double asterisk for hydrogen
inclusion. For anions, Rydberg states, and very electronegative atoms with a lot of electron
density, like fluorine, diffuse functions are needed to accurately reproduce polarizabilities or
binding energies of dispersion forces (107). These diffuse functions are designated by a plus sign
next to the basis set. The Dunning correlation consistent basis sets are optimized using CI
wavefunctions designed to converge smoothly as more Gaussians are added. These basis sets are
optimal if a calculation does not define core electrons as frozen in post-HF computations like
MP2, CISD, CCSD(T) but are overkill for simpler HF methods. In general, the more Gaussian
functions the more accurate the calculation.
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The process of selecting the proper level of theory, accuracy, and convergence threshold
is not well defined. Intensive and rigorous empirical evidence is necessary to validate any QM
simulations.

Table 4. List of quantum chemistry software
Program
AMBER

License

Post-HF
SemiGPU
HF
DFT
Empirical
Accelerated
MP CC CI

Free

Yes

No

No No No Yes

No

Academic

Yes

Yes Yes Yes Yes Yes

Yes

Gaussian

Commercial

Yes

Yes Yes Yes Yes Yes

Yes

Jaguar

Commercial

Yes

Yes Yes No No Yes

No

Free

No

Yes Yes Yes Yes Yes

Yes

GAMESS*

NWChem

Q-Chem
Commercial
Yes
Yes Yes Yes Yes Yes
Yes
*GAMESS software company split into three independent companies with different softwares, the
commercial US and UK versions and the open source Firefly version.
1.3.5 Quantum Mechanical Molecular Modeling (QM/MM)
As stated previously, most biochemical systems are far too large to be simulated at any
level of ab initio quantum theory. At the same time, classical molecular mechanics force fields
are not sufficient for modeling processes, where chemical bonds are formed or broken. To
overcome these limitations at either extreme, methods have been developed to treat a small
subset of a system at a high resolution level of quantum chemistry (QM), while retaining the
computationally cheaper molecular mechanics force field (MM) for the larger partition. This
approach allows for the study of chemical reactivity in large systems, such as enzymes, or
covalent drug or residue interactions.
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The main advantage of hybrid QM/MM methods is their computational efficiency. The
calculation time of doing classical MM simulations scales as O(N 2), with N as the number of
atoms in the system. The majority of the calculation cost comes from computing the electrostatic
interactions term in which every particle interacts with every other particle. The use of a cutoff
radius, periodic pair-list updates, and recent variations of the PME method have been able to
reduce the time complexity between O(N) and O(N 2) (108). That is to say a system with double
the number of atoms would take between double and quadruple the computing power to
simulate. The other route of QM scales at best as O(N3) for DFT or even as bad as O(N7) for very
high level coupled cluster calculations, where N is the number of basis sets. Restricted Hartree–
Fock calculations can scale as ~O(N2.7), but the accuracy sacrifice is not usually worth it at these
scales. Generally, QM regions are small and typically isolated, so the increased computational
cost of QM is mitigated by only making the part of the system that is of interest to be treated
quantum-mechanically, such as the active site of an enzyme, and the remaining system is treated
classically. Further speed increases come from using semi-empirical methods to approximate
certain computationally costly parts of the QM calculation as experimentally derived constants.
While QM/MM seems a superior method, implementing it correctly as to not sacrifice the
accuracy of QM or the speed increase of MM is a difficult and sometimes insurmountable
problem. (109) The most prominent issue is dealing with electrostatics and how to transfer
charges between the QM and MM regions. In QM, atoms are not a well-defined quantity in a
molecule as there is no quantum mechanical operator that corresponds to an atom. Because
electrons are defined by Gaussian distributions, this delocalized behavior leads to ambiguity in
the definition of an atomic charge which is critical for MM force fields. Some procedures use
population analysis schemes to essentially sum over all electron density using the basis functions
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of a given atom to yield a partial charge, known as Mulliken charges. This scheme, however,
depends on how the atoms are centered and breaks down as the basis functions become more
delocalized. Another scheme is to define atoms as “critical points” of the charge density. This
procedure is more stable than Mulliken/Lowdin schemes with respect to basis set expansion.
This assists in convergence when more basis sets are added to the system, but it is not clear if
this means it is a correct charge design. This particular scheme is implemented in the QM
program Gaussian (110). The more common charge expression scheme is ElectroStatic Potential
(ESP) fitting where charges are determined by fitting charges which best reproduce the
electrostatic potential generated by the molecule. Despite this method’s good fit with MM
potentials, multiple solutions for the fit exist and many are clearly unreasonable for the system,
especially for the interior of a molecule. Restricted ESP-Fitting (RESP) attempts to avoid these
unphysical solutions of ESP charges. The most difficult charge embedding method is covalent
embedding. This arises when the QM region of a system is linked to the MM region by covalent
bonds. The covalent embedding procedure cuts the bond at the QM/MM threshold and adds two
“link” atoms to the system. A hydrogen is added to the newly generated QM “molecule” and a
single simplified atom type is bonded to the MM region leading to an overlap of both regions.
This method is almost always required in biological contexts since proteins are just very large
molecules. Potential problems emerge with this link atom concept as extra degrees of freedom
need to be removed, i.e. the link atom somehow needs to be connected to the MM part of the
simulation. The electronic structure at the boundary will be very different if the hydrogen atom
and the atom it replaces do not have similar electronegativities. These can be adjusted in semiempirical methods, but can still cause issues especially for excited states. Further, most force
fields do not include any concept of polarizability, but the QM region will redistribute charges.
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For certain configurations, this can lead to significant imbalances and amplification of errors.
The best practice to mitigate these potential problems is to choose boundary locations where
there is minimal charge fluctuation expected, e.g. carbon atoms at least three unconjugated atoms
away from any chemical reactions. Schrödinger’s Q-Site (111) program has many built-in scripts
to assist with covalent embedding and implements frozen orbital methods as well. All covalent
embedding schemes should be treated with ample caution as it is possible to break almost every
implemented scheme. As always, rigorous testing with multiple simulations and perturbations of
any QM/MM partitioning is a necessity.
Ultimately, it is still not clear if QM/MM actually helps to alleviate the problems of either
QM or MM or just leads to more difficulty in and of itself.

1.3.6 Ligand Docking
A major area of research where virtual techniques are greatly sought is in drug discovery.
Pharmaceutically active compounds work by binding to specific proteins and either activating or
inhibiting them to some degree. The primary pedagogy in making a drug is to maximize how
long it sticks to the intended target. For the most part, the longer, the better. To this end and in
many diverse forms, molecular docking has been developed as a virtual way to quantify the
number and relative strength of potential interactions of a molecule with a protein target of
interest.
The more common docking procedure is rigid receptor docking, where the protein or
receptor is frozen and held fixed in space and some conformational selection or energy
minimization is performed on the ligands to generate an optimal pose in the binding site using a
simplified grid map. A docking grid is a characterization of the binding site’s electrostatic
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potential and key interactions in a 3D lattice. The program then estimates the free energy of
binding by implementing some form of energy-based scoring function that scales (α and β) and
sums some number approximated energetic contributions (E) like the generalized formula below.

Docking Score=α Evdw + β E Coulomb + Ehydrophobic + Etorsion + E Hbond + Emetal +.. .

(Eq. 14)

For rigid receptor classes of docking routines, the protein structures utilized must be in
the lowest energy, i.e. most probable, state. Crystal structures are a necessary starting point, but
due to substrate conformational selection or induced fit effects, significant computational studies
must be done to understand the structural dynamics of the protein. The crystallographic structure
is a position averaged snapshot of the lowest energy structure for that system. Often the
uncertainty in dynamic motion is needed for binding (conformational searching) and introducing
or excluding components will alter the system energetics (induced fit). Sufficient state sampling
with MD and/or MC is vital for proper state selection when beginning a docking simulation and
multiple crystal structures and conformations should be used to check convergence. Additionally,
few crystal structures possess atomic resolutions small enough to assume the protonation state of
a protein and often require non-physiological pHs in the crystallization methodology. Due to
these issues, special attention must be made to addressing side chain protonation states in
docking runs (see section 1.3.1.1 Determination of Protonation States).
Other docking schemes also exist to overcome the limitations of rigid receptor docking,
such as flexible or induced fit docking (Section 1.3.6.2 Induced Fit Docking) where the receptor
is essentially allowed to move and quantum polarized ligand docking that combines docking
with QM/MM techniques (Section 1.3.6.3 Quantum Polarized Ligand Docking).
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For many decades, dozens of different docking programs, procedures, and associated
tools have been developed for both commercial and academic use. This section will focus on the
more popular programs Autodock Vina (112), DOCK (113), GLIDE (114), GOLD (115), and
LigandFit (116) to give a general overview of what rigid receptor docking programs are
available.

Table 5. List of docking software
Program

Sampling Method

Scoring Method

genetic algorithm

DOCK

Accuracy

License

Scorea

Poseb

Force field

0.485

0.726

Open source

shape-based

Force field or
contact score

0.445

0.591

Freeware

GLIDE

systematic search

Empirical score

0.544

0.754

Commercial

GOLD

genetic algorithm

Empirical score

0.599

0.726

Commercial

Autodock Vina

LigandFit
Monte Carlo
Empirical score
0.479
0.689
Commercial
Score accuracy is defined by the rate of the top scoring pose having less than 2Å RMSD from
the native pose. b Pose accuracy is defined by the rate of a program being able to obtain a pose
less than 2Å RMSD from the native pose from all pose outputs. (117)
a

AutoDock Vina was designed as a successor to the popular AutoDock developed by Trott
and Olson (112) at the Scripps Research Institute in La Jolla, California. Like its predecessor,
AutoDock Vina is a free, open source program and shares some basic approaches as the original
AutoDock, using a genetic algorithm for processing poses and a MM based scoring function.
However, many independent tests of AutoDock have shown it is no longer considered a
sufficiently accurate docking software and has begun to fall out of use despite a large number of
published articles owing to the free license (117,118). AutoDock Vina was developed to address
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these issues and overhaul the program to offer significant improvements in the average accuracy
of binding mode predictions, while also being up to two orders of magnitude faster than
AutoDock 4 (119).
LigandFit is a CHARMM based program that uses MC techniques to sample
conformations of ligands initially docked into an active site based on shape followed by further
energy minimization. Originally developed by Venkatachalam et al. (116), LigandFit has scripts
capable of identifying an active site and generating grids using a cavity detection algorithm. The
program then fits a given ligand into the specified binding site through MC conformational
sampling whose parameters depend on the number of rotatable bonds in docked molecules and
matching the ligand to grid points. Those conformations then finally undergo energy
minimization and scoring based on the DockScore energy function.
DOCK is docking software initially developed by Irwin Kuntz (120) at the University of
California at San Francisco and versions have been available since 1988 free of charge for
academic institutions. The most current version, DOCK 6 (113), utilizes several improved
scoring options that include explicit terms for ligand and receptor desolvation and ligand
conformational entropy corrections. A scoring function based on AMBER with implicit solvent,
conjugate gradient energy minimization, and MD simulation capabilities are also present.
In 2004, the docking software GLIDE (Grid-based LIgand Docking with Energetics) was
developed by Friesner et al. (114) and is currently a module in the Schrödinger software suite,
commercially licensed by Schrödinger, LLC. GLIDE has become one of the more regarded
docking programs with its relatively high pose and energetic accuracies (See Table 5). More
recent docking software has shown even more promise in terms of speed and accuracy, but
GLIDE has reliably held its position for many years. GLIDE works by generating a set of grids
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with different types of fields representing the receptor binding site properties and geometries and
then, unique to GLIDE, it performs a complete systematic search of the orientational, positional,
and conformational space of the docked ligand. The best conformation is then further refined
through MC sampling. Afterwards, the torsional space of the ligand is exhaustively sampled to
generate a large number of potential binding poses. A hierarchical series of filters and scoring is
employed following the initial rough positioning to narrow down the range of alternatives to be
evaluated. A proprietary scoring function called GLIDEScore is used. Further minimization is
applied leading to a final energy evaluation with a composite scoring function that combines
empirical and MM force field based terms.
GOLD (Genetic Optimization for Ligand Docking) is another highly regarded,
commercially available docking program created in a collaboration between the Cambridge
Crystallographic Data Center (CCDC), GlaxoSmithKline, and the University of Sheffield (115).
The program implements a genetic algorithm based search method for generating ligand poses
and allows for some partial protein flexibility up to ten residues defined by the user. GOLD also
deploys a user interface with an interactive docking setup called Hermes that contains a variety
of constraint options and allows for the automatic consideration of cavity bound water
molecules. Multiple proprietary and standard scoring functions can be considered including
ChemScore, GoldScore, Piecewise Linear Potential (PLP), and the Astex Statistical Potential
(ASP). This range of assets has kept GOLD as one of the better docking platforms available.
Schrödinger’s docking software was utilized in this work as the primary docking software
due to the significant interconnectivity of programs, extensive literature review of the related
algorithms, and prior access to licenses. The following subsections describe Schrödinger’s
docking and energy scoring algorithms.
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1.3.6.1 SP and XP Docking. SP (Standard Precision) docking is the default and original
Glide scoring function (Eq. 15) using a series of hierarchical pose filters that perform
conformational searches of a ligand set against shape and properties of a receptor grid. It remains
one of the best docking algorithms according to benchmarking to date (Table 5) and provides a
quick estimation of the free energy of binding based on extensive empirical validation. The Glide
SP protocol has a reasonably fast docking speed (estimated 10-15 seconds/compound, overhead
excluded), but suffers considerable slowdown for larger molecules with more rotatable bonds
(114). XP (Extra Precision) docking is similar to SP, but uses a different energy function (Eq. 16)
and sampling approach to better resolve hydrophobic interactions. The XP scoring functions
accomplishes this by including water desolvation terms, ligand binding terms to specific protein
structural motifs, and incorporating hydrophobic enclosure terms with modified hydrogen
bonding conditions. This makes XP superior for interpreting binding sites with substantial
hydrophobic characteristics and/or complex hydrogen bonding in hydrophobic enclosures.
Unfortunately, this modified approach sacrifices substantial speed (approximately 2
minutes/compound) with the same dependency on number of rotatable bonds (121).
The main drawback for these docking programs are that both schemes are rigid docking
methods and do not account for protein flexibility. Further, while Glide does attempt exhaustive
pose screening, docking programs in general still suffer from poor ergodicity in possible pose
prediction evident by a significant decrease in accuracy and speed for larger molecules (approx.
>20-30 rotatable bonds). They also are dependent on normalizing arbitrary energy calculations
with experimental values and still persist with relatively high error (averaging approximately +/2 kcal/mol). Appropriate renormalization with control compounds and proper protein preparation
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can alleviate or at least codify some of this error, but the subjective nature of the scoring function
will and should always yield suspicion to any docking results.

GScore (SP)=0.05 E vdw + 0.15 ECoulomb + E Lipo + E Hbond + Emetal + Erewards + E RotB + E site

(Eq. 15)

XPScore=E vdw + ECoulomb + E hyd _ enclosure + E hb _ nn _ motif + E hb _ cc _ motif +
E PI + Ehb _ pair + E phobic _ pair + E desolv + Eligand _ srain

(Eq. 16)

1.3.6.2 Induced Fit Docking. IFD (Induced Fit Docking) is one of the few docking
algorithms capable of accounting for protein flexibility. IFD uses the docking program Glide to
account for ligand flexibility and the Refinement module in the Prime program to resolve
receptor flexibility (16,122–125). The Schrödinger IFD protocol attempts to model induced-fit
effects from alterations in binding site conformation due to ligand binding in order to increase
the accuracy of binding affinity estimates and prediction of possible binding modes. IFD starts
with initial ligand docking by Glide, employing a greatly reduced van der Waals radii and can
temporarily remove highly flexible side chains during this docking step. Following primary rigid
docking, the Prime structure prediction module deletes the residues surrounding the docked
ligand and reintegrates them into the site while energy minimizing them. Lastly, IFD executes a
final ligand re-docking to the recently generated low-energy protein structures and the resulting
complexes are scored via another function unique to IFD (Eq. 17). IFD can also use either SP or
XP scoring functionals for the GScore term, allowing proper definition of potential hydrophobic
features.
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The major disadvantage of IFD is the sizable computational time required for an IFD run,
on the the orders of hours per molecule. Further, handling entropy is still a major issue for most
molecular mechanics. The IFD protocol does not account for entropy or work required to get to
the calculated state. This can lead to very high estimated binding affinity for some theoretical
poses where the energy barrier of the conformation represented would be physically impossible
or extremely fleeting, such as hydrophobic ligands being buried in core residues. Because of this,
it is advised to not use IFD as a general docking protocol, only implement IFD for flexible
binding sites and rigid docking for inflexible ones.

IFDScore=E prime + 9.057 GScore+1.428 ECoulomb(GScore)

(Eq. 17)

1.3.6.3 Quantum Polarized Ligand Docking. QPLD (Quantum Polarized Ligand
Docking) is another Schrödinger docking program designed to compute exact energies through
ab initio quantum calculation and allows for the treatment of ligand polarization (126,127).
While some advancements have been made in polarizable force fields (Section 1.2.4 More
Complex Models), classical force fields in general are not capable of considering induced
charge polarization. Docking methods rely on classical MM force fields and when charge
polarization plays a larger role in the binding mechanism of a particular protein, the accuracy of
the docking method is reduced. The QPLD protocol alleviates this limitation by generating
multiple binding poses through conventional docking and then performs a single-point energy
calculation on each complex and derives new partial atomic charges from electrostatic potential
fitting. The updated molecule is then re-docked and scored with better handling of induced
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polarization due to a highly charged active site or for a ligand that is particularly susceptible to
polarization.
Similar to IFD, QPLD is very computationally expensive with simulations requiring
hours per molecule. QPLD is also a rigid docking method, not accounting for protein flexibility
in any way. Additionally, docking tautomers of the ligand is a rough, low-resolution, approach
that has been proven to increase hit rates by approximating repolarization effects on atoms with a
labile hydrogen (128,129). If an active site can induce and stabilize a tautomeric form of a
molecule, a simple rigid docking of explicitly defined tautomers can simulate QPLD to some
extent. QPLD is needed to explore more subtle effects of highly charged binding sites or of
molecules that are susceptible to polarization without labile hydrogens.

Δ GQPLD =Evalence (P)+ Ecoul ( P)+ Evdw (P)+α E vdw (P /L)+ EQM ( L)+ Gsolv (C)+G ideal (C) (Eq. 18)

where P is the protein, L is the ligand, and C is the complex.

1.3.6.4 Constituent Partitioning Consensus Docking. Each docking algorithm
previously described is fine tuned to accommodate and accurately analyze specific circumstances
and conditions a ligand-protein complex may have. However, these programs are often not wellsuited outside their intended function or calibration range. Further, while the specific cases for
which these methods have been attuned are studied extensively, proper implementation practices
are poorly defined. Consensus docking is the practice of combining more than one virtual
screening program with differing scoring functions to improve screening results in a
complementary fashion. However, all current approaches to consensus docking only utilize rigid
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docking methods (130–136). Constituent Partitioning (CP) consensus docking attempts to apply
docking protocols that specialize in determining pose prediction and scoring from more
encompassing physical properties (e.g. polarizabilty, receptor flexibility, solvent interaction, etc.)
and weighting the output of each simulation to yield more insight into individual protein-ligand
complexes. CP consensus docking with appropriate controls helps to resolve the optimal
algorithm to use without needing direct measurements of the complex being simulated.

Table 6. Interpretations of Binding Site Characteristics from CP Consensus Docking.
Docking
Procedure

Docking Scores
High Correlation

Low Correlation

SP

- Rigid site backbone
- homogeneous charge distribution
- Minimal hydrophobic and solvent
interaction

XP

- Significant hydrophobic environment
- Minimal site hydrophobicity
with hydrogen-bonding residues

IFD

- Induce fit upon ligand binding
- Flexible backbone site

QPLD
MM/GBSA

- Flexible site backbone
- heterogeneous charge distribution
- Significant hydrophobic and solvent
interaction

- No induced fit effects upon binding
- Rigid site backbone

- Highly charged site
- Homogeneous charge distribution
- Docked ligands highly susceptible to
- Docked ligands are not polarizable
repolarization
- Significant solvent interactions
- Highly flexible site backbone

- Solvent interaction minimal
- Low site flexibility

The first task is to identify control molecules with accurate, experimentally derived
binding affinities. From practice, approximately 8 – 12 compounds are sufficient for generating
linear regression statistics with the current degree of docking error, connoting a diminishing
return for larger numbers of controls. Additionally, a wide range of binding affinities is required
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(strong binders, moderate binders, and non-binders as decoys). After run each docking protocol,
a Pearson sample correlation function (Eq. 19) is applied to estimated free energies of binding
(Δ˚G) from the docking runs and the known experimental binding energies (Table 15 gives an
archetypal example of this).

n

∑ ( x i−⟨ x ⟩)( y i−⟨ y ⟩)
r xy =

i=1

√∑
n

√∑

(Eq. 19)

n

2

(x i−⟨ x ⟩)

i=1

2

( y i−⟨ y ⟩)

i=1

Where x i are the individual docking scores for each control compound, y i are the associated
experimentally derived energies, and ⟨ x ⟩ ,⟨ y ⟩ are the sample averages. If the experimental
binding affinities are given as a KD, they must be converted to Δ˚G (Eq. 20) as Eq. 19 is meant
for linear correlations.

o

Δ G=RTln(K D)

(Eq. 20)

Where R is the ideal gas constant and T is the temperature at which the experiments were run. r
has a value between -1 and +1 and the strength of correlation depends on experiment and number
of values used for correlation. For the following studies, a basic guide was developed where r >
0.9 was considered a very strong correlation, 0.9 > r > 0.8 was strong, 0.8 > r > 0.7 was
moderate, and r < 0.7 was deemed poor. The strength of correlation helps to infer protein
dynamics and binding characterizations needed to understand binding mechanisms, build better
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computational models, and increase accuracy and reliability of data from modeling by being able
to delineate sources of model error.
Model results with the higher Pearson correlation for controls are the optimal docking
protocols for that particular protein (Table 6). Strong correlations also imply certain postulates of
dominant binding site features. Proteins with rigid backbones, homogeneous charge distribution,
minimal hydrophobic interactions, and low potential for solvent intrusion in the binding site are
likely best described by SP docking (Section 1.3.6.1 SP and XP Docking). The same binding
site with a greater degree of hydrophobic enclosure would be better interpreted by XP docking.
More flexible sites require IFD (Section 1.3.6.2 Induced Fit Docking) and can still be simulated
under SP or XP scoring functions. Higher correlations under QPLD (Section 1.3.6.3 Quantum
Polarized Ligand Docking) demonstrate dependence on ligand repolarization upon binding.
These sites have more extreme charge distributions and will induce polarization on a susceptible
ligand. More non-polar ligands may not be as sensitive to electrostatically heterogeneous
environments, so some chemoinformatic metrics on the ligands being docked are important to
exclude the need for the higher computational cost of QPLD. MM/GBSA (Section 1.3.2.3
MM/GBSA) coupled with short MD runs is ideal for highly flexible binding sites with a
significant degree of possible solvent interaction since the Generalized Born and Surface Area
continuum solvation accounts for solvent effects without the need for explicit solvent molecules
over a trajectory. These methods combine to give a more detailed understanding of a protein
binding site. For the computational cost of a few dozen docking simulations, a commensurate
representative algorithm can also be deduced, helping to discard unnecessary calculations (See
Table 15 for an example). If a simplified rigid docking protocol is sufficient to predict binders,
then any further calculation is wasted effort. CP consensus docking improves the overall
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accuracy and performance of individual models, reduces the computational burden for drug
discovery projects, and provides unique mechanistic insight into binding dynamics for any given
protein.

1.3.7 Virtual Target Screening
Virtual Target Screening (VTS) is a system designed to virtually screen a molecule of
interest (MOI) to a large library of protein structures. The current protein library consists of
1,451 structures. The system is calibrated with a set of small drug-like molecules that are docked
against each structure in the protein library to produce benchmark statistics. VTS was originally
employed as a theoretical assay of potential kinase activity and gauge of potential biological
promiscuity. The calibration procedure allows the analysis to accurately predict inhibitor–kinase
binding affinities when KD < 10 μM (defining a hit) and KD ≥ 10 μM are both considered (72%
accuracy in the best case) (137). Therefore, the VTS system is able to robustly discriminate
protein binders from nonbinders and give some inclination as to potential binding promiscuity of
the molecule of interest with respect to the protein group tested.

1.3.7.1 Calibration. As stated previously, scoring algorithms are defined in a fairly
arbitrary manner. The ligand-protein complexes used as training sets to scale the output metrics
of these scoring functions carry over bias and are not diverse enough to span the continuum of
possible interactions. Four major echelons of increasing difficulty must be reached for a
molecule to be considered a hit:

1) Overcome the intrinsic thermal energy of water.
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2) Out-compete other random molecules for the binding site.
3) Displace the native binding partners of the binding site in question.
4) Optimize specificity for the binding site.

Additionally, for drug discovery at least, the affinity for which a ligand binds to a
receptor is not the most useful number. One of the more important characteristics that makes a
good drug is its ability to displace the natural ligand from the receptor, or apparent inhibition. If a
molecule has an impressive picomolar binding affinity, the compound’s relevance is nearly null
if the native ligand binds in the femtomolar regime (e.g. (stept)avidin-biotin or Ras GTP
binding). Conversely, an estimated KD of single digit micromolar is relatively substantial
compared to a biological effector affinity near the millimolar range (e.g. Neurotransmitters or
many kinase’s affinity for ATP). Further, if a binding site has a more generalized range of
binding partners (e.g. esterases and lactamases), the binding sites are adapted to be promiscuous
for more random types of molecules. Docking algorithms are unable to account for these general
cases that comprise a significant degree of protein binding modes. Therefore, to inter-compare
docking scores between disparate protein binding sites, a common metric must be developed to
properly renormalize the arbitrary scoring into a physically definable characteristic for each
individual protein binding site.
Our approach utilizes a diverse compound set to represent a random molecule binding to
a site and analyzing the ability of that site to discriminate between random compounds and
known binding ligands. Then, employing robust statistical analyses, create a universal ruler with
which to measure each protein binding site’s propensity to bind a random molecule. This
technique gives a lower bound on what a “good” docking score is for any particular binding site.
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There are certain caveats to this and are expounded on in the following section (1.3.7.2 Scoring
and Confidence Intervals). To further adjust docking scores toward differentiating between
moderate binders and potent inhibitors, the native ligand or known binder can be used a control
to renormalize and test if the algorithm is capable of yielding physically relevant results.
Coupling these two factors with Eq. 22 and the ligand specificity metric (Section 1.3.7.3 Ligand
Specificity) uniquely solves each separate issue mentioned above.
For calibration, each protein must be adequately prepared (Section 1.1 Preparation and
Best Practices for Modeling) and identify each possible binding site. A diverse set of molecules
is then docked to the site. The original prototype (137) used the NCI Diversity Set (138) for this
purpose. However, statistical analysis (Figure 1) showed poor diversity of the NCI diversity set
and led to developing a new calibration set based on a theoretical compilation of billions of
virtual chemical entities designed by Virshup et al (139). This small molecule universe (SMU)
set is superior since the compounds are only meant to probe the virtual site and should not biased
toward any existing chemical entity. High diversity of this compound list is also required to
properly sample as much of the possible chemical space within practical bounds. Figure 1 also
shows the far greater chemical diversity of the SMU set, prompting its use in current iterations of
VTS.
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Figure 1. Diversity analysis of SMU (Left) and NCI diversity set (Right). A Self organizing map
of 116 weighted chemical descriptors was computed. Each region is colored from red to blue
indicating the number of compounds in each sector. The number of compounds define in each
sector is also shown in the colored box. The distance between each mapped value is represented
by gray-scale connecting lines between the boxes with the scale legend on the bottom.
Calibration gives a relative lower bound on what docking score values should be
considered as a hit. However, further refinement may be needed for validation of binding metrics
beside estimated free energy of binding. The ability of a docking program to reproduce
crystallographic binding poses within thermal limits is also necessary. As such, pose evaluation
is also automatically performed if a co-crystallized ligand is detected. A 2Å average deviation is
expected from thermal fluctuations (Table 3) and is the commonly accepted threshold for
evaluating docking poses (140). A “self-dock” procedure is utilized where the co-crystallized
ligand is evaluated by the docking program. The following section (Section 1.3.7.2 Scoring and
Confidence Intervals) details the incorporation of self-dock metrics into the final VTS scoring.
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If reproducible literature values also exist for the control ligands, that information is
evaluated as well. However, the ongoing reproducibility crisis (141–145) is showing affect in
drug discovery as many biochemical assays performed throughout literature are consistently
found to be dubious and incorrect (146,147). Between the poorly understood severity of
molecular aggregation(148–151), limited standardization of assay protocols (152–155), and coequal treatment of surrogate species for human systems (156–158), most databases on
biochemical assay results are heavily contaminated with these unreliable results and are,
therefore, useless as a control. This issue has severely limited the use of statistically significant
sample sizes for assessing the physical application of binding energy estimations.
Following calibration and native ligand control analysis, the MOI is docked to each
processed protein in the library and the scores are related to the calibration metrics for final
scoring.

1.3.7.2 Scoring and Confidence Intervals. The original VTS prototype (137) relied on
qualitative measurement to relate the VTS calibration to the MOI. A comprehensive scoring
algorithm (Eq. 21) was created to evaluate MOI docking runs to protein grid database calibration
metrics in a quantitative and statistically robust manner. The functional is based on a weighted
average of confidence interval calculations derived from distribution regression analysis.

VTS_Score=
( VTS_SD)(SDME)(SD_CI)+(VTS_CDF)( VTS_CI)( VTS_Boltz)
F (x d_score )
(SDME)(SD_CI )+( VTS_CI)(VTS_Boltz)

[
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]

(Eq. 21)

The score is dichotomized into two primary weights, native ligand self-dock comparison and
VTS comparison, where each functional term is defined as follows (Eqs. 22-28),

x d_score−C H
1
F( xd_score )=1− π arctan
√ k BT

(

With x d _ score as the MOI docking score, C H

2

O

2

O

)

+

1
2

(Eq. 22)

as the heat capacity of bulk water (5.611

kcal/mol for 310K body temperature, 5.410 kcal/mol for 298K room temperature), k B as the
boltzmann constant, and T

as temperature. F ( x d _ score ) is a function intended to give a

confidence interval formulation for quantifying probability of binding when compared to the
inherent thermal energy distribution in bulk water. The expected distributions of MOI docking
scores are estimated as a Gaussian distribution with a documented error (114) of +/- 2 kcal/mol
average docking energy error taken as the standard deviation ( σGlide in Eq. 24). The thermal
energy distribution in bulk water is estimated as another Gaussian with the thermodynamic
resolution limit of k B T as the expected variance. Taking these two Gaussians as a ratio yields
the probability distribution of the MOI-protein complex remaining associated. This distribution
is also represented as a Cauchy distribution. Integrating the Cauchy distribution for the given
MOI docking score and heat capacity allows for a confidence interval to be calculated from the
density function (Eq. 22).

The self-dock docking score (SD_score) is the docking score from re-docking a cocrystallized ligand back into the binding site. This allows for control over normalizing both the
calibration set and docking algorithm performance with respect to a known binder. The Self60

Dock Confidence Interval (SD_CI, Eq. 23) is the normal cumulative distribution function giving
the confidence interval of the self-dock ligand having a better (In this case, a more negative
estimated binding energy) expected docking score than the calibration set.

2

SD_Score

SD_CI=1−

∫

−

1
σ p_cal_total √2 π

−∞

e

(τ−μ p_cal_total )
2

2 σ p_cal_total

∂τ

(Eq. 23)

Where μ p _ cal _ total and σ p _ cal _ total are the and average and standard deviation of calibration set
docking scores for a particular target, respectively. Both of these values are derived from Figure
2 (mu = μ p _ cal _ total , Sigma = σ p _ cal _ total ). If the SD_CI is insignificant, the docking
algorithm is not adequate for reproducing proper controls for that particular protein-ligand
complex and the weighted average will only rely only on the calibration set.

For defining a probability that a MOI docking score lies outside the calibration
expectation range, the average calibration set docking scores for each individual target protein
binding site are averaged and fitted to a normal distribution (Figure 2 and Eq. 24).

x d_score

VTS_SD=1−

∫

−∞

2

−

1
σ Glide √2 π

e

( τ−SD_Score )
2
2 σGlide

∂τ

(Eq. 24)

The VTS Self-Dock comparison score (VTS_SD) sets a lower bound on the minimum
docking score for a MOI to be statistically relevant. An interesting note is that the average
calibration docking score average (mu in Figure 2) is slightly lower than the average thermal
energy of water (~5.5 kcal/mol) and the standard deviation (Sigma in Figure 2) is near k B T
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(~0.593 kcal/mol at 298K). This may imply some emergent evolutionary cutoff for protein
binding sites to assist in selection of the intended native ligand, using the inherent thermal energy
of water to prevent non-specific molecules from binding.

Figure 2. Gaussian distribution fit of calibration set average docking scores.

Standard deviation of calibration set docking scores on a target protein binding site can
be used to evaluate the expected error intrinsic to the binding site (Eq. 25).

σp_cal_total

VTS_CI=1−
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(Eq. 25)

Where σ σ

p_cal_total

is the standard deviation of standard deviations. This variance analysis is

normally handled by a χ 2 distribution (159). However, the probability density function needed
for a confidence interval of a χ 2 distribution has no simple forms. Therefore, estimation with a
log-normal distribution is preferred and found to be an acceptable approximation (160). The VTS
Confidence Interval (VTS_CI, Eq. 25) is then calculated from fitting the calibration set docking
score standard deviation to a log-normal function (Figure 3), allowing for estimation of
expectation values, or likely range of scores, for the protein binding site. If the standard deviation
of calibration set docking scores is too high compared to average values (mu in Figure 3), then
the VTS algorithm is not capable of discriminating between random molecules, control ligands,
and MOIs due to high variance in the associated docking scores. This term drops the relevance of
calibration set comparison in the final scoring (Eq. 21).
The Self Dock Mean Error (SDME, Eq. 26) is used to calculate the difference between
the native ligand re-dock pose and the crystallographic pose and relate it to a confidence interval.

(

SDME=

RMSD
RMSDmin

−1.363

)

(Eq. 26)

Where RMSD is the calculated root mean squared deviation of the native ligand re-dock pose
from the crystallographic pose and RMSDmin is the minimum cutoff for evaluating docking poses
estimated at the commonly accepted threshold of 2Å (140). The exponent is determined from a
power-law distribution fit of Self-Dock RMSD values (Figure 4). Eq. 26 is a simplified
approximation for obtaining a probability distribution of the associated power law (161). For
obvious reasons, if the SDME is insignificant, then the docking algorithm is not able to
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reliability reproduce physical data and results in the weighted average, VTS_Score (Eq. 21), to
rely only on calibration data.

Figure 3. Log-normal distribution fit of calibration set standard deviations.

Testing if the calibration set top score distribution has better docking energies than bulk
water helps to assess if the VTS scoring method is even relevant to the target protein binding
site.
x 2.5σ −C H
1
VTS_Boltz=1− π arctan
√k B T
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(Eq. 27)

Eq. 27 is the same form of Eq. 22 with x 2.5 σ as the top 1.24% of calibration molecule docking
scores. Top scores are defined by the most negative docking energies. The percentage was made
64

to closely approximate the top 20 and top 200 metrics and Boltzmann factoring (VTS_Boltz)
used in the original VTS prototype (137). If the VTS_Boltz score is too low, the the weighted
average, VTS_Score (Eq. 21), will rely primarily on self-docking.

Figure 4. Power law distribution fit of self dock RMSD.

The primary VTS metric is comparing the MOI docking score to calibration set average
docking score. This is done by integrating over the normal distribution of calibration scores
evaluated at x d _ score which is the MOI docking score. This produces a confidence interval from
the cumulative distribution function of MOI docking scores compared against the calibration set
(VTS_CDF, Eq. 28).
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VTS_Score is then defined as the certainty of a “hit” with scores between 0, defining a
model with absolutely no predictive value, and 1, perfect predictive model fit. The confidence
interval method is used to provide an intuitive measurement of the likelihood a MOI will bind to
a target protein with an arbitrary cutoff of estimated binding affinity. The cutoff used for this
work is 10 μM KD or -8.505 kcal/mol at 310K (Eq. 20). A VTS_Score of 0.95 will correspond
with the estimated binding affinity required to define a hit for a particular target being -8.505
kcal/mol at 310K, indicating an approximately 95% chance that the MOI will bind with a 10 μM
KD or less. This corresponds closely with a prediction interval of 2σ. Increasing the cutoff can
help decrease the false positive rate while sacrificing true positives.

1.3.7.3 Ligand Specificity. The VTS protocol has many diverse applications in
biochemistry and drug discovery efforts. One of particular promise is the possibility for assessing
a ligand’s effectiveness to exclude binding to diverse protein sites. This Ligand Specificity (LS)
analysis can be used to infer the promiscuity of a MOI and related compounds. Even with a
limited subset of proteins in the prototype library, the capacity for a ligand to differentiate
binding pockets can be quantified. Fitting the final VTS score of a MOI from each protein to a
beta distribution (Eq. 29) allows the estimation of the mean (Eq. 30) VTS_Score for that MOI.

f ( x ; α ,β)=

Γ (α+β) α−1
x (1−x )β−1
Γ (α) Γ (β)

(29)

Where Γ is the gamma function, and α and β are the shape parameters to be fitted. The
expectation value, E[ X ] or LS, is defined as follows,
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LS=E[ X ]= α
α +β

(30)

Since the VTS scores are between 0 and 1, the expectation values for the beta distribution are
also between 0 and 1. 0 is defined as a ligand being perfectly specific and 1 is defined as
perfectly promiscuous, or binding all proteins with equal affinity. This measure can give
significant information about potential off-target effects and understanding about the degree of
biological selectivity for certain chemical compositions. Unfortunately, testing this parameter has
been hampered by poor accounting of aggregation-based promiscuity in most chemical databases
(148–151). The ligand specificity described here pertains to potential inherent non-specific
binding motifs in chemical space, as opposed to colloidal aggregation. As such, obtaining a
significant number of high quality binding data against a large number of biochemical targets
controlled for aggregation to test the LS metric has proven untenable so far.

1.3.7.4 Enzyme Selectivity. The ability for an enzyme to select a single specific
molecular substrate amidst a sea of similar chemical entities is often considered absolute.
However, many enzymes have been known for sometime to bind and catalyze many different
substrates and reactions. Some early examples of non-selective enzymes are chymotrypsin (162),
pepsin (163), L-asparaginase (164), pyruvate decarboxylase (165), and carbonic anhydrase (166).
Continued testing and characterization of proteins has slowly started to erode the old notions that
protein binding sites are optimized through billions of years of evolution to recognize one, and
only one, substrate (167). Our work on VTS has also shed unexpected light on this phenomenon
of enzyme promiscuity toward substrate binding. Since the process of binding site calibration
essentially exposes the site to a wide degree of chemical scaffolds, it is useful in characterizing
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the site’s selectivity. The variance calculated from Eq. 25 yields an expected range of scores for
all protein binding sites in the database. Figure 3 shows that most proteins are capable of binding
only a small range of molecules, though many appear to be highly promiscuous. A simple fit to a
normal distribution for each site generates an expected range of scores through estimation of
standard deviation (Figure 5).
A wider distribution, or larger standard deviation, of docking scores indicates that a
binding site can interact strongly with a broad range of chemical space, implying a limited ability
for a site to discriminate between a variety of molecules. A thinner distribution with a small
standard deviation demonstrates the site’s ability to discriminate against random molecular
topologies, relating a higher selectivity for a specific molecular entity. This metric enables VTS
to assess the target’s druggability. If a target is inherently promiscuous, it is likely not amenable
to specific drug targeting and is, therefore, a weak candidate for drug discovery efforts.

1.3.8 Homology Modeling and Protein Folding
Homology modeling refers to regenerating the three-dimensional structure of a protein
from the constituent amino acid sequence using known experimental structures of homologous
proteins. Also known as comparative modeling or template-based modeling, homology modeling
can be helpful when no other structural data exists as this structural information is vital in the
study of protein function, dynamics, and understanding interactions with ligands and other
proteins. The low-resolution structure predicted by homology modeling can contain useful
information about spatial arrangements of important residues in a protein and may help guide the
design of new experiments or structure identification, such as site directed mutagenesis.
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Figure 5. Representative normal distribution fits of calibration set docking energies. Example of
a highly promiscuous binding site (Top) and a relatively selective on (Bottom). Distribution fits
marked as red line.
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Obtaining structural data is not a trivial task and can be prohibitively difficult to solve
experimentally, even taking decades to solve the structure of one protein. This process can be
hindered by the difficulty of obtaining enough material through cloning, expression, and
purification of milligram quantities of the protein, and difficulties associated with crystallization,
such as post-translational side chain modifications and optimizing salt, pH, and temperature
conditions. As it stands, genetic sequence determination far exceeds experimental structure
determination and this gap will likely only grow. This presents a demand for faster
computationally based approaches, though, substantial research in this area has yielded limited
progress.
Current research and modeling techniques of ab initio quantum mechanical or classical
MD simulations studying the prediction of protein structure from sequence alone consistently
yields poor results (168). For QM, the computing power required to simulate even the smallest
proteins is often untenable and must neglect environmental factors such as protein chaperons,
membrane interaction, interactions with ribosome, and other numerous folding factors. While
MD is computationally cheaper than QM, folding timescales are much longer than most feasible
simulation timescales (see Table 3) for proper statistical sampling. Furthermore, current MM
force fields are not sufficiently accurate for reproducing known folds; even lower and mid level
QM are inadequate to the task. Chemical bonds and metal coordination are also difficult to
mimic in a simulation, but are obviously required in real folding processes. Finding simpler
physics-based rules that predict protein structure by looking at patterns of hydrophobic,
hydrophilic, or charged amino acids has also been attempted for some time, albeit with little
success (169,170).
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Out of this disappointing imbroglio, some basic knowledge-based methods have emerged
using a felicitous quirk in evolution that proteins with similar sequences tend to be homologs,
evolving from a common ancestor (171). The fold of the protein also tends to be conserved
during evolution; even some proteins with only 15% sequence identity can have similar
structures. To this end, well over 100,000 protein structures have already been solved and that
information could be used to help predict new structures. This is where template-based modeling
(homology modeling) is used when one or more likely homologs of known structure can be
identified. Ab initio structure prediction, or “de novo” prediction, is still needed if no homologs
exist, but these approaches also take advantage of available structural data in subtler ways.
The sequence identity to the template structure and the quality of the sequence alignment
are the major factors impacting the quality of a homology model. Gaps in alignment, commonly
called indels, are an extensive complication that indicate a structural region present in the target
does not appear in the template. Structure gaps in the template can also occur, caused by poor
resolution in the experimental structure or when a deletion or insertion mutation exists in a
solved structure introducing serious local errors (172). The use of multiple templates, referred to
as composite modeling, can help alleviate some of the issues arising from gaps, but the differing
local structures of the template around the gap and high probability of a missing region in one
template also being absent from other structures in the same protein family complicate this
method (173). Gaps are most common in loops where the difficulty of experimentally resolving
the region greatly increases due to high local flexibility. Although some guidance can be
provided from other templates, the longer the gap, the less accurate the model. Smaller gaps can
be modeled with reasonable accuracy provided the local alignment is correct. Gaps beyond 8 or 9
residues require ab initio structure prediction techniques which do not often increase model
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accuracy enough to afford the computational cost (174). The quality of a model also declines
rapidly with decreasing sequence identity. At around 70-80% sequence identity, the RMSD
between matching Cα atoms for a typical target is about 1-2Å, enough to start reversing dihedrals
and impacting loop structures (See Table 3). This is still within normal crystal structure
resolution. Yet in loop regions where the amino acid sequences of the target and template
proteins may be completely different, errors are significantly higher. At 25% sequence identity,
there is only a 3-4Å agreement at best (175). This is where crystal structures become unreliable
as positional data accuracy for core domain residues deteriorates and information on loop
structures is completely lost (see section 1.1.2 X-Ray Crystal Structure Resolution).
All said, homology models are useful for initial alpha carbon placement of key residues
in folded proteins, assisting mutagenesis experiments, and forming hypotheses on structurefunction relationships. Further, there has been significant progress in structure prediction over
the last few decades due to improved algorithms and increased coverage in experimentally
determined structural databases. Some of the most success is seen in GPCR receptor
pharmacology and analysis of other transmembrane proteins that are notoriously difficult to
resolve through experiment (176).
Unfortunately, even the latest accuracy benchmarks fall far short of experimental
standards. The Critical Assessment of protein Structure Prediction (CASP) is a bi-annual,
community-based competition for predicting protein structures that has been held since 1994
(177). CASP uses a Global Distance Test (GDT) metric that is analogous to RMSD, but isn’t
influenced as much by outliers (178). As such, GDT tends to be much more forgiving than
RMSD resolution standards. According to the latest CASP review (179), the most accurate
homology models still struggle to achieve over 80% correct alignment on average for even the
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simplest structures. For CASP, correct alignment of a modeled residue is when the predicted side
chain’s Cα is less than 3.8Å from the corresponding experimentally derived residue position after
optimal superpositioning. This is comparable to practical experimental cutoffs of 3-4Å described
previously.
Homology models to date are ultimately unreliable in predicting conformational shifts
induced by insertions or deletions or proffering any details of side-chain orientation. This issue
discourages the use of homology models in ligand docking or drug design unless the sequence
identity with the template is greater than 80% with at least 90-95% homology in the binding site.
Even at this point, homology models are still considerably less reliable than an empirical
crystallographic, NMR, or other experimentally derived structure. Moreover, at very high
sequence identities, >95%, as many as one in ten models have an RMSD greater than 5Å
compared to the empirical structure (20). Therefore, while the accuracy of predicted structures is
increasing slowly but steadily, the issues associated with accurate refinement methods, sequence
alignment, and template identification, still prevent a wider embrace of homology models in
general research. Despite current difficulties, structure prediction is and will be even more
critical in the future, demanding continued research by dedicated experts.

1.4 Informatics
Informatics involves the practice of information processing and the engineering of
information systems to transform data, information, and knowledge into more useful or readable
applications. Informatics and its various sub-disciplines are worth a book on their own and this
section is only a very simplified discourse denoting some aspects relevant for the audience or
referral to other chapters.
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The most basic form of informatics involves storing and categorizing data. There exist
numerous and wide ranging databases for biochemistry from the RCSB PDB repository for
protein structures to PubChem (180,181) and ChEMBL (182–184) that serve as databases for
chemical compounds and their associated biochemical activities in various assays. The next tier
of informatics is to use this data by translating the language of chemical and biological results
into a form machines can understand by way of machine learning, pattern recognition, regression
analysis, and so on for designing and refining models widely applied in science, business, and
government. This data mining can change the point of view of complex interactions, fortifying
the quality of knowledge in any field and expanding its scope into others. Subsections of
discipline specialized informatics include cheminformatics and bioinformatics that are highly
beneficial to biochemistry.

1.4.1 Cheminformatics
Cheminformatics attempts to reduce the dimensionality of chemical space through
characterization and categorization of molecular properties, pharmacokinetics, structure activity
relationships, and pharmacophore modeling. Millions of compounds can be screened in seconds
through substructure matching and fingerprint-based similarity searches with clustering and
diversity selection to improve real and virtual compound libraries. Supervised learning
techniques coupled with self-organizing maps that help reduce complexity, along with high
dimensional information and principal components analysis, can produce quantitative models for
structure-activity relationships and provide insight into new compound formulations. Programs
that can computationally predict properties such as pKa, water solubility, intestinal absorption,
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plasma-protein binding, etc. directly related to the biological effect of a drug and its subsequent
metabolism, referred to as ADME-tox, are greatly valued in medicinal chemistry.
Canvas (185–187) is a user interface specific to chemoinformatic processing developed
by Schrödinger. Chemistry Development Kit (CDK) (188,189) is an open source software
alternative developed with the Java programming language for bioinformatics and
chemoinformatics applications. These applications can computationally assay ADME-tox, yield
chemical similarity metrics, and build pharmacophores and structure activity relationships (SAR)
from experimental data, as well as many other precise functions. SAR prediction assumes that
similar molecules will have similarity activities, therefore, once a standard curve is perfected
from empirical data, only chemical similarity fingerprints are needed to predict binding affinity.
Quantitative structure-activity relationships (QSAR) go another step further in addressing the
supposed connection between chemical structure and biological activity by including additional
theoretical descriptors of physio-chemical properties (163). While these metrics are invaluable,
computational efforts in accurately assessing ADME have been fraught with difficulty (191,192).
In addition to requiring substantial amount of rigorous data to build reliable models, ADME and
SAR prediction software algorithms are minimally based in physical law and are and are
notorious for misleading end‐users with contradicting results. Overall, in silico approaches still
largely lack the required predictability to fully engage their use in drug discovery (193).

1.4.1.1 Pharmacophore Modeling. Pharmacophore modeling utilizes a course-grained
three-dimensional mapping of electronic and steric aspects of a biological target to inform and
rank the fundamental molecular interactions required for ligand binding. A pharmacophore
model attempts to reduce the essential features of the receptor or SAR down into simpler sub-

75

space definitions such as hydrophobic centroids, aromatic rings, hydrogen bond acceptors or
donors, cations, and anions (194). Robust models can screen libraries consisting of millions of
small compounds withing hours or even minutes with varying precision. The molecules in these
screening libraries are preprocessed to be in the lowest energy, bio-relevant form. This does
impose some additional bias to the procedure, trading accuracy for speed (195). Each
conformation is then fitted to the pharmacophore query by attempting to align the predetermined
pharmacophore features of the target to the molecule. The pharmacophore query uses spheres to
estimate optimal influence. If the essential features of a molecule fit in the spheres, the molecule
is considered a hit. Partial matching can also be implemented if the query is found to be
excessively complex for matching a given library by defining fewer features deemed more
critical for binding.
Depending on what information is used to generate the model, ligand-based or structurebased pharmacophore are two methods for generating a model. The Schrödinger program Phase
(196–198) can used to implement either strategy. If no empirical structure exists for a protein
target, a ligand-based pharmacophore model is an indispensable tool for a drug discovery
campaign. This strategy searches for the common chemical characteristics between many ligands
with conclusive experimental binding data to extract the principal interactions requisite for
binding to the target. Conversely, structure-based methods rely only on mapping critical binding
features from the protein binding site directly. This type of model probes the site through various
means, including fragment based docking and steric mapping, to generate a pharmacophore
query. Despite the low resolution of the method, the pharmacophore approach is useful in rapidly
generating potential hits to be followed up with more rigorous modeling and experiments.
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1.4.2 Bioinformatics
Bioinformatics assists in combing genome, proteome, and metabolic data with specially
designed methods and software tools for analysis and interpretation of immense biological
databases. An inherently interdisciplinary field, bioinformatics incorporates mathematics and
statistics with biology and computer science. There are many disparate bioinformatics software
that focus on different divisions of cellular function.
For genome centric applications, sequence and structure analysis tools like EMBOSS
(199) and clustalw (200) are useful for genetic sequence alignment, rapid database searching,
and motif and domain analysis.
On the proteome level, many . With respect to structural information, the Protein Data
Bank (PDB) is the definitive worldwide repository of large biological molecule 3D structures,
including nucleic acids and proteins (7,8). For protein sequence alignment and database
searching, FASTA (201) is the most widely used format in bioinformatics, using local alignments
to a collection of fragments for similarity searches. BLAST (202–205) (Basic Local Alignment
Search Tool) is another ubiquitous searching tool for perform fast similarity searches of proteins
or DNA.
The domain of metabolic space encompasses all of the aforementioned branches,
rendering an extreme complexity of subject area. As such, few programs are capable of spanning
this discipline with any significant effect. Metacyc (206) is a curated database dedicated to
studying metabolic pathways and the associated enzymes and metabolites and includes tools for
database searching and limited pathway perturbation.
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1.4.3 Best Practices in Statistics
Chemoinformatics and bioinformatics are relatively new fields referring to a novel
branch of science straddling the traditional domains of biology, chemistry, and informatics.
These discipline specific informatics attempt to exploit chemical and biological data by the
creation and application of information-based methodologies. Therefore, the effective use of
informatics in these domains necessitates a sound mastery of their underlying mathematical and
statistical principles. First, an understanding of what is being measured is needed. Populations
are difficult to measure in their entirely, so often smaller subsets are sampled to simplify
experiments and are used to extrapolate details about the whole population. Separate and distinct
quantities arise to describe the population itself versus the quality of its sample. The most
common methods applied are the mean, median, and mode of a sample. These three quantities
help approximate the values expected of the dataset distribution, but are not in any way
interchangeable except in unique distributions rarely seen in any dataset and great care must be
taken to understand which quantity should be used for minimal ambiguation. Other statistics
characterize the spread in values of the dataset elements. Standard deviation is the square root of
the variance, or mean squared deviation from the sample mean, and is the more useful
descriptive quantities for understanding spread in a population dataset. Standard error, standard
deviation divided by the number of samples, is only appropriate when discussing the quality of a
sample (i.e. the expected deviation of a sample’s mean from the population’s true mean) and says
nothing useful about the population distribution. Standard error will always be less than the
standard deviation and is a common misleading statistical abuse to show smaller experimental
error or significance. Standard error discusses error in a single experiment, whereas standard
deviation discusses error across multiple independent experiments.
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Statistics are intended to make data easier to understand but are often used in a
misleading fashion in an attempt to trick the casual observer into believing something other than
what the really data shows. Most misuses are not done intentionally and, without any formal
background in statistics, can easily happen. Professional scientists, even statisticians and
mathematicians, can be fooled by simplified or improper methodology, despite careful review
and proofreading. Scientists have been regularly known to delude themselves with statistics
stemming from a poor understanding or education of probability theory and a lack of testing
standardization (141–145). Misuse of statistics can be come from many directions including
discarding unfavorable data (i.e. cherry picking), overgeneralization with poorly representative
sample sets, sample bias, inappropriate estimation of error (e.g. using standard error instead of
standard deviation), false causality, and confusing statistical significance with practical
significance (152). First and foremost, remember that statistical methods are based on many
assumptions which are seldom fully met. An automatic skepticism of results and conclusions is
mandatory in science and best practices should always include careful experimental planning,
data analysis, drawing logical conclusions, and thorough reporting. Either by intent, or through
ignorance or carelessness, statistical fallacies are highly destructive.

1.5 Summary
This chapter has been intended to provide a quick overview of general technologies,
methods, and best practices for computational modeling to individuals who may be new to the
discipline. Further reading into any of the described methodologies is greatly encouraged. The
techniques described in this chapter are largely focused on drug discovery and biochemistry, but
can be employed in many fields of study.
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A general list, but by no means exhaustive, of popular software that has a comprehensive
range of molecular modeling programs is provided below (Table 7). Commercially available
software tends to be marginally superior in accuracy and efficiency compared to free or opensource software but differs most in ease of use or access to a larger range of inter-compatible
modeling methods. CHARMM and Schrödinger are some of the best in this area, however,
Schrödinger software is far more expensive. CHARMM, on the other hand, requires more third
party software and significant understanding of the underlying code and UNIX operating systems
to access the program’s full potential. Nonetheless, anyone can pull together a comprehensive
modeling platform from individual open-sourced programs with enough study and persistence.
Further, each tool possesses their own pros and cons, resulting in no single modeling program or
methodology being superior in every aspect compared to others. As such, any individual should
learn as many different techniques and softwares as possible to ensure success in any modeling
endeavor.
Due to the versatile, comprehensive, and integrated nature of its software, as well as
available licensing, the majority of this work was based on Schrödinger programs. This
introduction centered around the establishing the theoretical framework for the next three
chapters, which focus on practical application of the aforementioned molecular modeling
techniques in drug discovery projects.
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Table 7. Software for computational modeling
DFT

SemiEmpirical

Yes1

Yes

Yes

Yes2

Yes1

Yes1

Yes

Yes No

No

Limited

No

Limited

Yes2

Yes Yes

No

Limited2

No

No

Yes

Yes

Yes No Limited2

No

No

No

Open Source

No

No

Yes Yes

No

NWChem

Commercial

No

No

Yes No

Yes

Yes

Yes

Yes

Q-Chem

Commercial

No

No

No No

Yes

Yes

Yes

Yes

a

Yes

Yes

Yes Yes

Limited

Yes

Yes

Yes

Program

Model
QM
MD MC
QM/MM
Builder
(Post-HF)

License

Viewer

Freea

No

Yes

Yes No

Yes

CHARMM* Commercialb

Yes1

Yes

Yes Yes

GROMACS

Open Source

No

No

LAMMPS

Open Source

Yes2

MOE

Commercial

NAMD

AMBER*

Schrödinger* Commercial

Limited Limited2

Yes2

YASARA
Commercialb Yes
Yes Yes No
No
No
No
Yes
* Program consists of many individual and possibly separately licensed and developed softwares
1
Requires separate modules not included in primary program
2
Has interface for required third-party software
a
Some software modules have license restrictions
b
Limited access or downgraded free version available
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2 The Atypical Protein Kinase C Small Molecule Inhibitor ζ-Stat, and Its Effects on
Invasion Through Decreases in PKC-ζ Protein Expression
2.1 Introduction
In 2019, it is estimated that approximately 1.7 million new incidences of cancer will be
diagnosed and 600,000 cancer deaths will occur (207). Cancer has become the leading cause of
death in 21 states, despite decreases in cancer death rates since 1991 (208). Specifically, ovarian
cancer is estimated to reach 22,530 diagnoses and cause 13,980 cancer deaths per year (207).
This constitutes 5% of cancer deaths among women and is responsible for being the most lethal
gynecological cancer diagnosis (209).
The most common ovarian cancer diagnosis is epithelial ovarian carcinomas (EOC),
which constitutes 85-90% of diagnosis (209). Of this percent, clear cell ovarian carcinoma
(CCOC) represents 5% of incidence and presents unique pathological features and a chemo
resistant phenotype (210,211). CCOC is the third most common subtype of ovarian cancer, has a
higher risk of reoccurrence, and lower survival rate (210). Furthermore, CCOC is characterized
as a non-serous (NS) ovarian cancer and has been found to be more invasive than high grade
serous ovarian carcinoma (HGSOC). It has been found that patients with NS tumors have poor
prognosis (212). Consequently, CCOC is proposed to be associated with endometriosis and it has
been suggested that the pre-cancerous lesions from endometriosis can lead to CCOC (relative
risk = 12.4) (213). Endometrial cancer and CCOC have been shown to have an overexpression of
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Protein kinase C (PKC) isoforms which play important roles in these cancers development and
resistance (214).
Protein kinase C (PKC) is an enzymatic family of proteins that have been found to be a
component in cancer progression (215). These proteins phosphorylate the serine and threonine
residues of substrates and are generally activated by compounds such as diacylglycerol (DAG),
calcium (Ca2+) and phorbol esters (215). There are three classifications within the PKC family
which include the conventional PKC-α, βI, βII (splice variant), γ, the novel PKC-δ, ε, η, θ, and
the atypical PKC-ζ, ι/λ (215).
The atypical PKC isoforms, PKC-ι and PKC-ζ, have been suggested to participate in the
increased proliferation of ovarian cancer (216). PKC-ι has also been identified as a highly
amplified gene in CCOC (210) and is noted for its role in apical-basal polarity loss (216). In
addition, due to mutations in the PIK3CA gene and inactivation of Phosphatase and Tensin
Homolog (PTEN), the Phosphoinositide 3-Kinase (PI3K)/ Serine Threonine Kinase 1 (AKT)/
Mechanistic Target Of Rapamycin Kinase (mTOR) pathway has also been upregulated in CCOC
(211,217–219). The upregulation of this pathway increases the expression of downstream
survival targets (e.g. PKC-ζ). PKC-ζ has been shown to be involved in tumorigenesis, tissue
invasion, and cancer progression through the modulation of cell migration machinery, such as
Ras Homolog Family Member A (RhoA), Rac Family Small GTPase 1 (Rac1), and Epithelial
Cell Transforming 2 (Ect2) (220–222).
The ECT2 gene is highly amplified in CCOC and may increase migratory behavior (210).
Ect2 is a Rho GTPase specific guanine nucleotide exchange factor (GEF) which activates this
family of proteins by the addition of a phosphate group to Guanosine diphosphate (GDP) (223).
The overexpression of Ect2 protein promotes increased activation of the Rho GTPases, which in
turn can facilitates invasion through cytoskeleton reorganization (224).
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Previous studies have indicated that novel aPKC inhibitors ICA-1S and ζ-Stat (Figure 6)
decreased the migratory behaviors of colorectal cancer cells and were selective for PKC-ι/λ and
PKC-ζ, respectively (222,225). These small molecule inhibitors were also shown to decrease cell
viability in colorectal cancer and melanoma (222,225).

Figure 6. Atypical PKC inhibitors. The molecular structures and molecular weights of ICA-1S
and ζ-Stat. ICA-1S was synthesized by United Chemistry Resources and ζ-Stat was distributed
by the NCI.

Furthermore, computational molecular docking was performed on PKC-ι and a homology
model of PKC-ζ (since there is no crystal structure available) with ICA-1S and ζ-Stat (225). In
this study, the authors suggested that ICA-1S bound to a potential allosteric pocket (225).
However, a more in-depth analysis of ζ-Stat is needed for subsequent studies. The further
development of computational modeling is pivotal for drug discovery optimization and helps
push these small molecule inhibitors towards a clinical setting. Computational studies can
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generate mechanistic understandings of the activity these compounds present, can allow for
inhibitor improvement, and can institute further signaling investigations.
It has been suggested that the distal downstream signal cascade of PI3K/aPKC pathway
should be targeted due to the genotypic and phenotypic reliance of this pathway in CCOC for
survival and invasion. The aims of this study were to further determine the binding mechanisms
of ζ-Stat, expand on the tissue range of these compounds by investigating the effects in CCOC
cell lines, investigate the therapeutic potential of ζ-Stat in CCOC, and to illustrate the disruption
of invasion via the PKC-ζ signaling cascade.
2.2 Materials and Methods
2.2.1 Antibodies and Reagents
The small molecule inhibitors, ζ-Stat and ICA-1S, were obtained from the National
Institute of Health (NIH) branch National Cancer Institute (NCI) and United Chem Resources in
Birmingham Alabama, respectively. The sources of cell lines, reagents and antibodies were:
TOV21G and ES-2 CCOC cell lines (American Type Culture Collection, USA); SHT290 normal
endometrial stromal cell line (Kerafast, USA); MCDB 121, Media 199, F12K, penicillin and
streptomycin, trypsin, Dulbecco’s phosphate buffered saline (DPBS) and Mito + (Corning,
USA); McCoy’s media (HyClone, USA); Opti-MEM I (Gibco, USA); Fetal bovine serum (FBS,
Atlanta Biologicals, USA); human insulin (MP Biomedicals, LLC, France); dimethyl sulfoxide
(DMSO, Sigma Aldrich, USA);

Water-Soluble Tetrazolium (WST-1, Roche, USA); Halt

protease and phosphatase inhibitors cocktail and Protein A/G magnetic beads (Thermo Scientific,
USA); anti- PKC-ζ (9372s, 1:1000, Cell Signaling, USA); anti- PKC-ι (610178 1:1000, BD,
USA); anti-β-actin (A3854, 1:40000, Sigma Aldrich, USA); anti-RhoA (ab54835,1:4000,
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Abcam, USA); anti-Ect2 (07-1364, 1:1000, Millipore, USA); Donkey anti-rabbit IgG Alexa-488
(A21206, 1:500, Invitrogen, USA) ; Goat anti-rabbit (170-6515, 1:2000, Bio-Rad Laboratories,
USA); Goat anti-mouse (170-6516, 1:2000, Bio-Rad Laboratories, USA); Activated Rac1
pulldown kit (BK035, Cytoskeleton, USA); 96-well transwell insert and basement membrane
extract (BME; both Corning Inc., Corning, NY, USA); RNA bee (Amsbio, United Kingdom);
Qiagen RT Kit ( 205113, Qiagen, Germany); RhoA PCR primers (HP100025, Sino Biological,
USA); Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) PCR primers (Eurofins, USA)
2.2.2 Analysis of Somatic Gene Mutations For Ovarian Cancer, CCOC and CCOC
Cell Lines
The selection of CCOC cell lines employed the COSMIC database (226). Initially, the
search was focused on all ovarian subtypes in the database. The search was then re-focused on
clear cell carcinomas. Furthermore, the COSMIC cell line project was utilized for the analysis of
mutations in TOV21G and ES-2 cells (226).
2.2.3 Computational Analysis of aPKCs
2.2.3.1 Protein Preparation. Protein model systems for PKC-ι and PKC-ζ were prepared
using the Schrodinger software suite (25). Protein structure coordinates were downloaded from
the Protein Data Bank (PDB) (227,228). The PKC-ι model was generated from the PDB 3A8W
entry co-crystallized with adenosine triphosphate (ATP) (229). The apo structure, PDB 38AX,
was used to cross reference conformational states from Molecular Dynamics (MD) simulations.
No crystal structure currently exists of PKC-ζ, necessitating the need for homology modeling to
attempt to produce a potentially viable docking model for PKC-ζ. Two PKC-ζ models were built,
one utilizing SWISS-MODEL (19,20,230) and another employing the Prime homology program
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(16,66,67) using the human PKC-ζ sequence (UniProt Q05513) and the crystallized PKC-ι
structures as templates. PDB systems were prepared with the Protein Preparation Wizard
(PrepWizard) in Maestro (231,232). Cofactors used in crystallization (such as sulfate or
phosphate ions), ligands, and additional protein dimers were deleted. Bond orders were then
assigned, including disulfide bridges, and original hydrogens were deleted and later replaced to
reduce bad contacts and other crystal artifacts before protonation and hydrogen bond
optimization. All waters were retained for assisting in the determination of side chain protonation
states and initial hydrogen bond optimization. Missing side chains were added and optimized
using Prime. Hydrogen atoms were then added to the protein, remaining cofactors, and to any
added structural waters. The program PROPKA (50) was used for the prediction of protein
ionization states at 7.4 pH and ProtAssign was used for hydrogen bond optimization. After
automatic hydrogen assignment, visual inspection was used to flip residues and change
protonation states at protein-protein interfaces if and when appropriate.
2.2.3.2 Molecular Dynamics. MD simulations were performed with the Desmond MD
program (233–236). A cubic simulation box was created extending at least 10Å from the protein
with imposed periodic boundary conditions. TIP3P waters (237) were added to solvate the
simulation box and was then electrically neutralized by introducing sodium ions. The OPLS-3
all-atom force field (34) was then applied to all atoms. The SHAKE algorithm (238) was used to
constrain all bonds in the system and the REference System Propagator Algorithm (RESPA)
(239) with an integration time step of 2 fs was employed. The Particle Mesh Ewald (PME)
algorithm was used to calculate long-range electrostatics with a real-space cutoff of 13 Å. Van
der Waals interactions were cutoff at 16 Å. The systems were simulated in an NPT ensemble
using the Nose−Hoover temperature coupling scheme (240) at a temperature of 310 K and a
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constant pressure of 1 atm using the Martyna-Tuckerman-Tobias-Klein (MTTK) barostat
(241,242).
All systems were energy minimized with a truncated newtonian conjugate gradient
(TNCG) method (243) followed by multiple restrained minimizations to randomize systems
before equilibration and final simulation. Heavy atoms of the protein were held fixed during
heating for an initial 12 ps NVT ensemble simulation at 10 K with the Berendsen thermostat
(244). This was followed by simulations at 1 atm in the NPT ensemble for 12 ps at 10 K and 24
ps at 310 K. Unrestrained equilibration MD was then performed for 24 ps at 310 K and 1 atm.
Finally, unconstrained production MD was performed on PKC-ι and PKC-ζ systems for 250 ns.
Energies were recorded every 2 ps and trajectory frames were recorded every 5 ps.
Final system equilibration was determined by the observation of asymptotic behavior of
the potential energy, Root Mean Square Deviation (RMSD), and Radius of Gyration (Rg)
profiles and visual inspection of trajectories guided by Root Mean Square Fluctuation (RMSF)
profiles (Figures 8-11).
2.2.3.3 Consensus Docking. After equilibration was determined, a hierarchical average
linkage clustering method based on RMSD was utilized to determine an average representative
structure for the equilibrated PKC-ι system. The program PROPKA was then implemented again
on the equilibrated structure to test consistency of side chain protontion states at 7.4 pH. The
representative structure was then used for consensus docking incorporating five diverse and
complimentary docking methods described below. By applying these varied energy scoring
methods, the weaknesses of each method can be identified for a particular model and error
statistically minimized, yielding a more accurate summary of ligand binding dispositions and
affinities.
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As a check for the placement of the grids used in the docking studies and for further
analysis of the binding cavities for the ATP binding site and the potential allosteric site,
Schrödinger's SiteMap program (245–247) was employed. SiteMap searches the protein structure
for likely binding sites and highlights regions within the binding site suitable for occupancy by
hydrophobic groups, hydrogen-bond donors, acceptors, or metal-binding functionality of the
ligand.
The ligands ICA-1S, ζ-Stat, and ATP were prepared using the program LigPrep (248) and
the OPLS-3 all-atom force field was applied to all ligand atoms.
2.2.3.4 Rigid Receptor Docking (RRD). Rigid docking simulations were performed by
Glide (114,121,125). Glide uses a GlideScore fitness function based on Chemscore (249,250) for
estimating binding affinity, but includes a steric-clash term, adds buried polar terms to penalize
electrostatic mismatches, and modifies other secondary terms. Docking simulations used both the
standard precision (SP) and extra precision (XP) methods. XP mode is a refinement algorithm
enforced only on good ligand poses. Sampling is based on an anchor and refined growth strategy
and the scoring function includes a more complete treatment of some of the SP energetic terms,
such as the solvation and hydrophobic terms. Docking grids were defined by a rectangular ligand
atom inclusion outer box of 22Å and ligand centroid constraint inner box of 10Å in the x, y, and
z directions originating from the binding cavity centroid defined by SiteMap for the proposed
allosteric site and by the original co-crystallized ATP ligand centroid for the ATP binding site.
2.2.3.5 Induced Fit Docking (IFD). The IFD methodology (16,122–125) incorporates
both the docking program Glide to account for ligand flexibility and the Refinement module in
the Prime program to account for receptor flexibility. The Schrödinger IFD protocol attempts to
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model induced-fit effects from alterations in binding site conformation due to ligand binding in
order to increase accuracy of binding affinity estimates and prediction of possible binding
modes.
The position of the cubic docking grid for the ATP binding site was centered on the
original co-crystallized ligand centroid and from the binding cavity centroid defined by SiteMap
for the proposed allosteric site with a box size of 29 Å for both. A constrained minimization of
the receptor was performed with an RMSD cutoff of 0.18 Å. An initial softened potential Glide
docking of the ligand set was then implemented with the standard precision (SP) mode and a van
der Waals scaling factor of 0.5 was applied to the non-polar atoms of the receptor and ligands.
The resulting top 20 poses of the ligands were used to sample protein plasticity by
conformational searches and minimizations of binding pocket residues within 6 Å of any ligand
pose for all complexes obtained. The new receptor conformations were then redocked using
complexes within 30 kcal/mol from the best scoring structure. Glide docking parameters for this
step were reset to the default hard potential function with a van der Waals scaling of 1.0 and SP
mode.
The estimated binding affinity of each complex was reported in the GlideScore and used
to compare differences between each ligand while the Emodel score is used to inter-compare
poses of the ligands. Emodel places more significance on weighting force field components
(electrostatic and van der Waals energies), making it better for comparing conformers as opposed
to comparing chemically-distinct species.
2.2.3.6 Quantum Polarized Ligand Docking (QPLD). To account for ligand
polarization upon binding, Quantum Mechanics/Molecular Mechanics (QM/MM) docking was
performed by the Schrödinger QM-Polarized Ligand Docking Protocol (QPLD) (126,127). The
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protocol first employs RRD using Glide in SP mode. In this step, the top five poses of each
ligand in the initial RRD were used. Potential ligand polarization induced by the protein were
then calculated with Qsite (111,251,252) at the B3LYP/6-31G* level. The ligand force fields
were then reconstructed with QM/MM modified charges, redocked, and five poses of each ligand
were saved for evaluation.
2.2.3.7 Molecular Mechanics and Generalized Born Surface Area (MM/GBSA). The
MM/GBSA method combines molecular mechanics energy terms and implicit solvation models
to calculate the binding-free energy based on docking complexes. The protocol, implemented by
the Prime MM-GBSA module, calculates optimized free energies for the free protein and free
ligand and references them with the original bound complex energy (253). Polar contributions
are calculated using the Generalized Born (GB) model (254), an implicit solvent model is based
on a variable dielectric surface Generalized Born (VD-SGB) approach, where the variable
dielectric value for each residue was fit to a large number of side-chain and loop predictions
while the non-polar energy is estimated using the solvent accessible surface area (SASA) (255).
The simulation was performed based on receptor–ligand complex structures obtained from
induced fit docking. The obtained ligand poses were minimized using the local optimization
feature in Prime, whereas the energies of complex were calculated with the OPLS-3 force field
and Generalized-Born/Surface Area continuum solvent model (256). During the simulation
process, the ligand strain energy is also considered. A known issue with MM/GBSA is that scores
do not accurately reproduce absolute physical binding affinities but display great efficacy at
ranking compounds in a relative manner (257–260). We developed a correlation function using a
single-layer logistic regression to rescale MM/GBSA scores based on the other docking score
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algorithms. This retains the ranking accuracy of MM/GBSA and allows us to proportion the
results in a minimally biased and physically relevant manner.
2.2.3.8 Virtual Target Screening (VTS). VTS is a system designed to virtually screen a
molecule of interest to a large library of protein structures. The current protein library consists of
1,451 structures with a concentration of kinases. The system is calibrated with a set of small
drug-like molecules are docked against each structure in the protein library to produce
benchmark statistics. VTS was employed as a theoretical assay of potential kinase activity and
gauge of potential biological promiscuity. The calibration procedure allows the analysis to
accurately predict inhibitor–kinase binding affinities when Kd < 10 μM (defining a hit) and Kd ≥
10 μM are both considered (72% accuracy in the best case) (137). Therefore, the VTS system is
able to robustly discriminate protein binders from nonbinders and give some inclination as to
potential binding promiscuity of the molecule of interest with respect to the protein group tested.
2.2.4 Cell Culture
The CCOC cells lines TOV21G and ES-2 were cultured in MCDB 131: Media 199(1:1
ratio) and McCoy’s medium, respectively, supplemented with 10% FBS, 100 units/ mL of
penicillin and 100μg/mL of streptomycin. The immortalized normal human endometrial stromal
cell line, SHT290, was maintained in F12K: Media 199 (1:1 ratio) and supplemented with 5%
FBS, 0.1% Mito +, 2μg/mL of human insulin, 100 units/mL of penicillin and 100μg/mL of
streptomycin. All cell cultures represented were passaged less than 10 times. Cell cultures were
maintained in an incubator at 37 °C and 5% CO2 atmosphere.
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2.2.5 Atypical PKC Expression During Rapid Growth and Cell Cycle Arrested
SHT290, TOV21G and ES-2 cells were seeded into 100mm plates and grown to 50%
confluency. Rapidly growing cells were harvested at 50% confluence and the cell cycle arrested
cells were serum starved for an additional 48 hrs in reduced serum medium Opti-MEM I (N=3).
2.2.6 Preliminary Screening of TOV21G and ES-2 with ICA-1S and ζ-Stat
TOV21G and ES-2 cells were seeded into 100mm plates and grown to 50% confluency.
Control cells were treated with equal amounts of DMSO (vehicle) and treatment cells were
treated with 3µM concentrations of ICA-1S and ζ-Stat for 24, 48 and 72 hrs (N=3). Cells were
collected at 24, 48 and 72 hrs and run on a Western blot.
2.2.7 Cell Viability Assay
Cells were seeded in to 96-well plate at 800 cells per well with 200µL of media. Cells
were treated with different concentrations of DMSO (vehicle to match treatment, N=12) and ζStat (1μM, 3μM, 5μM and 10µM, N=3). After 72 hrs of treatment, the cell viability was analyzed
using WST-1 at wavelengths 450 and 630 nm. The plates were read on a BioTek SynergyHT
microplate reader. Standard curves for each cell line was generated based on the number of cells
added and the absorbance recorded.
2.2.8 Cell Lysate Collection
Media was extracted from the vessel and 250μL of lysis buffer [Pierce® Immuno
Precipitation Lysis Buffer, 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and
5% glycerol] with protease and phosphatase inhibitors was added to the plates. Cells were
scraped and collected from the vessel (on ice) and the suspension was sonicated for 3 x 5 s cycles
on ice. The samples were centrifuged at 4°C at 12,000 x g for 15 ms. The supernatant (cell
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lysate) was removed from the cellular membrane pellet and placed in a secondary micro
centrifuge tube. Protein content was measured per Bradford Assay Reagent on a BioTek
SynergyHT microplate reader at 595nm.
2.2.9 Western Blot Analysis
Cell lysates containing equal amounts of protein (20-40µg) were loaded in each lane and
run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transblotted
to a 0.45µm nitrocellulose membrane. Cell lysates were probed with the primary antibodies
against PKC-ζ, PKC-ι, RhoA and β-actin (for loading control) and re-probed with secondary
antibodies

for

development.

Immunoreacted

bands

were

visualized

by

enhanced

chemiluminescence per the manufacturer’s instructions [Thermo Scientific™ SuperSignal™
West Pico PLUS Chemiluminescent Substrate]. Band densitometry was performed with ImageJ
FIJI (261) software and normalized densities were derived by the ratio of the protein of interest
over the control (β-actin).
2.2.10 Endpoint PCR
The mRNA from TOV21G and ES-2 cells treated with vehicle control and 3μM of ζ-Stat
was isolated via the manufacture’s protocol for RNAbee. The mRNA was then quantified using
the BioTek Synergy HT Take5 plate and cDNA was synthesized using the Qiagen reverse
transcription (RT) kit per the manufacturer’s protocol. Endpoint polymerase chain reaction
(PCR) was performed with primers for RhoA and the house keeping gene GAPDH (forward
5’CCA-CCC-ATG-GCA-AAT-TCC-ATG-GCA-3’ and reverse 5’TCT-AGA-CGG-CAG-GTCAGG-TCC-ACC-3’). PCR products were analyzed on an agarose gel (N=3).
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2.2.11 Rac1 Activation Assay
Cells were cultured in 150mm plates and lysed as previously described. The cells were
treated with DMSO (control) and 10µM of ζ-Stat for 72 hrs and harvested (N=4). Glutathione Stransferase (GST) was tagged to the protein binding domain (PBD) of p21 activated kinase
(PAK). A positive control and negative control were performed to determine assay efficiency.
Briefly, 500µg of protein were balanced in 200µL of cell lysis for each sample. The positive
control received 200µM of non-hydrolyzable guanosine 5'-O-[gamma-thio] triphosphate
(GTPγS) and the negative control received 200µM of guanosine diphosphate (GDP). These
samples were incubated at room temperature (RT) for 15 ms. All samples (positive, negative,
DMSO control and treatment) were incubated with GST-tagged PAK-PBD agarose beads for 1hr
4°C. These samples were pelleted at 5,000 x g (at 4°C) and washed with Wash Buffer. The
pelleted beads were re-suspended with 20µL of 2X Laemmli sample buffer and boiled at 95°C
for 2 ms.
2.2.12 Preparation of cytoplasmic and nuclear extracts
TOV21G and ES-2 cells were seeded in 100mm tissue culture plates (1.5x10 5). Cells
were treated for 72 hours with 10μM ζ-Stat (DMSO control) and harvested with trypsin. The
instructions provided by the manufacturer were followed to fractionate the cytoplasmic and
nuclear portions. The extracts were analyzed via immunoblots and translocation of Ect2 was
investigated.
2.2.13 Fluorescent Microscopy
TOV21G cells were seeded into 4 chambered slides at a 500 cells per well concentration
and after 24 hrs, were treated with a vehicle control (DMSO) and 10µM of ζ-Stat every 24 hrs
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for 72 hrs. Cells were then fixed with 4% paraformaldehyde for 15 ms and immunostained with
Ect2 antibody at 4°C overnight with light agitation. The slides were incubated with Alexa 488
rabbit secondary antibody for 1 hr at room temperature RT. Subsequently, the slides were stained
with Phalloidin conjugated to Texas red dye for 30 ms at RT, mounted with solution containing
4′,6-diamidino-2-phenylindole (DAPI) and imaged on an Olympus BX53 Digital Upright
Fluorescent Microscope.
2.2.14 Invasion Assay
For the evaluation of invasion, cells were serum starved for 48 hrs, followed by
detachment and plating into the upper chamber of a 96-well (8 µm) transwell permeable support,
coated with 0.1X BME. Serum (10%) containing media was loaded into the lower chamber as a
chemoattractant. Subsequently, TOV21G cells at the upper chamber were treated with 10μM of
ζ-stat for 24 hr (N=4). Two experimental treatment groups for the cells were performed: Control
(DMSO vehicle) and treatment. The invasive cells that passed into the lower chamber were then
fixed with 4% paraformaldehyde, stained with 2% crystal violet in 2% ethanol, washed with
distilled water and photographs were captured after drying using a light microscope Motic
AE31E. For migration, a similar protocol was followed except without coating the transwell
insert with BME. The assay was quantified with ImageJ FIJI software.
2.2.15 ζ-Stat in-vivo
The following experiments outline the investigations of ζ-Stat in TOV21G clear cell
carcinoma ovarian xenografts. We have an Institutional Animal Care and Use Committee
(IACUC) approved by Adrienne Booker for the discussed studies. The study involved 12
athymic female nude mice weighing between 20-25g and >10 weeks of age. The 12 mice were
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divided into two groups after TOV21G cells were implanted (1 x 10 6 cells/per mouse flank in
0.2mL of media). The first group was the vehicle control group (N=6), which received 100 µL of
1x DPBS. The second group (N=6) was injected with 100 µL of 20mg/kg of ζ-Stat dissolved in
1x DPBS. The tumor volume was calculated using the formula: length x width x width x ½.
Three days after the implantation of the cells, tumors were treated as of day 0. The treatments
were administered every other day subcutaneously intra-tumor and around the tumor site for 35
days.
At the end point of the experiment, tumors and heart serum were harvested. Tumors were
imaged and measured, and blood serum was analyzed for enzymatic levels of glucose (GLU),
blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST)
and alkaline phosphatase (ALKP) at the Moffitt Research Facility. Briefly, blood chemistry
analysis was performed by initially collecting whole blood in a serum separator tube, which then
sat for 20 ms at RT before centrifugation. Once the blood was centrifuged the serum was
separated and placed in a specialized sample cup made for the IDEXX CatalystDx. The cup
containing the serum and the desired chemistry slides were then placed into the CatalystDx for
analysis.
2.2.16 Statistical Analysis
R studio software was used for statistical analyses. A one-way ANOVA with a Tukey’s
multiple comparisons test was performed for Western Blot analyses and cell viability. A twotailed unpaired student T-test was utilized for the statistical significance of the particle counts for
cell migration and invasion, day to day tumor volume, mouse body weight and individual
enzyme levels. The Pearson’s Correlation Coefficient (PCC) was utilized for co-localization and
was analyzed using ImageJ FIJI software, using the Coloc2 plugin.
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2.3 Results
2.3.1 PIK3CA and ARID1A Are in the Top Mutated Genes in All Ovarian Tissue
Types and in CCOC
To understand the genetic landscape of ovarian cancer, we utilized the Catalogue of
Somatic Mutations in Cancer bioinformatics database (COSMIC) (226). The results
demonstrated that the top mutations in ovarian cancer overall are TP53 (p53), FOXL2 (Forkhead
box protein L2), KRAS (Kirsten Ras oncogene homolog), PIK3CA (Phosphatidylinositol 4,5bispohsphate 3-kinase catalytic subunit alpha), ARID1A (AT-rich interaction domain 1A) and
BRAF (B-Raf proto-oncogene) (Table 8). The search was then refocused to only contain CCOC
samples and the top two mutated genes found were PIK3CA (33%) and ARID1A (50%) (Table
9). These results suggest that one of the most common gene mutations in ovarian cancer and
CCOC is PIK3CA, which is approximately 10% of mutated samples in all the ovarian tissue in
the database. Due to this, the downstream survival targets PKC-ζ and PKC-ι are likely to be
overexpressed, amending the need for their explicit targeting.
In addition, the PIK3CA mutation was used to select two cell lines that would be
representative of this mutation in CCOC. Two commonly utilized cell lines, TOV21G and ES-2
were selected based on their genetic profile. While both cell lines possess a PIK3CA mutation,
TOV21G has an ARID1A mutation and ES-2 has a TP53 mutation (Table 9).
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Table 8. Six most common gene mutations in all ovarian cancers.
Somatic mutations in all ovarian tissue types
Gene

TP53

Protein Product

p53

Protein
Function

Percent
Chromosomal Mutation
Location
of
(human)
Samples
Tested

Tumor suppressor,
regulates cell
cycle

Transcription
FOXL2 Forkhead box protein L2 factor

KRAS
PIK3CA

Kirsten Ras oncogene
Regulation of cell
homolog, (KRAS protodivision
oncogene, GTPase)
Phosphatidylinosital-4,5- Phosphorylates
bisphosphate 3-kinase certain signaling
catalytic subunit alpha molecules

ARID1 AT-rich interaction
domain 1A
A

BRAF

B-Raf proto-oncogene,
serine/threonine kinase

Highest
Percent
Mutation

Mutation
Type
Substitution

17p13.1

46

3q23

20

100

12p12.1

12

100

Substitution
missense

3q26.3

10

96.88

Substitution
missense

Regulate
transcription by
altering chromatin
structure

1p35.3

9

This protein plays
a role in
regulating the
MAP
kinase/ERKs
signaling pathway,
which affects cell
division,
differentiation,
and secretion.

7q34

7

55.89,20.23 missense,

other
Substitution
missense

Substitution
missense,
40, 38.26, deletion
frame shift,
23.48
insertion
frame shift

97.63

Substitution
missense

The table describes the six most common gene mutations in all ovarian cancers according to the
Catalogue of Somatic Mutations in Cancer database (COSMIC). The gene name, protein
product, general function, chromosomal location, percent of all samples with mutation, highest
type of mutation and most common mutation type are listed.
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Table 9. Somatic mutations in CCOC and CCOC cell lines.

Gene
ARID1A
PIK3CA

Somatic mutations in
CCOC
Percent Mutation of
Samples Tested
50
33

Somatic mutations in cell lines
TOV21G
Y551fs*72,Q758fs*75

ARID1A
PIK3CAH1047Y

TERT

17

KRASG13C

TP53
KRAS

11
8

PTENK267fs*9, G143fs*4

ES-2
S241F

TP53
PIK3CA

The table describes the five most common gene mutations in CCOC according to the Catalogue
of Somatic Mutations in Cancer database (COSMIC). The gene name and percent of samples
with mutation are listed. The gene mutations for TOV21G CCOC cells and ES-2 CCOC cells are
listed with specific mutation type.

2.3.2 Select Inhibitor Effects on PKC-ζ and PKC-ι Protein Expression
To determine which inhibitors affect PKC-ζ and PKC-ι protein expression in CCOC,
Western Blots were employed with ICA-1S and ζ-Stat (Figure 6) as potential inhibitors. Initially,
the expression of these aPKCs were investigated in rapidly growing cells (50%) and cell cycle
arrested (serum free, SF) (Figure 7A). The density of each band was quantified using analytical
software. The results showed that ICA-1S did not affect PKC-ζ or PKC-ι protein expression
(Figure 7B); however, ζ-Stat substantially decreased the expression of PKC-ζ in TOV21G cells
(p value 0.00225, F = 9.5709, t = -4.413) and ES-2 cells (not significant) but not PKC-ι protein
expression (Figure 7C). These results suggest that ζ-Stat is selective to PKC-ζ decreased
expression and could be used to interrupt the PKC-ζ pathways.
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Figure 7. PKC-ζ and PKC-ι protein expression in rapidly growing and serum starved cells and
the effects of ICA-1S and ζ-Stat on PKC-ζ and PKC-ι protein expression in SHT290, TOV21G
and ES-2 CCOC cell lines. (A) SHT290, TOV21G and ES-2 cell lines were harvested at 50%
and 48 hrs after serum starvation (SF) (N=3). The membranes were probed with anti-PKC-ζ and
PKC-ι to investigate protein expression. (B) TOV21G and ES-2 cell lines were treated with 3μM
ζ-Stat for 24, 48 and 72 hrs. An untreated control and vehicle control (DMSO) are also
illustrated. The immunoblots were probed with PKC-ζ, PKC-ι and β-actin (loading control)
(N=3). (C) The raw data’s densitometry was quantified using ImageJ software and analyzed with
a one-way ANOVA. Standard deviation is represented. (** p < 0.01)

2.3.3 In-silico Results and Model Validation
2.3.3.1 Model Viability. RMSD and Rg plots of PKC-ι (Figure 8) displayed asymptotic
behavior beyond 7 ns. RMSD appeared to equilibrate near 2.3 Å, similar to the reported
crystallographic resolution of 2 Å (229). Any additional fluctuation is likely from the disordered
tail regions and missing residues 446 – 454 as evidenced from the PKC-ι RMSF plot (Figure 9).
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From these analyses, the MD model is considered viable due to the ability of the model to
accurately maintain the lowest energy structure under significant perturbation.

Figure 8. RMSD (Bottom) of backbone atoms and Radius of Gyration (R g, Top) of all atoms
graphs for PKCι Molecular Dynamics simulation. Equilibration appears to occur after 7 ns with
an average RMSD of 2.3 Å.
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Figure 9. RMSF (Root Mean Square Fluctuation) plot for PKCι Molecular Dynamics
simulation. Graph shows RMSD per residue of α-carbon over length of simulation. Most
displacements are under 2 Å aside from tail regions and chain discontinuities from missing
residues 446 – 454.

To date, no crystallographic structure exists of PKC-ζ. As such, a homology model was
attempted using the Schrödinger program Prime (16,66,67) with the human PKC-ζ sequence
(UniProt Q05513) and the crystallized PKC-ι structures as templates. PKC-ι was chosen as the
primary template due to its highest sequence identity (49.0%) and homology (53.8%) given from
a BLAST search (205) coupled with highest overall structural resolution. A pre-generated
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SWISS-MODEL (19,20,230) homology model was used as a control for structural reference. The
Prime model (Figure 12C) was identical to the SWISS-MODEL variant, so only the Prime
model was used for further analysis. RMSD and Rg plots of the PKC-ζ homology model (Figure
10) do show asymptotic behavior after 1.2 ns, however the RMSD equilibration is averaged to
4.4 Å and is clearly outside any acceptable resolution. The R g plot also shows a significant
expansion indicative of unfolding with internal water infiltration. RMSF plots (Figure 11) also
show substantial backbone movement beyond 2 Å at regions of PKC-ζ residues differing from
PKC-ι with notable disruption of predicted secondary structure. These factors conclude that the
homology model does not represent a physical low energy structure and therefore cannot be used
for further modeling. Despite this, the ATP binding region is largely stable with RMSF well
within reasonable values (Figure 12D). This allows inclusion of the PKC-ζ homology model
ATP binding site with docking studies to compare binding modes between PKC-ι and PKC-ζ
ATP binding sites (Figure 12C – yellow region).
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Figure 10. RMSD (Bottom) of backbone atoms and Radius of Gyration (R g, Top) of all atoms
graphs for PKCζ Molecular Dynamics simulation. Some asymptotic behavior does appear to
occur, however, an average RMSD of 4.5 Å and increasing R g implies unfolding and significant
deviation from any structural energetic minimum.
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Figure 11. RMSF (Root Mean Square Fluctuation) plot for PKC-ζ Molecular Dynamics
simulation. Graph shows RMSD per residue of α-carbon over length of simulation. The ATP
region, approximately residues 300 – 450, show displacements under 2 Å. Most homologous
residues show RMSD values well above 2 Å.

106

Figure 12. Computational modeling results. Binding site characterization for PKC-ι ATP site
with co-crystallized ATP shown for reference (A) and the PKC-ι potential allosteric site with ζStat docking result shown for reference (B). SiteMap analysis for each site is also shown (A and
B). Yellow volume denotes hydrophobic regions, red volumes demarcate hydrogen bond donor
sites, and blue volumes define hydrogen bond acceptor sites. The final homology model structure
of PKC-ζ (C) generated is displayed with cartoon ribbons and colored by sequence identity to the
PKC-ι reference structure. Blue are identical residues between both structures with cyan
highlighting dissimilar amino acids. Red indicates sequence spans with no structural template.
The ATP binding region is also delineated by a yellow domain and a magenta domain localizes
the suspected allosteric site, both defined by SiteMap. Post-MD RMSD analysis (D) is illustrated
with cartoon ribbons colored by RMSD per residue over the length of the simulation. Continuous
color shift is used to show residue displacement from original structure with blue representing a
minimum of 0 Å RMSD, white representing mid values of 4 Å RMSD, and red representing a
maximum of 8 Å RMSD. Consensus docking scores (E-G) are measured in kcal/mol and
represent estimated free energies of binding (ΔGo). Green highlighting features the best scoring
molecule for a particular site and yellow highlight focuses the averaged consensus scoring for
each compound. Theoretical KD values are calculated from free energies of binding (ΔG o). VTS
results are also listed (H).
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The Schrödinger program SiteMap was used for optimizing placement of grids used in
the docking studies and to search for any other potential binding sites. A possible allosteric site
for PKC-ι was identified by SiteMap near residues 397 – 400 in the activation segment of the
PKC-ι c-lobe consisting of a pocket made by α-helices E and F and the interhelical loop between
α-helices H and I (Figure 12C – magenta region). SiteMap also scores regions based on
potential hydrogen bonding, hydrophobicity, and pocket volume. Scores of 0.8 or greater are
considered the cutoff for distinguishing between drug-binding and non-drug-binding sites. The
PKC-ι ATP site was scored at 1.004 and the potential allosteric site was scored at 0.779. The
potential allosteric site score is notably within SiteMap calibration error and was still included in
docking studies due to proximity of the pocket with the PKC-ι activation segment and for the
possibility of induced fit effects opening the site.
2.3.3.2 Docking Results. Minimal direct binding data exists for PKC-ι and PKC-ζ so a
consensus docking approach was utilized to gauge the optimal docking algorithm for the ATP
and potential allosteric site. The approach detailed utilizes five different computational methods
of discerning theoretical binding affinities: two unique scoring functions (SP and XP) for ridged
docking methods, IFD to account for potential induced fit effects, QPLD can resolve polarization
effects through QM/MM techniques, and MM/GBSA is superior in clarifying penalties for
solvent interactions. Employing these functions when little empirical evidence exists to correlate
results helps identify weaknesses of each technique for a particular model. Error can also be
statistically minimized, yielding a more accurate summary of ligand binding dispositions and
affinities.
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Staurosporine was used as a docking control for the ATP site since binding data exists for both
PKC-ι (261 nM Ki (262), values converted from IC50s) and PKC-ζ (131 nM K i (263), values
converted from IC50s). ATP is not used as a docking control due to poor model forcefields and
lack of direct binding data.
Docking results are summarized in Figure 12E, F, and G. Docking scores for
staurosporine controls are well within reasonable agreement with literature values. Docking
scores and poses for each molecule are nearly identical for the ATP site of PKC-ι and PKC-ζ and
both prefer staurosporine by a significant margin (Figure 12E and F, green highlight). XP
scoring consistently yielded scores in closest agreement to literature values and highest Pearson
correlation to overall averages. IFD and QPLD have poorer correlation and control accuracy,
suggesting a less pronounced influence of charge factors and induced fit effects since including
polarization and site flexibility does not increase docking accuracy. MM/GBSA scores exhibit
similarly reduced correlation and high variance, entailing that solvent effects are also not likely a
major factor for binding; this is understandable given the pocket depth. These analyses signify
that the hydrophobic centers of the site (Figure 12A) are the dominant factors in ligand binding
with the ATP site for both models. As opposed to the pan-kinase inhibitor, staurosporine, ICA-1S
and ζ-Stat display negligible binding with the ATP site.
The potential allosteric site was also studied (Figure 12G), but only for PKC-ι since the
corresponding PKC-ζ allosteric site model could not be validated. As such, no conclusions
should be drawn concerning possible interactions of these compounds with any potential
allosteric sites on PKC-ζ (only the ATP site achieved an apparent suitable stability for docking
studies). Of the three molecules, the potential allosteric site appears to prefer only ICA-1S with a
theoretical KD of 1.4 μM. A recent study by Ratnayake et al. (225) measured myelin basic protein
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(MBP) phosphorylation by PKC-ι and PKC-ζ in the presence of ICA-1S, ICA-1T (the
phosphorylated version of ICA-1S), and ζ-Stat. Docking figures match expected activity of PKCι for ζ-Stat having negligible inhibition. ICA-1S activity as a PKC-ι inhibitor gives some support
to the existence of the potential allosteric site, since modeling suggests that ICA-1S does not
interact significantly with the ATP site, but does display binding at concentrations similar to
experimental values for inducing inhibition. Unfortunately, the data for PKC-ζ is less clear. All
the modeling can show is if the two compounds in question can effectively bind to the ATP site
of PKC-ζ. This may indirectly imply an allosteric site exists for PKC-ζ if inhibition is
experimentally observed and the compound in question does not appear to have favorable
docking to the ATP site. For ICA-1S, there is negligible affinity for the ATP site and experiment
reflects a lack of inhibition. Modeling also suggests an allosteric mechanism may be present for
ζ-Stat as binding is also negligible for the ATP site. Experimental inhibition should be observed
for any compounds that compete for the ATP site since there is no significant difference between
the ATP sites of PKC-ι and PKC-ζ.
2.3.3.3 Virtual Target Screening Results. VTS uses a large curated protein structure
library to which molecules of interest are docked. Statistical calibrations and baselines are
applied to average and relate docking scores with each individual and class of proteins. A kinaseenriched library (1,451 proteins, 464 transferases, and 65 unique kinases) was assigned for
docking with the three compounds. A hit on a protein is classified as the potential (p value <
0.05) of the molecule of interest to bind to the specified protein with a theoretical KD of 10 μM or
less. This analysis can infer the specificity of a molecule for a particular class of proteins. The
VTS results for each compound are listed in Figure 12H.
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The staurosporine control gave an expected baseline commensurate of a pan-kinase
inhibitor. It displayed low to moderate total protein activity with moderately high interaction
with general transferases and hit a majority of kinases, alluding a clear preference for kinases.
ICA-1S demonstrated a low total protein activity with a slight but pronounced increase in affinity
for transferases and kinases. This suggests a possibility of seeing some expected broad kinase
interference for ICA-1S. ζ-Stat, however, portrays significant specificity in VTS. It has similar
low hit percentages for all protein classes, implying little to no expected kinase activity.
2.3.4 Inhibition of Cell Viability
The effects of ζ-Stat on CCOC cellular viability was investigated via WST-1
methodologies. The results revealed that 10μM ζ-Stat did not significantly effect SHT290 normal
endometrial stromal cells, but did significantly decreased the viability by 37% in TOV21G cells
(p value 0.0436, F = 4.2461, t = -3.058) and by 57% in ES-2 cells (p value 0.00363, F = 7.2918,
t = -4.220) (Figure 13A-C). These results suggest that ζ-Stat decreases the viability of CCOC
but has negligible effects on normal endometrial stromal cells.
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Figure 13. Cell proliferation and viability of SHT290, TOV21G and ES-2 CCOC cell lines. (A)
SHT290, (B) TOV21G and (C) ES-2 cells were treated for 0, 24, 48 and 72 hrs with 1μM, 3μM,
5μM and 10μM ζ-Stat. WST-1 assays were run after 72 hrs of ζ-Stat treatment (Vehicle control
N=12, treatment N=3). A standard curve for each cell line is also represented. Standard deviation
is represented. A one-way ANOVA was tested for the WST-1 assays. (* p < 0.05, ** p < 0.01)

2.3.5 Analysis of the PKC-ζ/Ect2/Rac1/RhoA Pathway
To determine the downstream effects of ζ-Stat on invasion, immunofluorescence, Western
Blots and semi-quantitative endpoint PCR techniques were utilized. Vehicle control and ζ-Stat
treated TOV21G cells were probed with anti-Ect2 and imaged. The results showed that Ect2 was
present in the filamentous extensions in control cell. After treatment, the polarity of the
filamentous extensions decreased and Ect2 was found to be more abundant around the nucleus
(Figure 14A-B). Western results demonstrated that 3μM of ζ-Stat decreased RhoA protein
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expression as well as mRNA expression (Figure 14C-D). These results suggest that the decrease
in PKC-ζ protein expression reduces the expression of RhoA at the genomic level.
Furthermore, Ect2 localization was observed by immunofluorescence with and without
treatment. The PCC showed that the control had a lower amount of Ect2 nuclear localization
(0.57) in comparison to the treated (0.72) TOV21G cells (Figure 15A). In contrast, ES-2 cells
had little effect as both the control and the treated cells had a PCC value of 0.69 (Figure 15B). In
addition, the filamentous actin (F-actin) organization was investigated via phalloidin stain. In
Figure 15C, the F-actin in the control for TOV21G showed filamentous extensions, whereas in
the treated cells, the F-actin seemed to aggregate within the cell, rounding the edges.
Moreover, TOV21G cells were treated with 10μM ζ-Stat and seeded into 96 welled
transwell plates. After 24hrs of treatment, the cells were fixed and stained to determine the
effects ζ-Stat on invasion and migration. Our data showed that ζ-Stat drastically decreased
invasion and migration when compared to the control (Figure 7A). After the images were
quantified, the data revealed that the decrease in invasion and migration was statistically
significant (Figure 7B; invasion p value 0.002826, t = 4.859; migration p value < 0.001, t =
6.1887). To further illustrate this point, Rac1 activation was investigated utilizing a GST pull
down method. The negative and positive control display how well the assay data fits the intended
model (p value < 0.001, t = 7.675). Compared to the sample control, the amount of activated
Rac1 pulled down from treated samples was only 37% (p value 0.044, t = -3.044; Figure 7D).
These data reinforce the theory that ζ-Stat decreases the invasion and migration of CCOC
through a decreased activation of Rac1.
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Figure 14. Effects of ζ-Stat on Ect2 localization and RhoA protein and genomic expression. (A)
TOV21G cells were seeded on a four-chamber slide and treated for 72 hrs with 10μM ζ-Stat. The
slide was fixed with formaldehyde and immunostained with anti-Ect2, phalldoidin dye, and
DAPI. Original magnification is 40X and scale bar is 20μm. (B) Ect2 is visualized in the
filamentous extension of the TOV21G cell. (C) A Western Blot for TOV21G and ES-2 cells
treated for 72 hrs with vehicle control (DMSO) and 3μM ζ-Stat is represented with an
immunoblot that was probed for PKC-ζ and RhoA (N=3). (D) TOV21G and ES-2 cells were
treated for 72 hrs with 3μM ζ-Stat and harvested with RNAbee for mRNA semi-quantification.
Endpoint PCR was run with RhoA and GAPDH primers (mRNA control) (N=3).
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Figure 15. Immunofluorescent staining of Ect2. (A) TOV21G and ES-2 cells were probed with
anti-Ect2, phalloidin dye and DAPI. The Pearson’s correlation coefficient is represented in white
at the bottom left corner of the merged images. Original magnification is 40X and scale bar is
20μm. (B) A visualization of the organized filamentous actin in TOV21G cells treated with
vehicle control (DMSO). (C) A visualization of Ect2 localization in TOV21G cells treated with
10μM ζ-Stat for 72 hrs.
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Figure 16. PKC-ζ regulates invasion and migration of TOV21G ovarian cancer. (A) TOV21G
cells were grown, serum starved for 48hrs, and placed in the upper chamber of transwell plate
coated with 0.1x BME and serum (10%) containing media was placed in the lower chamber as a
chemo attractant. Following treatment with 10μM ζ-stat for 24hrs, cells that invaded through
BME and migrated into the lower chamber were stained with crystal violet and observed under
microscope. Original magnification is 10x and scale bar represents1mm. (B) Invasion (N=4) and
(C) migration (N=4) fixed and stained cells on the lower chamber were quantified using ImageJ
FIJI software, average and plotted. Standard deviation error bars are represented. (** p < 0.01,
*** p < 0.001). (D) Activated Rac1 (GTP bound) was pulled down using GST tagged PAK-PBD
and analyzed by Western Blot. Densitometry of activated Rac1 bands were plotted (N=4).
Standard deviation error bars are represented.
2.3.6 Analysis of ζ-Stat in TOV21G Tumor Xenografts
To determine the effects of ζ-Stat in-vivo, we injected athymic nude female mice with
TOV21G cells and sequentially treated mice for 35 days. At the endpoint of the experiment, the
tumors were harvested, and the blood serum was screened for enzymes associated with kidney
and liver failure, as well as glucose levels for screening diabetes. Our data exhibited statistically
significant changes in tumor volume between vehicle control and treated mice (Figure 17A)
starting on day 14 (p value 0.006343, t = 3.4389) up until day 35 (p value 0.001136, t = 4.4827).
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Results also demonstrated that ζ-Stat decreased tumor growth by more than 50% by the endpoint
of the experiment (Figure 17B-C). The treatments did not lower the mouse population’s body
weight (Figure 17D) and did not have a significant effect on the enzyme panel (Figure 17E-F).
These preliminary results suggest that ζ-Stat can be used for the treatment of CCOC and does not
cause short-term toxicity.

Figure 17. Effects of ζ-Stat on in-vivo xenografts with athymic nude mouse models. (A) Six
vehicle control mice and six treatment mice were injected with 1 x 10 6 cells/per mouse flank in
0.2mL of media of TOV21G CCOC cells. Vehicle control mice tumors were treated with 1x
DPBS and treatment mice were treated with 20mg/kg of ζ-Stat. Tumors were measured every
other day and plotted. An unpaired student T test was performed, and standard deviation error
bars are presented (* p < 0.05, ** p < 0.01). (B) Tumors were harvested after 35 days of
treatment and a picture was taken. (C) Endpoint treated tumor volumes were graphed as a
percent of the control (D) Mouse weight was recorded once per week. An unpaired student T test
was performed, and standard deviation error bars are presented (no significant difference
observed). (E-F) Endpoint blood serum was taken and screened for glucose (GLU), blood urea
nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline
phosphatase levels for toxicity. A unpaired student T test was performed, and standard deviation
error bars are presented (no significant difference observed).
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2.3.7 ζ-Stat Interrupts the PKC-ζ/Ect2 via PKC-ζ Protein Decrease
Our predicted pathway models that PKC-ζ scaffolds Ect2 to the cellular membrane
(Figure 18). This mis-localization of Ect2 permits the wild-type Ect2 more access to Rac1 and
therefore increases its activation. Upon increased Rac1 activation, CCOC invasion is increased.
PKC-ζ protein level decrease via ζ-Stat, releases Ect2 from the membrane scaffold, and relocalizes Ect2 to the nucleus, limiting its access to cytosolic Rac1 and decreasing Rac1
activation.

Figure 18. ζ-Stat decreases the amount of PKC-ζ, therefore decreasing the scaffold of Ect2 in the
cytoplasm. The hypothesized pathway illustrates the scaffolding of Ect2 via PKC-ζ in the
cytoplasm. Treatment with ζ-Stat decreases PKC-ζ expression thereby there is less PKC-ζ to bind
Ect2, allowing Ect2 to re-localize to the nucleus. This decreases Ect2 cellular access to Rac1,
reducing Rac1 activation and cell migration.
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2.4 Discussion
In this study, we discovered that the small molecule inhibitor, ζ-Stat, is a prospective drug
candidate to investigate as a novel potential treatment for CCOC. We also investigated the PKCζ/Ect2/Rac1 activation pathway and found that ζ-Stat decreases the invasive behavior of CCOC
by decreasing cytosolic Ect2 and Rac1 activation.
2.4.1 Targeting aPKCs in CCOC
To understand the therapeutic potential of a protein target, there must be an appreciation
of the underlying genetic abnormalities specific to the cancer type. The TP53 gene (tumor
suppressor p53) is the most commonly mutated gene in all ovarian cancers and is especially a
prognostic marker of HGSOC (264). In contrast, CCOC typically has a wild type TP53 and
mutations in the tumor suppressor ARID1A (265). Although PRKCZ and PRKCI are not in the
top mutated genes in CCOC, PIK3CA is mutated (~30%) and is located on the third
chromosome’s long arm. Interestingly, PIK3CA (3q26.32), ECT2 (3q26.31) and PRKCI (3q26.2)
are all located on the long arm of chromosome three and in proximity. The ARID1A (1p36.11) is
also located up stream of PRKCZ (1p36.33) on the short arm of the first chromosome. It has
been noted that mutations and deficiencies in ARID1A have been shown to sensitize cancers to
PARP and PI3K inhibitors (266–268).
Previous literature has suggested that the atypical PKCs should be the focus of targeted
treatment (210). One explanation for this is that the atypical PKC isoforms have been linked to
signaling pathways needed for cancer survival and growth. A study performed by Yao et al.
illustrated the dramatic changes to prostate cells malignancy upon PKC-ζ silencing (269). In our
study, when CCOC (TOV21G and ES-2) cells grew rapidly and were cell cycle arrested (serum
starved), the aPKCs were present in both conditions. However, the expressions of PKC-ζ and
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PKC-ι were found to be very low in the normal endometrial stromal cells. These findings may
indicate that CCOC cells have a reliance on aPKC overexpression for cell viability. An
interesting complication in other types of CCOC is that ζ-Stat does not specifically limit
expression of PKC-ζ but also effects downstream targets in the PKC-ζ/Ect2/RhoA pathway. As
shown in Figure 2, ζ-Stat had a negligible effect on PKC-ζ expression in ES-2 cells, however in
Figure 5, there was a decrease in RhoA protein and mRNA expression. This leads to the
conclusion that ζ-Stat has generalized effect on the pathway dependent on cell type. Furthermore,
these data support that PKC-ζ/Ect2/RhoA pathway contains relevant targets for CCOC due to the
lack of overexpression in normal tissue and the overexpression in cancerous cell lines.
Equally important, a previous study showed that the knock down of PKC-ζ using siRNA
decreased the expression of RhoA and Rac1(270). Furthermore, this study illustrated that the
knock down of PKC-ζ decreased the invasive behavior of breast cancer cells by more than 40%.
Our data supports previous data and reiterates the therapeutic potential for targeting PKC-ζ in
CCOC.
2.4.2 aPKCs are Involved in the Localization of Ect2
The mis-localization and overexpression of Ect2 has been linked to aPKCs and Ect2
dependent malignant transformation (271). Cytoplasmic Ect2 has more access to Rho GTPases
and increases the protein family’s activation. Liu et al. identified Ect2 as an activator of the
Par6/Par3/aPKC polarity complex and further showed that Ect2 stimulated PKC-ζ activity (272).
Moreover, the oncogenic activity of Ect2 was shown to be regulated by aPKC via the
phosphorylation of the Thr 328 site and a mutation in this site (T328A) rendered the Ect2 unable
to interact with Par6/aPKC complex or activate Rac1 (273). Upon treatment with ζ-Stat, the
decrease of PKC-ζ disturbs the localization of Ect2 in TOV21G cells. This specific effect is not
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seen in ES-2 as correlations are equal before and after ζ-Stat treatment. Therefore, it does not
seem that PKC-ζ is not the specific target but more of the generalized PKC-ζ/Ect2/RhoA
pathway.
2.4.3 ζ-Stat has Therapeutic Potential in CCOC
A common treatment regime for ovarian cancer patients typically involves chemotherapy
(paxitaxol), PARP (poly ADP ribose polymerase) inhibitors and bevacizumab (targets
angiogenesis) (217). However, concerns for current treatments still involve toxicity, drugresistance, reoccurrence and the side effects to the patients (274). Our data showed that mice
treated with ζ-Stat did not have significant side effects when compared to mice treated with the
vehicle control. In particular, the mice did not have significant fluctuations in body weight, or
differences in the enzyme panel which screened for liver and kidney damage. Further, the
viability of normal endometrial stromal cells did not change significantly upon treatment of
10μM ζ-Stat. All these data support the prospect that this compound may be a less toxic
alternative maintenance drug for CCOC.
The presence of PKC-ζ and PKC-ι in proliferation, invasion and migration make this
protein a unique target for therapies. In the previous literature, ζ-Stat was shown to decrease the
invasion and migration of melanoma cells and increase apoptosis (225) It has also been
suggested the ζ-Stat is selective to PKC-ζ in melanoma and colorectal cell lines (222,225). In
support of the previous data, our data showed that ζ-Stat had a dramatic effect on CCOC
invasion and migration.
However, new evidence supports the theory that ζ-Stat does not inhibit kinase activity of
PKC-ζ through the ATP binding region. Our computational and in-vitro data advocates that ζ-Stat
decreases the expression of signaling proteins (PKC-ζ and RhoA). This phenotypic effect
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consistently modifies kinase interaction networks which results in decreases in cellular viability,
invasion and tumor growth (222,225). The effects that ζ-Stat elicited was decreased PKC-ζ
protein, re-localized Ect2 to the nucleus in TOV21G cells (ARID1A mutant) and decreased the
presence of activated Rac1. ζ-Stat specifically decreased the protein expression of PKC-ζ in
comparison to PKC-ι, however this mechanism is still unknown. The data suggests that ζ-Stat
may be generating an epigenetic effect, which in turn regulates the expression of these proteins.
It has been suggested that using aPKC inhibitors can epigenetically regulate the expression of
aPKCs through transcription factors, such as FOX01 (225).
Additionally, according to the computational data, ICA-1S exhibited poor binding with
the PKC-ι and PKC-ζ ATP site and had a predicted moderate affinity with a possible PKC-ι
allosteric site. This fits well with previously performed MBP phosphorylation experiments (225).
Some expected kinase activity with mid-range binding promiscuity is anticipated for this
molecule. However, this conclusion is contradicted by some evidence from the experiment,
therefore it could simply be that the generated PKC-ζ model is insufficient for correlating
physical data. ζ-Stat exhibits extremely poor binding with the ATP site and PKC-ι allosteric site.
With no expected kinase activity and low binding promiscuity, any inhibition seen using ζ-Stat is
likely specific for unique binding pockets.
To further the exploration of ζ-Stat being a potential therapeutic for CCOC, a mechanistic
understanding of the direct protein binding is required for PKC-ζ and PKC-ι.
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2.9 Supplemental Figures

Figure 19. Raw Western blot images for TOV21G and SHT290 Figure 7A. (A) Western blot of
PKC-ι in TOV21G and SHT290 cells at 50% and serum free (SF). (B) Western blot of PKC-ζ in
TOV21G and SHT290 cells at 50% and serum free (SF). (C) Western blot of β-actin in TOV21G
and SHT290 cells at 50% and serum free (SF). Rows 3 and 4 were used for the TOV21G image
and rows 7 and 8 were used for the SHT290 image.
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Figure 20. Raw Western blot images for ES-2 Figure 7A. (A) Western blot of PKC-ι in ES-2
cells at 50% and serum free (SF). Bands are loaded in the opposite order. (B) Western blot of
PKC-ζ in ES-2 cells at 50% and serum free (SF). Bands are loaded in the opposite order. (C)
Western blot of β-actin in ES-2 cells at 50% and serum free (SF). Bands are loaded in the
opposite order.

Figure 21. Raw Western blot images for TOV21G Figure 7B. (A) Western blot of PKC-ι and its
corresponding β-actin in TOV21G cells. (B) Western blot of PKC-ζ and its corresponding β-actin
in TOV21G cells.
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Figure 22. Raw Western blot images for ES-2 Figure 7B. (A) Western blot of PKC-ι and its
corresponding β-actin in ES-2 cells. (B) Western blot of PKC-ζ and its corresponding β-actin in
ES-2 cells.

Figure 23. Raw Western blot images for TOV21G Rac1 PD utilizing GST PAK-PBD Figure
16D. (A) Western blot of Rac1 exposure time of 1 minute. Rows 1 and 2 are the positive and
negative control, respectively. (B) Western blot of Rac1 exposure time of 2 minutes. The positive
control is saturated (marked in pink). Rows 5 and 6 are the vehicle control and 10μM treatment
for TOV21G cells.
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Figure 24. Raw Western blot images for TOV21G RhoA and PKC-ζ protein decrease (A)
Western blot of RhoA in TOV21G cells with vehicle control (Row 2) and 3μM treatment (Row
3). (B) Western blot of PKC-ζ in TOV21G cells with vehicle control (Row 2) and 3μM
treatment (Row 3). (C) Western blot of β-actin in TOV21G cells with vehicle control (Row 2)
and 3μM treatment (Row 3).
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3 Ligand-mediated protein degradation reveals functional conservation among sequence
variants of the CUL4-type E3 ligase substrate receptor cereblon1
3.1 Introduction
Cereblon (CRBN) binds to thalidomide and other immunomodulatory drugs, including
lenalidomide (Len) and pomalidomide (Pom), and is one of many DDB1 and CUL4-associated
factors (DCAFs) that target specific protein substrates for ubiquitylation and proteasomemediated degradation by the DDB1–CUL4A–Roc1–RBX1 E3 ubiquitin ligase complex (Figure
33A) (275–277). Despite their teratogenic properties (278), immunomodulatory compounds have
antineoplastic activity in multiple myeloma (279), myelodysplastic syndrome (MDS) associated
with a somatically acquired deletion in chromosome 5 (del(5q) MDS) (280), and B cell
malignancies (281–283) based on the substrates that are selected for proteosomal destruction by
the bridging actions of these small molecules (Figure 33A) (275,276,284–287). Len, Pom, and a
newer derivative CC-122 (avadomide) (288) also potentiate the activation of T cells. Although
this function has been studied less thoroughly, it is thought that the drug-induced proteosomemediated degradation of transcriptional repressors of T cells, Ikaros and Aiolos, may be
necessary for this response in addition to their defined role in antineoplastic activity (Figure
33A) (289–291). Unlike human cells, mouse cells are resistant to these compounds, including
antiproliferative multiple myeloma (292) and thalidomide-associated teratogenicity (293).
Whereas the overall amino acid sequence of mouse CRBN is highly conserved (Figure 33B),
and it forms the DDB1 interaction (277), minor species–related sequence variations in the
1

This work has been previously published in the Journal of Biological Chemistry (294).
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thalidomide-binding domain (TBD) of CRBN are thought to lead to nonconserved drug binding
or altered E3 ligase recruitment functions. A single amino acid substitution, Val-388, which is
changed to isoleucine in mouse (Ile-391), has been reported to render mouse CRBN unable to
degrade Ikaros, Aiolos, and CK1α binding through a β-hairpin–loop motif that is recognized only
when CRBN is complexed with the immunomodulatory drugs (295). Therefore, a dysfunctional
drug-induced substrate requirement possibly mediates drug resistance (295). Thus far,
conservation of mouse CRBN's E3 ubiquitin–ligating function has not been definitely shown due
to this loss of function, as the native ligands that are regulated through this pathway are poorly
defined. Moreover, drug-binding affinity due to the V388I variant has not been studied in detail.
A better understanding of this defect is important for future drug discovery efforts aimed at
controlling intracellular protein degradation and understanding CRBN's endogenous role as an
E3 ubiquitin ligase substrate receptor.
Here, we focused our analysis on nonprimate CRBN. Using drug binding assays to
several CRBN sequence variants, we investigate whether these structural changes are likely to
result in functional inactivation. We focused on CRBN's substrate recruiting function in mouse
and human T cells, as this is poorly studied and important for defining applications in immune
therapy. Both the Bradner and Crews laboratories conjugated JQ1, an established chemical
inhibitor of bromodomain and extraterminal domain (BET) family members, to a thalidomide
analog to promote the CRBN-dependent degradation of BRD4 (296,297) Linkage of the BETbinding ligand (JQ1 or OTX-015) to an IMiD redirects CRBN-E3 ligase activity toward BRD4,
allowing for analysis of different substrates through a similar TBD-dependent mechanism
(Figure 33). Moreover, the E3 ubiquitin protein–targeting approach, coined proteolysis targeting
chimera (PROTAC) (298–300), may be broadly applied clinically and experimentally to study
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the function of proteins that are difficult to target and in cells that are insensitive to genome
editing techniques. Here, we use a PROTAC probe to investigate cellular engagement of an
immunomodulatory drug with mouse CRBN. Collectively, our findings are important to
understand sequence variants of CRBN and provide the first investigation of the E3 ubiquitin
ligase substrate-conjugating function of CRBN in a nonprimate vertebrate model.

3.2 Results

3.2.1 Resistance of mouse cells to immunomodulatory compounds.
Comparative analyses of CRBN sequences from representative vertebrate species
revealed that Ile-391 is conserved among many nonprimate mammals (mouse, rat, dog, manatee,
and opossum), birds (chicken and zebra finch), reptiles (alligator), amphibians (Xenopus), bony
fish (zebrafish and spotted gar), and cartilaginous fish (whale shark) (Figure 33B) (301).
Interestingly, both chicken and zebrafish are susceptible to thalidomide-induced teratogenicity
despite expressing the Ile-391 variant (277). In contrast, Val-388 is present in all examined
primate sequences (human, chimpanzee, gorilla, orangutan, gibbon, macaque, baboon, green
monkey, squirrel monkey, marmoset, tarsier, and Sunda flying lemur) with the exception of the
gray mouse lemur sequence, which encodes Ile in this position (Figure 33B). Therefore, Val-388
is a recently derived feature present in most primates.
Immunomodulatory drug–induced ubiquitin-mediated degradation of Ikaros and Aiolos
(encoded by IKZF1 and IKZF3, respectively) (275,302) appears sufficient to augment IL-2
production by T cells (303) in the absence and presence of anti-CD28 co-stimulation
(289,304,305). In Len-treated human T cells stimulated with anti-CD3ϵ antibody to cross-link
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the T-cell receptor (TCR), levels of IL2 mRNA (Figure 34A) and protein (Figure 34B) were
significantly increased relative to DMSO (vehicle)-treated cells. Comparing purified human
(Figure 25A) and mouse T cells (Figure 25B) pretreated with vehicle or 10 μM Len, only
human T cells displayed the expected Len-induced increase in IL-2 when stimulated in the
absence (Figure 25, A and B) or presence (Figure 34, C and D) of anti-CD28 antibody using
doses of anti-CD3ϵ that ranged from 0.01 to 10 μM.
Thalidomide, Len, and Pom's antiproliferative effects in multiple myeloma cell lines also
reportedly differ based on the presence of mouse CRBN (292,295,306). In U266 (Table 11),
H929 (Table 11), and MM1.S multiple myeloma cell lines (Figure 25C and Table 11), the
antiproliferative effects (IC50 values) of Pom ranged from 0.05 to 0.51 μM, and for Len, they
ranged from 1.5 to 10 μM. In contrast, the mouse multiple myeloma cell line 5TGM1 was
resistant to immunomodulatory drugs (Figure 25D and Table 11). Further, Ikaros protein
expression was unaffected in primary mouse T cells versus almost completely depleted in human
cells (Figure 25E), as predicted from previous structural and functional studies in multiple
myeloma cell lines and in the Ba/F3 mouse lymphoma cell line (287,295).
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Figure 25. Mouse cells are resistant to immunomodulatory drugs. Shown are T cells purified
from healthy donor peripheral blood mononuclear cells (A) or from mouse spleens of C57BL/6j
mice (B) and stimulated in the presence of increasing concentrations of anti-CD3ϵ antibody in
the presence of 10 μM Len or vehicle control (DMSO) without anti-CD28. IL-2 production was
determined from the culture supernatant by ELISA. The human MM1.S (C) or mouse 5TGM1
(D) multiple myeloma cells were cultured for 7 days with increasing concentrations of Len, Pom,
and vehicle (DMSO). Percentage relative cell viability is shown. E, Western blot analysis of
Ikaros, CRBN, and β-actin (loading control) in human and mouse T cells stimulated with antiCD3ϵ 5 μg/ml + 1 μg/ml anti-CD28 antibody for 24 h with DMSO and 10 and 20 μM
lenalidomide and pomalidomide. Results are representative of three independent experiments.
Statistical analysis was conducted using ANOVA, followed by Dunnett's multiple comparison
test. *, p < 0.05; ***, p < 0.001 (see also Figure 34). Error bars, S.D.
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Figure 26. Structure of cereblon is conserved across different species. A, ribbon overlays of
human (purple; PDB code 4TZ4) and chicken (blue; PDB code 4CI2) X-ray crystal structures
and post-MD structure of mouse (yellow; PDB code 4TZ4) cereblon. Human
immunomodulatory drug–binding site residues His-378, Trp-380, Trp-386, and Phe-402 and
ligands thalidomide (yellow), lenalidomide (green) and pomalidomide (blue) are shown for
reference. B, superposition of ligand poses of lenalidomide for the post-MD equilibrated systems
of the CRBN thalidomide-binding site after IFD for hCRBN (red), hmCRBN (green), and
gCRBN (orange), shown with the post-MD equilibrated protein structure of hCRBN (red) for
reference. C, overlays of human and mouse cereblon show nonconserved residues Ile-391 for
mCRBN (human Val-388), Val-380 for mCRBN (human Glu-377) (mouse shown in italic type)
(see also Figure 43 – Figure 45).
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3.2.2 Thalidomide-binding domain of CRBN has a conserved immunomodulatory
compound–binding motif
Next, the sequence variants of CRBN were studied in more detail. Based on crystal
structures, immunomodulatory compounds bind to a conserved pocket within the C-terminal
TBD of CRBN (Figure 33 and Figure 26A) (307,308). These interactions are governed by
hydrogen bonding, aromatic quadrupole, and van der Waals interactions. Analysis of the X-ray
crystal structures of CRBN (human (hCRBN), mouse (mCRBN), and chicken (gCRBN)) in
complex with thalidomide, Len, and Pom, respectively (Figure 26A), shows negligible
variations of root mean square deviation (RMSD) between the inhibitor poses. Thus, an in-depth
theoretical investigation of the molecular binding mechanics of immunomodulatory compounds
in complex with CRBN was conducted to explore possible differences in drug interactions
between mouse and human CRBN caused by induced fit or protein flexibility.
For molecular dynamics (MD), simulations of the crystal structures of hCRBN (Protein
Data Bank (PDB) code 4TZ4) (307) and gCRBN (PDB codes 4CI1, 4CI2, and 4CI3) (307) in
complex with DDB1 were used. The crystal structure of mCRBN (PDB codes 4TZC and 4TZU)
(308) is monomeric and truncated to contain only the TBD (108 defined residues compared with
380 defined residues for hCRBN and gCRBN) and is not suitable for computational modeling.
The amino acid differences in mouse CRBN (when compared with human CRBN) include
C366S, E377V (which may be specific to rodents), and V388I (Figure 26C). Therefore, to
further increase sampling and determine any structural dependence on these residues, the original
hCRBN sequence of the equilibrated representative structure was mutated to the mouse
sequence. The mCRBN analog and hmCRBN hybrid developed from the hCRBN system is
capable of reproducing the crystal ligand poses of mCRBN (PDB codes 4TZC and 4TZU) with
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minimal conformational deviation (Figure 26C) and was used for modeling purposes. Binding
modes do not appear to differ between models and compounds, as there are no significant
differences in RMSD calculations between X-ray crystal binding poses (Table 12) and post-MD
equilibrated models (Figures 2, B and C). Induced-fit docking (IFD) also predicts no observable
difference in binding affinity between models and compounds (Table 12). All poses are within
1.8 Å RMSD, which is the expected threshold for the IFD protocol (124).
Although Val-388 of hCRBN recruits Ikaros, Aiolos, and CK1α upon immunomodulatory
compound binding (295), the side chain is >6 Å away from the immunomodulatory drug, and it
is thus unlikely to alter binding affinity to the drugs. The second distinct amino acid is Glu-377,
which in the mouse is Val-380 and could establish a weak hydrogen bond with Len's amino
group. However, hydrogen-bond analysis (Figure 38) of MD simulations suggests that minimal
interaction occurs between this residue and bound immunomodulatory drugs, mainly due to the
backbone dihedral strain tending to force the charged carboxyl moiety away from the binding
site.

3.2.3 Immunomodulatory compound binding is conserved in CRBN sequence
variants
Amino acids in mouse CRBN–TBD at Val-380 (equivalent to human Glu-377) and Ile391 (equivalent to human Val-388) (Figure 27, A–C) appear to have no relevance in the
structure or corresponding immunomodulatory drug–binding interaction based on theoretical
modeling. To test the effects of these two nonconserved amino acids on binding affinity, the
recombinant human TBD motif (residues 319–425) was expressed in Escherichia coli (Figure
39A) and mutated to the mouse variants (Figure 27, A–C). Immunomodulatory drug binding
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was then analyzed using two distinct assays, an intrinsic tryptophan fluorescence assay (IF)
(Figure 27, D–G) and isothermal titration calorimetry (ITC) (Figure 27, H–K). The C366S
amino acid mutation was not studied in binding assays, as it is more than 20 Å away from the
immunomodulatory drug–binding pocket. The TBD is structurally stabilized by four cysteine
residues (Cys-323, Cys-326, Cys-391, and Cys-394) that coordinate a single zinc ion(307,308),
located ∼18 Å from the drug-interacting site. To gain insights into the role of zinc, mutations in
the CXXC domain of the TBD were also generated. Mutating any of the cysteine residues
resulted in insoluble protein that aggregated in inclusion bodies (Figure 39B). This is indicative
of misfolding due to loss of Zn2+ ion coordination. To rule out improper folding or
destabilization, a zincon assay (309) was performed on purified protein of all expressed
recombinant CRBN–TBD proteins. These analyses revealed a 1:1 stoichiometric ratio of Zn 2+
bound to the TBD recombinant protein (Figure 39, C–F). Moreover, protein secondary structure
consistent with proper folding was also evident using CD (data not shown). Both IF (Figure 27,
D–G) and ITC (Figure 27 (H–K) and Figure 40) analyses demonstrated similar KD values at
equilibrium for thalidomide and the immunomodulatory compounds tested in binding to WT,
E377V, V388I, and E377V/V388I hmCRBN–TBD (Table 10) with no binding observed by
phthalimide (Figure 40, I–L), used as a negative control.
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Figure 27. Human and mouse CRBN binds IMiDs with similar affinities. A, sequence alignment
of human CRBN and human-to-mouse mutations. Mutations introduced to convert human to
mouse are highlighted in red. B, IMiD interaction in the hydrophobic binding pocket. C,
lenalidomide (green) interacts with the TBD site (gray) through hydrogen bonds (dashed black
lines) with backbone residues His-378, Ser-379, and Trp-380 van der Waals interactions (dashed
green lines) that occur with the side chains of Trp-380, Trp-386, Trp-400, and Phe-402 (mouse:
Trp-383, Trp-389, Trp-403, and Phe-405). The two residues differing between the human and the
mouse proteins are highlighted in cyan. Shown are titration of human TBD WT (D), E377V (E),
V388I (F), and E377V/V388I (hmCRBN–TBD) (G) to lenalidomide (red), pomalidomide
(green), thalidomide (blue), and phthalimide (black) by intrinsic tryptophan fluorescence assay.
KD values were calculated based on the magnitude of fluorescence differences (1 − F/F0). H–K,
isothermal titration calorimetry saturation curve using Len for human TBD and mutants (see also
Figures S3–S5 and Table 10). Error bars, S.D.
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Table 10. Binding affinity (KD, [μM]) of immunomodulatory compounds to WT and mutant
human CRBN-TBD determined using ITC and fluorescence intensity assay.
KD

TBD

Assay

hCRBN

ITC

11 ± 3

16 ± 4

65 ± 40

NB

NP

FI

13 ± 2

16 ± 3

38 ± 12

NB

16 ± 2

ITC

22 ± 3

35 ± 8

37.4 ± 10

NB

NP

FI

27 ± 4

22 ± 6

74 ± 20

NB

NP

ITC

NB

NB

NB

NB

NP

FI

NB

NB

NB

NB

NP

ITC

9.6 ± 2

35 ± 9

97 ± 100

NB

NP

FI

22 ± 2

30 ± 7

36 ± 8

NB

NP

ITC

10 ± 1

28 ± 7

43 ± 20

NB

NP

FI

14 ± 4

16 ± 4

39 ± 1

NB

13 ± 2

ITC

14 ± 2

8±2

34 ± 2

NB

NP

hCRBN-H378A
hCRBN-W380A
hCRBN-E377V
hCRBN-V388I
hmCRBNE377V/V388I

Lenalidomide Pomalidomide Thalidomide Phthalimide

FI
13 ± 3
19 ± 4
30 ± 8
NB
Data represent mean ± S.D. FI, fluorescence intensity; NB, non-binding; NP, not performed.

dBET1

NP

To assess the impact of binding pocket residues, Ala mutations of two residues were
generated (Table 10) (281,301,302) to test the impact of hydrogen bond formation and
hydrophobic interaction with Trp-380. The W380A mutation completely abolished ligand
interactions. Although His-378 forms two hydrogen bonds with the glutarimide ring (Figure
27C), mutating this residue to Ala showed only minor impact on binding. Pom and Len affinities
were reduced, while thalidomide displayed increased affinities. This suggests that the backbone
carbonyl of H378A may retain the hydrogen bond interaction with the NH group of the
glutarimide ring. To further probe the role of His-378 side chain in immunomodulatory drug
binding, we conducted a pH dependence study to measure the binding affinity of Len to CRBN–
139

TBD by ITC. The KD values measured at pH 4.5, 5.5, 6.5, and 7.5 are 21.4 ± 3, 23.7 ± 8, 23.8 ±
7, and 11.3 ± 2 μM, respectively. Some impact was seen at pH 7.5, indicating deprotonation of
the His-378 imidazole group has marginal impact on the immunomodulatory drug binding to the
TBD. However, the protein microenvironment influence on the histidine glutarimide ring can
easily overcome small deviations of 1 or 2 bulk pH. Thus testing affinities under the
aforementioned conditions are likely insufficient.

3.2.4 N-terminal stabilization of CRBN–immunomodulatory compound interactions
Finally, we compared binding affinities of Len to CRBN–TBD and full-length CRBN–
DDB1 protein complex using ITC to assess the impact of residues outside of the TBD. The fulllength CRBN–DDB1 complex displayed a KD value of 0.64 μM ± 0.24 μM (pH 7.0) (Figure
28A). This affinity is similar to published data using a fluorescence polarization-based
assay(307). Moreover, these results are consistent with a single binding site within the protein
complex. To gain more insight into immunomodulatory compound binding to CRBN–TBD, we
synthesized N-methyl-Len as a negative control, where the N-methyl group of the glutarimide
ring is predicted to cause steric hindrance in the binding pocket (Figure 41) and lacks the key
hydrogen bond donor to His-378. As expected, N-methyl-Len did not bind to either the CRBN–
TBD or CRBN–DDB1 complex (Figure 28B), as measured by ITC, indicating that the complex–
drug interaction is mediated predominantly by the glutarimide binding pocket of the TBD.
Interestingly, the binding affinity of Len to the CRBN–TBD is about 30-fold lower than the fulllength CRBN–DDB1 complex. Moreover, full-length CRBN and CRBN–TBD have endothermic
and exothermic reactions, respectively. Therefore, residues in the full-length protein appear to
augment protein-ligand interactions in the binding pocket.
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Figure 28. Lenalidomide binds to the TBD and CRBN–DDB1 protein complex. ITC binding
curves of lenalidomide (A and C) and N-methyl-lenalidomide (B and D) titrated with CRBN–
DDB1 complex (A and B) and CRBN–TBD (C and D). E and F, schematic view of lenalidomide
interaction in the binding pocket of full-length human cereblon; human full-length CRBN
(salmon) and DDB1 (blue) with bound lenalidomide (magenta) (PDB code 5FQD) superimposed
with mouse TBD-CRBN (cyan) (PDB code 4TZU). Hydrogen bonds and hydrophobic
interactions are shown in red and black dashed lines, respectively (see also Figure 41). Data in
figure represent mean ± S.D.
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3.2.5 Acquired ubiquitin-proximity ligation in mouse cells establishes conserved
ligase functions of mouse and human CRBN variants.
The substrate-recruiting function of CRBN was then investigated using dBET1, which
maintains the CRBN–TBD targeting domain but switches the substrate-recruitment domain to
recognize BRD4 and other JQ1-associated targets(296). Using IF (Figure 29A), the saturation
binding curves for dBET1 are similar to that of Len, whereas, as expected, JQ1 alone does not
bind to the CRBN–TBD. The structures of dBET1 and N-methyl-dBET1 (used as a negative
control, based on the results of N-methyl-Len) are provided in Figure 29B to show the CRBNand BET-targeting groups. Moreover, N-methyl-dBET1 confirms that this analog is interacting
with similar residues in the TBD. Next, the function of dBET1 in activated human T cells was
assessed, and results are shown in Figure 29 (C–G); statistical analysis is provided in Table 13.
Unlike Len and Pom, which activate T cells, BRD4 and c-Myc inhibition is expected to induce
cell death or functionally repress these cells, as they are critical mediators of T-cell proliferation
and survival(310,311). Relative viability of activated T cells is reduced by dBET1 treatment
compared with DMSO and is more active relative to treatment with increasing doses of JQ1
(Figure 29C), suggesting that growth suppression by the heterobifunctional conjugate is superior
to JQ1, as shown previously in leukemia cells (296). Importantly, decreased BRD4 protein
expression is only evident with dBET1 treatment, whereas both dBET1 and JQ1 suppress the
activation of c-Myc protein expression by Western blot analysis (Figure 29D) and flow
cytometry (Figure 29E; summary of data in Figure 29F), as expected, through BRD4 functional
repression. Notably, the effect on BRD4 is reversed by incubation with N-methyl-dBET1 at
doses of 0.1–10 μM. Repression of c-Myc at very high doses of N-methyl-dBET1 is consistent
with activity of the JQ1-targeting molecule (Figure 29, D and F). From these results, we
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conclude that human T cells respond to dBET1 through interactions that are mediated by the
hydrophobic pocket of the CRBN–TBD. Finally, the suppressive effects observed with dBET1
treatment shows that the CRBN-targeting molecule in this compound is no longer activating IL2, as shown in Len and Pom (Figure 29G).

Figure 29. Functional activity of lenalidomide, JQ1, and dBET1 in human T cells and binding
affinities of JQ1, dBET1, and Len to human CRBN. A, saturation binding curves of human TBD
WT titrated with lenalidomide (KD = 15.6 ± 2.2), JQ1 (no binding), dBET1 (K D = 26.0 ± 2.1),
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and N-methyl-dBET1 (no binding) by fluorescence assay (see also Table 10 for a summary of all
KD values). B, structure of dBET1 and N-methyl-dBET1. C, human T cells purified from
peripheral blood mononuclear cells from healthy donors and stimulated with anti-CD3ϵ/CD28.
At the time of TCR stimulation, DMSO (vehicle control), the indicated concentrations of JQ1
and dBET1, 10 μM Len, and 10 μM Pom were added to the cell cultures. Cell viability was
determined after 72 h by flow cytometry using Zombie NIRTM staining. D, Western blot
analysis for expression of BRD4, CRBN, c-Myc, and vinculin in human T cells stimulated with
anti-CD3ϵ/CD28 and treated simultaneously with vehicle (DMSO, 0.1%), JQ1, dBET1 (10 μM),
and N-methyl-dBET1 (10 μM) for 48 h. Unstimulated cells are not shown in D. E, c-Myc
expression by flow cytometry (histogram data) is shown following 48-h stimulation with antiCD3ϵ/CD28. Drug treatments and doses are indicated. Expression of c-Myc requires stimulation
based on comparison with unstimulated cells (unstim). Values represent percent positive relative
to unstimulated cells based on gate (dotted line). F, quantification of flow data shown in E
represented as percentage of DMSO. Bar height is the mean of individual values shown
representative of three independent experiments. Error bars, S.D. from an exemplary experiment.
G, unstimulated (unstim) or anti-CD3ϵ/CD28–stimulated T cells were treated with 10 μM Len,
10 μM Pom, and the indicated doses of JQ1 or dBET1. ELISAs were used to quantify IL-2
concentrations (pg/ml) from supernatants harvested at 48 h. Results shown are representative of
three independent experiments. Bar height, mean of individual values; error bars, S.D. from an
exemplary experiment. Results of statistical analysis are provided in Table 13.

Next, saturation binding curves of V388I-TBD mutant titrated with Len (KD = 15.6 ± 2.2
μM), dBET1 (KD = 26.0 ± 2.1 μM), and N-methyl-dBET1 (nonbinding control) show that the
mode and binding affinity of dBET1 are similar to those of the human-TBD protein (Table 10
and Figure 30A). Mouse T cells were purified from Crbn+/+ and Crbn−/− mice and used to
evaluate the role of mouse CRBN in BRD4 degradation (Figure 30, B and C), activationinduced proliferation, viability, and c-Myc and CD98 (Myc target gene) (Figure 30, D–G)
expression in response to dBET1 treatment (Figure 29B). TCR stimulation with anti-CD3ϵ +
anti-CD28 is required for the induction of c-myc in primary mouse T cells (data not shown).
Both JQ1 and dBET1 suppressed c-Myc in activated T cells, but the reduction in protein
expression of BRD4 was only observed after dBET1 treatment in Crbn+/+ mouse T cells,
consistent with proteasome engagement (Figure 30B) through a CRBN-dependent mechanism.
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Pomalidomide treatment failed to impact BRD4 expression and further supports redirection of
CRBN's ubiquitin-conjugating function through JQ1. To assess whether dBET1 is interacting
directly with the TBD of mouse CRBN in vivo, an assay was performed using mouse Crbn +/+ T
cells treated with Pom in the presence and absence of dBET1. Results shown in Figure 30C
show that at high concentrations of Pom (10-fold excess), the impact of dBET1 on c-Myc and
BRD4 expression was reversed, suggesting that dBET1 is directly engaging the TBD of mouse
CRBN. We next examined proliferation (i.e. division index) measured by dilution of cell trace
violet (CTV) using methods described previously (312), expression of a c-Myc target gene
(CD98), and viability using flow cytometry (Figure 30D). Histograms (Figure 30D) and
summarized results (Figure 30, E–G) show that the division index (based on CTV data) and
CD98 expression (median fluoresce intensity (MFI)) are induced through activation
(unstimulated versus DMSO) and that there is a differential response to dBET1 treatment in
Crbn+/+ and Crbn−/− T cells at 0.1 and 1 μM. The suppression of T cells at 10 μM is probably
related to the JQ1-targeting molecule, because proliferation, c-Myc–regulated CD98 expression,
and viability were suppressed independently of CRBN expression. Moreover, BRD4 degradation
by dBET1 is similar in MM1.S human and 5TGM1 mouse multiple myeloma cells, confirming
the conserved ubiquitin-conjugating functions of CRBN (Figure 42).
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Figure 30. Functional activity of lenalidomide, pomalidomide, JQ1, and dBET1 in mouse T
cells. A, saturation binding curves of human V388I mutant TBD titrated with lenalidomide (K D =
18 ± 4), JQ1 (no binding), dBET1 (KD = 18 ± 3), and N-methyl-dBET1 (no binding) by
fluorescence assay (see also Table 10). B, mouse T cells purified from spleens of C57BL/6j mice
with homozygous deletion of Crbn and WT littermates were stimulated with anti-CD3 ϵ/CD28 in
the presence of 0.1% DMSO (vehicle control), 10 μM Pom, 10 μM JQ1, or 10 μM dBET1.
Western blots for BRD4, c-Myc, CRBN, and vinculin (loading control) expression are shown. C,
Western blot analysis showing expression of BRD4, c-Myc, and vinculin from Crbn +/+ T cells
stimulated with anti-CD3ϵ/CD28 for 12 h with the indicated doses of dBET1, Pom, or combined
treatment. D, purified Crbn+/+ and Crbn−/− mouse T cells stimulated with anti-CD3ϵ/CD28 and
treated with 0.1% DMSO (vehicle control), 10 μM Len, 10 μM Pom, 10 μM JQ1, or increasing
doses of dBET1 for 72 h. Histogram plots from one experiment show proliferation (determined
by dilution of CTV) and CD98 expression of T cells. E, proliferation index based on CTV data
was used to calculate the amount of proliferation using an algorithm available with Flowjo
analysis software (Tree Star). F, expression of CD98 was calculated relative to unstimulated cells
using gates shown based on mean fluorescence intensities (MFI) of T cells as shown in D. G, cell
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viability was determined after 72 h by flow cytometry using Zombie NIRTM staining. Results
shown are representative of three independent experiments. Bar height represents mean of
individual values, and error bars represent S.D. from an exemplary experiment. Results of
statistical analysis are provided in Table 14.
3.3 Discussion
CRBN was first identified in mild autosomal recessive nonsyndromic intellectual
disability (313) but has poorly defined physiological functions. Interactions have been reported
with the AMP-activated protein kinase α1 subunit (314), TAK1–TRAF6 (315), and CD147–
MCT1 complex (316), where CRBN plays ubiquitin-independent roles in pathway regulation.
The mechanistic underpinnings for induced limb deformities in chickens and zebrafish, but not in
mice, appears dependent on sequence differences in mouse CRBN (295), which brings into
question whether these differences in CRBN render it functionally inactive. Although reference
CRBN sequences for nearly all examined primates possess Val-388, according to the Exome
Aggregation Consortium, the Ile-391 variant occurs in humans at a frequency of 0.005%
(rs756414303). Our data show that mutating Val-388 to Ile (V388I) does not alter binding
affinity to the immunomodulatory compounds, suggesting that the contact between the
immunomodulatory drug and the CRBN–TBD is maintained and potentially functionally active.
When bound to immunomodulatory drugs (Len, Pom, and CC-122), CRBN induces the
destruction of three substrates, Ikaros, Aiolos, and CK1α (287), via a Val-388 interaction (275).
In T cells, the IKZF-family transcription factors repress IL2 so that ubiquitin-mediated
destruction may be responsible for promoting T cell activation (287,290). Our data solidify the
mechanistic involvement of CRBN Ile-391 in drug resistance in mouse cell lines, as suggested
previously by the finding that overexpression of hCRBN with Val-388, but not Ile-391, in Ba/F3
cells was sufficient to restore Ikaros protein destruction (287,295).
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As expected, using dBET1, there was no Ikaros degradation in mouse T cells or mouse
myeloma cell lines. However, we found that dBET1 impressively reduced the expression of
BRD4 in both human and mouse cells. Therefore, proximity-associated ubiquitin-conjugating
functions of mouse and human CRBN are confirmed using dBET1. Crbn−/− T cells
demonstrated that dBET1 functions through a CRBN–TBD–dependent process. Competition
with Pom further suggests that the TBD of human and mouse CRBN have similar binding modes
for immunomodulatory compounds, suggesting that there is both structural and functional
conservation. Thus, the endogenous E3 ubiquitin ligase activity and assembly of the CRBN–
DDB1–CUL4A–containing complex are fundamentally conserved across the vertebrate lineage,
including the mouse, and probably other species, expressing Ile-391. Moreover, other sequence
variants present in mouse CRBN, including difference in the N terminus, fail to impact its
substrate-recruiting functions when targeting BRD4. This observation, along with the high
degree of CRBN conservation, indicates that selective pressure has maintained the overall
structure and function in CRBN for over 400 million years.
Using ITC and fluorescence-based binding assays, we establish that the dissociation
constants of thalidomide and other immunomodulatory compounds to mouse CRBN are similar
to human CRBN, which is consistent with analysis of the crystal structure of human CRBN–
DDB1 in complex with Len (307,308). As suggested previously (307), the W380A mutant
completely abolished binding, which confirms that this is one of the key residues of the binding
pocket. Trp-380 also appears to work synergistically with other binding pocket residues (Trp386, Trp-400, and Phe-402) for ligand interaction. The KD values of immunomodulatory
compounds in complex with the human TBD (amino acids 319–425) are in the micromolar
range, similar to those of Caenorhabditis elegans and Magnetospirillum gryphiswaldense (317).
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Based on the conserved CRBN structure, we synthesized N-methyl derivatives of Len and
dBET1, which proved useful in assessing the functional contribution of this ligand interaction in
vivo in mouse and human cells.
Here, we show an interesting reliance of the rigid TBD-binding pocket on N-terminal
sequences, which plays a previously unappreciated role in optimal ligand binding. A
conformational change in full-length CRBN–DDB1 may occur upon ligand binding, as shown by
the difference in their ΔH and ΔS values (Figure 28). Notably, the CRBN–DDB1 complex and
CRBN–TBD show a marked difference in Len-binding affinity by ITC. In fact, a closer
inspection of the crystal structure of full-length CRBN in complex with Len illustrates that a
disordered loop in the TBD consisting of residues Asn-351, Pro-352, and His-353 stabilizes the
interaction of Len. Asn-351 forms a hydrogen bond to a carbonyl oxygen of Len's isoindolinone
ring, and both Pro-352 and His-353 form hydrophobic interactions with the aromatic system of
the immunomodulatory drug (Figure 28E). Importantly, the mouse TBD crystal structure shows
poor electron density in this loop structure, suggesting that it is a highly unstructured and
dynamic region. Alternatively, other residues outside the TBD could have stabilized this loop.
The side chain of Gln-100, which is located in the LON domain of CRBN, forms a weak
hydrogen bond interaction to the ϵ2NH group of His-378. This in turn positions the δ1NH of His378 as a hydrogen donor to the immunomodulatory drugs. These important structural domains
should be further investigated in immunomodulatory drug discovery.
Collectively, our results suggest that PROTAC molecules and possibly other CRBNbound compounds may adopt an active conformation that is susceptible to CRBN-directed,
cullin–RING E3 ligase–mediated polyubiquitination in mouse cells. PROTAC molecules are
designed to harness the CRBN-binding properties of IMiDs and initiate the degradation of
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oncogenic targets. Several IMiD-based BET-targeting PROTACs, such as dBET-1, ARV-825, and
BETd-260 have been developed to potently degrade BRD4 (297,318,319). Intracellular protein
degradation of FK506-binding protein (FKBP12) was also achieved by a conjugate of
thalidomide (296,320), but originally, methionine aminopeptidase-2 (MetAP-2) (300), estradiol,
and dihydroxytestosterone were degraded by engaging the Skp1–Cullin–F-box (SCF) ubiquitin
ligase through a 10-amino acid phosphopeptide derived from IκBα (298,321). PROTAC with
specificity for the von Hippel–Lindau ubiquitin ligase E3 have also been developed (322,323).
Recently, BRD4 and ERK1/2 degradation was induced by the interaction of two smaller
precursors molecules that undergo intracellular self-assembly, which improves solubility and
cellular permeability of thalidomide-containing PROTAC inhibitors (324). Importantly, our
studies establish that mouse platforms can indeed be used for preclinical development of dBET1
and possibly other PROTAC-based chemical degraders that are designed to redirect CRBN's
substrate-binding function toward specified endogenous proteins (296,298,300,318,324,325).
Toxicology and functional testing of such agents in rodents and mouse tumor models may yield
important preclinical information.

3.4 Experimental procedures

3.4.1 Animals and cell lines
Germ line Crbn-deficient mice (Crbn−/−) were described previously (313), and gene
deletion was confirmed using WT and Crbn-KO–specific primers. C57BL/6 (Crbn+/+) mice were
purchased from Jackson Laboratory (Farmington, CT) and were then bred to Crbn −/− mice. Crbn+/
+

and Crbn−/− littermates from Crbn+/− intercrosses were used for our studies. Mice were
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maintained and bred at the H. Lee Moffitt Cancer Center and Research Institute under a protocol
approved by the institutional animal care and use committee. The human multiple myeloma cells,
including U266, H929, and MM1.S, and the mouse multiple myeloma cell line 5TGM1 were
generous gifts of Drs. Ken Shain and Connor Lynch (Moffitt Cancer Center, Tampa, FL). All cell
lines were mycoplasma-free and sequence-verified.

3.4.2 T-cell isolation, activation, and drug treatments
Human polyclonal CD3+ T cells or CD8+ T cells were isolated from peripheral blood
donations to the Southwest Florida Blood Services. Because personal identifying information is
unavailable, the research was deemed nonhuman research. Human and mouse T cells were
isolated from Crbn+/+ and Crbn−/− splenocytes by immunomagnetic negative selection (Miltenyi
Biotec, San Diego, CA), and >95% purity was confirmed by flow cytometry. For drug treatment
experiments, 12-well flat bottom plates were coated with 5 μg/ml anti-CD3 ϵ (clone HIT3a
(eBioscience) or clone (145-2C11)) in 1× PBS at 37 °C for 60 min. Cells were plated at 2–4 ×
106 cells/well with anti-CD28 (clone CD28.2 (eBioscience) or clone 37.51 (eBioscience)).
Following 12 h of activation, the cells were treated with DMSO (0.1%, Sigma-Aldrich), Len (10
μM) (Celgene, NJ), Pom (Sigma-Aldrich), and JQ1 (doses indicated) (catalog no. SML0974,
Sigma-Aldrich). N-Methyl-Len, dBET1, and N-methyl-dBET1 were all synthesized at the
Moffitt Cancer Center (described in the supporting material) and used at the doses indicated.
After 12 h of drug treatment, cells were harvested, and protein levels were examined by Western
blot analysis. For proliferation experiments using mouse T cells, 0.1–10 μg/ml anti-CD3ϵ (clone
145-2C11, eBioscience) was used with cells plated with and without anti-CD28 for 72 h.
Cytokine expression was determined using supernatants that were harvested at 24 or 48 h and
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quantified from standard curves by ELISA according to the manufacturer's protocol. Kits were
purchased from eBioscience (IL-2) and R&D Systems for other cytokines. For functional
analysis of T cells treated with JQ1, murine CD3 + T cells from Crbn+/+ and Crbn−/− splenocytes
and human T cells were labeled with 5–10 μM CellTrace Violet (C34557, Thermo Fisher
Scientific) and activated with 5 μg/ml anti-CD3ϵ and 1 μg/ml anti-CD28 for 72 h in roundbottom 96-well plates. Cells were stained with CD98-PE (clone RL388, Biolegend), 7aminoactinomycin D (BD Pharmingen), and the Zombie NIRTM fixable viability kit (catalog no.
423105, Biolegend) and analyzed on a BD LSRII flow cytometer.

3.4.3 Quantitative real-time PCR
Isolated T cells from Crbn+/+ and Crbn−/− mice were lysed and homogenized (Qiashredder,
Qiagen), and total RNA was extracted (RNeasy, Qiagen) according to the manufacturer's
protocol. Complementary DNA was generated from isolated RNA (iScript cDNA synthesis kit,
Bio-Rad). RNA expression was analyzed by quantitative real-time PCR using Taqman Universal
PCR Master Mix for Taqman probes (Thermo Fisher Scientific) against (cDNA) c-Myc
(Mm00487804_m1) and (cDNA) β2 M (Mm00437762_m1). Samples were run on an Applied
Biosystems 7900 HT and Sequence Detection Systems software.

3.4.4 Treatment of multiple myeloma cells
Mouse and human multiple myeloma cell lines were plated at 2–4 × 10 6 cells/well in a
12-well plate with various concentrations of Len and Pom. To confirm target degradation, the
cells were treated with varying concentrations of dBET1 (0, 0.01, 0.1, 1, and 10 μM) for 12–24
h. Following drug treatment, protein levels were examined by Western blot analysis relative to
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vinculin or β-actin to normalize for protein expression. For proliferation studies, 1–2 × 10 4
cells/well were seeded in a 96-well plate and were treated with using the CCK8 (cell-counting-8)
kit (Dojindo, Rockville, MD) according to the manufacturer's protocol.

3.4.5 General chemistry information
All reagents were purchased from commercial suppliers and used without further
purification (except where mentioned otherwise). 1H NMR spectra were recorded on an AgilentVarian Mercury 400-MHz spectrometer with DMSO-d6 as the solvent. All coupling constants are
measured in hertz, and the chemical shifts (δH) are quoted in parts per million relative to TMS
(δ0), which was used as the internal standard. High-resolution MS was carried out on an Agilent
6210 LC-MS (electrospray ionization-TOF) system. HPLC analysis was performed using a
JASCO HPLC system equipped with a PU-2089 Plus quaternary gradient pump and a UV-2075
Plus UV-visible detector, using an Alltech Kromasil C-18 column (150 × 4.6 mm, 5 μM) and an
Agilent Eclipse XDB-C18 column (150 × 4.6 mm, 5 μM). The purities of the final compounds
used for the biochemical and functional studies were >95% as measured by HPLC. Melting
points were recorded on an Optimelt automated melting point system (Stanford Research
Systems). TLC was performed using silica gel 60 F254 plates (Thermo Fisher Scientific), with
observation under UV when necessary. Anhydrous dimethylformamide was used as purchased
from Sigma-Aldrich. Burdick and Jackson HPLC-grade solvents were purchased from VWR for
HPLC, HPLC-MS, and high-resolution mass analysis. dBET1 (HPLC purity 98%) was prepared
from JQ1 as described(296). Detailed information about the synthesis of N-methyl-Len, and Nmethyl-dBET1 synthesis are provided in the supporting material.
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3.4.6 Cloning, protein expression, and purification
The full-length hCRBN protein (isoform 1) in complex with DDB1 was a generous gift
from Celgene Corp. (San Diego, CA). The gene coding for the human TBD (amino acids 319–
425) was synthesized and subcloned into the BamHI-NotI restriction sites of the pGEX-6P-1
vector by GeneArt® gene synthesis. The gene was engineered with silent mutations that utilize
the favored E. coli codons. TBD E377V, V388I, H378A, and W380A mutations were performed
using PCR. Details of primer sequences are provided in the supporting material. Mutations were
confirmed by sequencing. The recombinant DNA plasmids were transformed into E. coli
RosettaTM 2(DE3)pLysS competent cells (EMD Millipore, Billerica, MA) for subsequent protein
expression. The GST-tagged TBD proteins linked with PreScission protease proteolytic site were
expressed and purified as follows. A single colony of freshly transformed cells was cultured at 37
°C for 16 h in 5 ml of Luria–Bertani (Thermo Fisher Scientific) medium containing 100 μg/ml
ampicillin (Sigma-Aldrich) and 34 μg/ml chloramphenicol (Sigma-Aldrich). 1 ml of the culture
was then used to inoculate 25 ml of Terrific Broth–phosphate medium (Thermo Fisher Scientific)
with 100 μg/ml ampicillin at 37 °C for 16 h. The culture was then transferred to 1.5 liters of
Terrific Broth–phosphate medium supplemented with 50 μM ZnCl2 (Sigma-Aldrich). The
resultant culture was incubated with continuous shaking at 250 rpm to an A600 of 0.70 and then
induced with isopropyl-β-d-thiogalactopyranoside (0.5 mm final concentration; Thermo Fisher
Scientific) at 16 °C for 20 h before harvesting by centrifugation at 6000 rpm for 30 min. The
cells were lysed by homogenization in 50 mm Tris (pH 8.0; Sigma-Aldrich), 500 mm NaCl
(Thermo Fisher Scientific), 1 mm TCEP (Sigma-Aldrich), 0.1% Triton X-100 (Sigma-Aldrich),
10 μM ZnCl2 (Acros Organics, Thermo Fisher Scientific), and protease inhibitor mixture (Roche
Applied Science). The protein was then purified by affinity chromatography on an AKTA
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Explorer or AKTA Purifier (GE Healthcare Life Sciences) using a GSH-Sepharose matrix (GE
Healthcare) pre-equilibrated with 50 mm Tris (pH 8.0), 500 mm NaCl, 1 mm TCEP, and 10 μM
ZnCl2 and eluted with the same buffer with the addition of 10 mm reduced GSH (SigmaAldrich). Purity of the protein in the different fractions was determined by SDS-PAGE, and the
best fractions were pooled. GST was cleaved from the pooled GST-TBD fractions by digestion
with PreScission protease at 4 °C for 4 h. GST was removed from the resultant digest by a
second round of GST affinity chromatography. Proteins were further purified by size-exclusion
chromatography in a Superdex 75 column (GE Healthcare Life Sciences). Fractions with >90%
purity were pooled, concentrated by ultrafiltration (10K Amicon tubes, EMD Millipore), and
stored at −80 °C.

3.4.7 Zincon assay
All chemicals used in this assay were purchased from Sigma-Aldrich. The assay was
adapted from previously published methods (309). A zinc concentration standard curve was
prepared in 50 mm borate buffer, pH 9.0, containing 4 m NaCl, 8 m urea, and 40 μM zincon (2carboxy-2′-hydroxy-5′-sulfoformazylbenzene) dye. Purified proteins were acidified with 300 mm
HCl to facilitate the release of the zinc ions bound to the protein. The protein polypeptide was
separated from the water-soluble layer by centrifugation. The solution was then spiked with 10–
20 μM zinc sulfate. Absorption spectra between 400 and 750 nm were recorded. λmax of free
zincon and zincon–zinc complex were measured at 480 and 620–630 nm, respectively.
Absorbance at 630 nm of different zinc concentrations was used to generate the linear regression
curve. The concentration of zinc-containing protein was extrapolated based on the linear
regression curve.
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3.4.8 ITC
The binding of CRBN–DDB1 complex and CRBN–TBD WT and mutant variants to
immunomodulatory compounds was analyzed with a MicroCal iTC200 titration calorimeter
(Malvern, Westborough, MA). The compound phthalimide was used as the negative control. The
proteins were rebuffered into binding buffer (50 mm HEPES (pH 7.5, Sigma-Aldrich), 200 mm
NaCl, 0.1 mm TCEP, and 0.6% DMSO). For the titrations of the protein constructs, a total of 19
aliquots (2.05 μl each) of the respective compounds (∼600 μM) were injected into 200 μl of the
protein solutions (40 μM) at 25 °C. The ITC cell mixture was constantly stirred at 1000 rpm and
recorded for 160 s between injections at low feedback. The corrected heat values were fitted
using a nonlinear least square curve-fitting algorithm (Microcal Origin version 7.0, OriginLab,
Northampton, MA) to obtain binding constants (K D) and values for n (number of binding sites),
ΔH (enthalpy), and ΔS (entropy).

3.4.9 Intrinsic tryptophan fluorescence assay
Binding of compounds to WT and mutant TBD was monitored by fluorescence
spectroscopy, using an adapted previously published method (288,317). All chemicals used in
this assay were purchased from Sigma-Aldrich unless otherwise stated. In this assay, changes in
emission spectra are induced by interactions of these compounds with the three Trp residues
(Trp-380, Trp-386, and Trp-400) in the binding site (307,308). TBD proteins (final concentration,
10 μM) were incubated with varying final concentrations (0–750 μM) of compounds in assay
buffer (50 mm Tris, pH 7.5, 200 mm NaCl, 0.1% Pluronic-F127, and 1 mm TCEP) to a final
volume of 40 μl in a black 96-well half-area plate (Corning, Inc.). A 0.5% final DMSO
concentration was used in each well. Samples were excited at 280 nm, and fluorescence emission
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intensities were measured at 340 nm using a Wallac Envision 2102 multilabel plate reader
(PerkinElmer Life Sciences). All measurements were done in triplicate and corrected for inner
filter effect to subtract for ligand-associated fluorescence, as described (326). The magnitude of
fluorescence difference (1 − F/F0) was measured, where F is the fluorescence emission at a given
concentration of ligand; F0 is the intrinsic fluorescence intensity of 10 μM TBD protein alone.
Graph plotting and curve fitting to obtain apparent dissociation constant (K D) values were
calculated by fitting the relative change in intrinsic fluorescence at 340 nm (1 − F/F0) versus
ligand concentration to a nonlinear regression with one-site binding hyperbola with GraphPad
Prism (GraphPad Software, La Jolla, CA).

3.4.10 Molecular Modeling Preparation
The preparation of the protein systems for hCRBN (PDB code 4TZ4 (307), mCRBN
(PDB codes 4TZC and 4TZU) (307), and gCRBN (PDB codes 4CI1, 4CI2, and 4CI3) (308) were
done using the Schrödinger software suite (Maestro, version 9.7, Schrödinger, LLC, New York).
Protein structure coordinates were downloaded from the PDB (227,228) and prepared with the
Protein Preparation Wizard (PrepWizard) in Maestro (Schrödinger Suite 2014-1 Protein
Preparation Wizard; Epik version 2.7, Schrödinger; Impact version 6.2, Schrödinger; Prime
version 3.5, Schrödinger) (231). Final system equilibration was determined by the observation of
asymptotic behavior of the potential energy, RMSD, and Rg profiles and visual inspection of
trajectories guided by root mean square fluctuation profiles (See Section 3.8.1 Supplementary
Computational Results). MD simulations were performed with the Desmond MD program with
additional details provided in the supporting Materials and Methods (Desmond Molecular
Dynamics System, version 3). After equilibration was determined, a hierarchical average linkage
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clustering method based on RMSD was utilized to determine an average representative structure
for each equilibrated system. The program PROPKA was then implemented again on the
equilibrated structures to test the consistency of side chain protonation states at pH 7.4 (Section
3.8.3 Determination of H378 Protonation States provides details for characterization of the
ionization states for certain side chains).
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The abbreviations used are:
CRBN cereblon
hCRBN

human CRBN

mCRBN

mouse CRBN

gCRBN

chicken CRBN

Len

lenalidomide
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Pom

pomalidomide

MDS

myelodysplastic syndrome

TBD

thalidomide-binding domain

BET

bromodomain and extraterminal domain

PROTAC

proteolysis targeting chimera

TCR

T-cell receptor

RMSD

root mean square deviation

MD

molecular dynamics

DDB1

DNA damage–binding protein 1

IFD

induced-fit docking

IF

intrinsic tryptophan fluorescence assay

ITC

isothermal titration calorimetry

CTV

cell trace violet

TCEP

tris(2-carboxyethyl)phosphine.

3.7 Supplementary Material

3.7.1 Supplementary Methods

3.7.1.1 Protein Preparation. The preparation of the protein systems for human cereblon
(hCRBN, PDB 4TZ4 (307)), murine cereblon (mCRBN, PDB 4TZC and 4TZU (307)), and
galline cereblon (gCRBN, PDB 4CI1, 4CI2, and 4CI3 (308)) were done using the Schrodinger
software suite (25). Protein structure coordinates were downloaded from the Protein Data Bank
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(PDB) (227,228) and prepared with the Protein Preparation Wizard (PrepWizard) in Maestro
(231,232). Bond orders were assigned, including disulfide bridges, and original hydrogens were
deleted and later replaced to reduce bad contacts and other crystal artifacts before protonation
and hydrogen bond optimization. Missing side chains were added and optimized using Prime
(16,66,67). Cofactors used in crystallization (such as sulfate or phosphate ions), ligands, and
additional protein dimers were then deleted. All waters were retained for assisting in the
determination of side chain protonation states and initial hydrogen bond optimization. Hydrogen
atoms were then added to the protein, remaining cofactors, and to any added structural waters.
The program PROPKA (50) was used for the prediction of protein ionization states at 7.4 pH and
ProtAssign was used for hydrogen bond optimization. After automatic hydrogen assignment,
visual inspection was used to flip residues and change protonation states at protein-protein
interfaces when appropriate. Specific attention was given to the tautomeric states for His
residues, which were assumed to be neutral, and potential metal-ligation and hydrogen-bonding
interactions were considered. The Nδ nitrogen for H378 was kept protonated for each system.
Four of the six crystallographic structures of CRBN used in this study appear to show the H378
δ-nitogen coordinated with the carbonyl oxygen of the ligand. This posits the assumption of a
hydrogen bond and that the H378 δ-nitrogen must therefore be protonated (327–331). PROPKA
analysis before and after simulations also confirm this assumption. As such, all MD systems
were generated with the neutral H378 δ-nitrogen as being protonated. All waters more than 3 Å
from heterogen (HET) groups were then removed.

3.7.1.2 Molecular Dynamics. hCRBN and gCRBN were co-crystallized with DNA
damage-binding protein 1 (DDB1), whereas mCRBN was truncated (108 defined residues for
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mCRBN compared to 380 defined residues for hCRBN and gCRBN) and monomeric (i.e. not
complexed with DDB1). DDB1 was included in the simulations for hCRBN and gCRBN. The
thalidomide binding domain for hCRBN and mCRBN differs by only three residues. Therefore,
to further increase sampling and determine any structural dependence on these residues, the
original hCRBN sequence of the equilibrated representative structure was mutated to the
mCRBN sequence with the following mutations, C366S, E377V, and V388I to form a hCRBN to
mCRBN mutant (hmCRBN). Another system was also constructed from the hCRBN
representative structure with the Nε nitrogen on the H378 residue protonated (hCRBN-pNε) to
compare and provide insight into the protonation states of H378. After protein refinement, a total
of five protein systems (hCRBN, hCRBN-pNε, mCRBN, gCRBN, and hmCRBN) were
constructed for MD simulation.
MD simulations were performed with the Desmond MD program (233–236). Periodic
boundary conditions were imposed on a cubic simulation box extending at least 10Å from the
protein. The simulation box was then solvated with TIP3P waters (237), electrically neutralized
by introducing sodium ions, and the OPLS-2005 all-atom force field (332,333) was applied to all
atoms. The SHAKE algorithm (238) was used to constrain all bonds in the system and the
REference System Propagator Algorithm (RESPA) (239) with an integration time step of 2 fs
was employed. Long-range electrostatics were calculated using the Particle Mesh Ewald (PME)
algorithm(88,89) with a real-space cutoff of 13 Å. A cutoff of 16 Å was employed for van der
Waals interactions. The systems were simulated in an NPT ensemble using the MartynaTuckerman-Tobias-Klein (MTTK) barostat(241,242) at a constant pressure of 1 atm and a
temperature of 310 K using the Nose−Hoover temperature coupling scheme(240).
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All systems were energy minimized with a truncated newtonian conjugate gradient
(TNCG) method(243) followed by multiple restrained minimizations to randomize systems
before equilibration and final simulation. Heavy atoms of the protein were held fixed during
heating for an initial 12 ps

NVT ensemble simulation at 10 K with the Berendsen

thermostat(244). This was followed by simulations at 1 atm in the NPT ensemble for 12 ps at 10
K and 24 ps at 310 K. Unrestrained equilibration MD was then performed for 24 ps at 310 K and
1 atm. Finally, unconstrained production MD was performed on the hCRBN and mCRBN
systems for 100 ns. Due to the stability observed in hCRBN, its close similarity to gCRBN, and
since the hCRBN-pNε system was derived from the equilibrated hCRBN system, the gCRBN
and hCRBN-pNε systems were only run for 50 ns. Energies were recorded every 2 ps and
trajectory frames were recorded every 5 ps.
Final system equilibration was determined by the observation of asymptotic behavior of
the potential energy, Root Mean Square Deviation (RMSD), and Radius of Gyration (Rg)
profiles and visual inspection of trajectories guided by Root Mean Square Fluctuation (RMSF)
profiles (Supplementary Material).

3.7.1.3 Consensus Docking. After equilibration was determined, a hierarchical average
linkage clustering method based on RMSD was utilized to determine an average representative
structure for each equilibrated system. The program PROPKA was then implemented again on
the equilibrated structures to test consistency of side chain protontion states at 7.4 pH. The
representative structure was then used for consensus docking incorporating five diverse and
complimentary docking methods described below. By applying these varied energy scoring
methods, the weaknesses of each method can be identified for a particular model and error
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statistically minimized, yielding a more accurate summary of ligand binding dispositions and
affinities.
As a check for the placement of the grid used in the docking studies and for further
analysis of the binding cavity, Schrödinger's SiteMap program (245–247) was employed.
SiteMap searches the protein structure for likely binding sites and highlights regions within the
binding site suitable for occupancy by hydrophobic groups, hydrogen-bond donors, acceptors, or
metal-binding functionality of the ligand.
The ligands thalidomide, pomalidomide, and lenalidomide were prepared using the
program LigPrep (248) and the OPLS-2005 all-atom force field was applied to all ligand atoms.

3.7.1.4 Induced Fit Docking. The representative structures were then used for docking
with the induced-fit docking (IFD) method in the Schrödinger software suite (122–124,334). The
IFD methodology incorporates both the docking program Glide (114,121,125,335) to account for
ligand flexibility and the Refinement module in the Prime program to account for receptor
flexibility. The Schrödinger IFD protocol attempts to model induced-fit effects from alterations
in binding site conformation due to ligand binding in order to increase accuracy of binding
affinity estimates and prediction of possible binding modes.
The position of the cubic docking grid was centered on the original co-crystallized ligand
centroids and was given a size of 29 Å. A constrained minimization of the receptor was
performed with an RMSD cutoff of 0.18 Å. An initial softened potential Glide docking of the
ligand set was then implemented with the standard precision (SP) mode and a van der Waals
scaling factor of 0.5 was applied to the non-polar atoms of the receptor and ligands. The resulting
top 20 poses of the ligands were used to sample protein plasticity by conformational searches
and minimizations of binding pocket residues within 6 Å of any ligand pose for all complexes
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obtained. The new receptor conformations were then redocked using complexes within 30
kcal/mol from the best scoring structure. Glide docking parameters for this step were reset to the
default hard potential function with a van der Waals scaling of 1.0 and SP mode.
The estimated binding affinity of each complex was reported in the GlideScore and used
to compare differences between each ligand while the Emodel score is used to inter-compare
poses of the ligands. Emodel places more significance on weighting force field components
(electrostatic and van der Waals energies), making it better for comparing conformers as opposed
to comparing chemically-distinct species.

3.7.1.5 Rigid Receptor Docking (RRD). Rigid docking simulations were performed by
Glide (114,121,125). Glide uses a GlideScore fitness function based on Chemscore (249,250) for
estimating binding affinity, but includes a steric-clash term, adds buried polar terms to penalize
electrostatic mismatches, and modifies other secondary terms. Docking simulations used both the
standard precision (SP) and extra precision (XP) methods. XP mode is a refinement algorithm
enforced only on good ligand poses. Sampling is based on an anchor and refined growth strategy
and the scoring function includes a more complete treatment of some of the SP energetic terms,
such as the solvation and hydrophobic terms. Docking grids were defined by a rectangular ligand
atom inclusion outer box of 22Å and ligand centroid constraint inner box of 10Å in the x, y, and
z directions originating from the binding cavity centroid defined by the original co-crystallized
IMiD ligand centroid for the CRBN TBD.
3.7.1.6 Quantum Polarized Ligand Docking (QPLD). To account for ligand
polarization upon binding, Quantum Mechanics/Molecular Mechanics (QM/MM) docking was
performed by the Schrödinger QM-Polarized Ligand Docking Protocol (QPLD) (126,127). The
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protocol first employs RRD using Glide in SP mode. In this step, the top five poses of each
ligand in the initial RRD were used. Potential ligand polarization induced by the protein were
then calculated with Qsite (111,251,252) at the B3LYP/6-31G* level. The ligand force fields
were then reconstructed with QM/MM modified charges, redocked, and five poses of each ligand
were saved for evaluation.
3.7.1.7 Molecular Mechanics and Generalized Born Surface Area (MM/GBSA). The
MM/GBSA method combines molecular mechanics energy terms and implicit solvation models
to calculate the binding-free energy based on docking complexes. The protocol, implemented by
the Prime MM-GBSA module, calculates optimized free energies for the free protein and free
ligand and references them with the original bound complex energy (253). Polar contributions
are calculated using the Generalized Born (GB) model (254), an implicit solvent model is based
on a variable dielectric surface Generalized Born (VD-SGB) approach, where the variable
dielectric value for each residue was fit to a large number of side-chain and loop predictions
while the non-polar energy is estimated using the solvent accessible surface area (SASA) (255).
The simulation was performed based on receptor–ligand complex structures obtained from
induced fit docking. The obtained ligand poses were minimized using the local optimization
feature in Prime, whereas the energies of complex were calculated with the OPLS-3 force field
and Generalized-Born/Surface Area continuum solvent model (256). During the simulation
process, the ligand strain energy is also considered. A known issue with MM/GBSA is that scores
do not accurately reproduce absolute physical binding affinities but display great efficacy at
ranking compounds in a relative manner (257–260). We developed a correlation function using a
single-layer logistic regression to rescale MM/GBSA scores based on the other docking score
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algorithms. This retains the ranking accuracy of MM/GBSA and allows us to proportion the
results in a minimally biased and physically relevant manner.

Figure 31. Synthesis of tert-Butyl (2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)carbamate.

3.7.1.8 Detailed Chemical Methods. Lenalidomide (259 mg, 1 mmol) and Boc2O (218
mg, 1.1 mmol) were mixed in THF (1 mL) in a sealed tube and stirred at 60 °C overnight. The
next day, Boc2O (110 mg, 0.5 equiv.), THF (1 mL), and DMF (0.5 mL) were added and the
solution was further stirred at 120 °C overnight. Water (20 mL) was added and the mixture was
sonicated. The precipitate was filtered, washed with water (10 mL), and dried. The resulting
solid was triturated using EtOH/EtOAc/hexanes and filtered to give the desired product as an offwhite solid (258 mg, 72%). Mp: 196–198 °C. HPLC–MS (ESI+): m/z 741.3 [(100%, 2M+Na)
+ ], 719.4 [(40%, 2M+H)+ ], 360.2 [(90%, M+H)+ ]. 1 H NMR (400 MHz, DMSO-d6): δ 11.00
(s, 1H), 9.21 (s, 1H), 7.74 (dd, J = 6.8, 1.7 Hz, 1H), 7.49–7.39 (m, 2H), 5.10 (dd, J = 13.3, 4.7
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Hz, 1H), 4.41 (d, J = 17.6 Hz, 1H), 4.32 (d, J = 17.6 Hz, 1H), 2.95–2.83 (m, 1H), 2.64–2.54 (m,
1H), 2.40–2.26 (m, 1H), 2.05–1.95 (m, 1H), 1.46 (s, 9H). Compound 1 was reported previously
(296). tert-Butyl (2-(1-methyl-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)carbamate (2): To a
mixture of 1 (100 mg, 0.278 mmol) and K2CO3 (38 mg, 0.278 mmol) in DMF (0.8 mL) was
added methyl iodide (0.017 mL, 0.278 mmol) dropwise at room temperature under Argon. The
mixture was stirred overnight. Water (10 mL) was added and extracted with EtOAc (2 × 20 mL).
The combined organic layers were dried (Na2SO4), filtered, and concentrated under reduced
pressure. The resulting yellow oil was purified by flash chromatography (SiO2) eluting with
hexanes in EtOAc (80% to 100%) 4 M HCl in dioxane r.t., 3.5 h 75% 3 N O NH2 NH O O N O
NHBoc NH O O Boc2O, THF/DMF (4:1) sealed tube 60-120 °C, 2 d N O NHBoc N O O MeI,
K2CO3 DMF, r.t., o/n N O NH2 N O O Lenalidomide 72% 1 39% 2 HCl to provide the title
compound as a white solid (40.37 mg, 39%). Mp: 192 °C (dec). HPLC–MS (ESI+): m/z 741.3
[(100%, 2M+Na)+ ], 719.4 [(40%, 2M+H)+ ], 360.2 [(90%, M+H)+ ]. 1 H NMR (400 MHz,
DMSO-d6): δ 9.20 (s, 1H), 7.73 (dd, J = 6.5, 2.3 Hz, 1H), 7.49–7.41 (m, 2H), 5.16 (dd, J = 13.4,
5.1 Hz, 1H), 4.42 (d, J = 17.6 Hz, 1H), 4.30 (d, J = 17.6 Hz, 1H), 3.02–2.90 (m, 1H), 2.99 (s,
3H), 2.80– 2.71 (m, 1H), 2.40–2.27 (m, 1H), 2.07–1.97 (m, 1H), 1.46 (s, 9H). 3-(4-Amino-1oxoisoindolin-2-yl)-1-methylpiperidine-2,6-dione (3 or N1 -methyl-lenalidomide): 2 (35 mg,
0.093 mmol) was stirred in 4 M HCl in dioxane (0.5 mL) for 3.5 h at room temperature. The
white suspension was concentrated under reduced pressure and the resulting solid was triturated
in DCM/hexanes, washed with EtOAc and hexanes (10 mL each), and dried to provide the title
compound as light yellow flakes (21.81 mg, 75%). Mp: 207 °C (dec). HPLC: 99% [tR = 11.6
min, 10% MeOH, 90% water (with 0.1% TFA), 20 min]. 1 H NMR (400 MHz, DMSO-d6): δ
7.29 (t, J = 7.5 Hz, 1H), 7.11 (d, J = 7.5 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 5.17 (dd, J = 13.4, 4.7

168

Hz, 1H), 5.20–4.80 (br s, 2H, disappeared on D2O shake), 4.28 (d, J = 17.0 Hz, 1H), 4.17 (d, J =
17.0 Hz, 1H), 3.05–2.91 (m, 1H), 2.99 (s, 3H), 2.80–2.70 (m, 1H), 2.39–2.25 (m, 1H), 2.08–1.97
(m, 1H). HPLC–MS (ESI+): m/z 569.2 [(30%, 2M+Na)+ ], 274.2 [(100%, M+H)+ ]. LC–MS
(ESI+): 569.2 [40%, (2M+Na)+ ], 296.1 [100%, (M+Na)+ ]. HRMS (ESI+): m/z calcd for
C14H15N3O3 (M+H)+ 274.1186, found 274.1176.

Figure 32. Structure of Me-dBET1.

2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6yl)-N-(4-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)acetamide (Me-dBET1): This was prepared from N-Boc aminoglutarimide (details to be
reported elsewhere) as a white solid. HPLC: 99% [tR = 24.7 min, gradient 5-95%, MeOH-water
(with 0.1% TFA), 30 min]. 1H NMR (400 MHz, Methanol-d4) δ 7.82 (dd, J = 8.4, 7.4, Hz,
1H),7.53 (dd, J = 7.2, 0.4 Hz, 1H), 7.47–7.38 (m, 5H), 5.14 (dt, J = 12.9, 5.1 Hz, 1H), 4.78 (s,
2H), 4.62 (ddd, J = 9.0, 5.2, 0.7 Hz, 1H), 3.44–3.34 (m, 3H), 3.30–3.22 (m, 3H), 3.11 (2 xs, 3H),
2.86–2.82 (m, 2H), 2.73–2.62 (m, 4H), 2.43 (2 x d J = 0.9 Hz, 3H), 2.12–2.03 (m, 1H), 1.72–
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1.69 (m, 3H), 1.67–1.59 (m, 4H); HPLC–MS (ESI+): m/z 821.2 [(100%, M+Na)+], 799.3 [(70%,
M+H)+]; HRMS (ESI+): m/z calcd for C39H39ClN8O7S (M)+ 798.2345, found 798.2368.

3.7.1.9 Detailed Protein Production of Wild-Type and Mutant CRBN. The primers used are
5'-CCAGTCTGTGTTGTAAACAGAGCCAAGAAACC-3'
GGTTTCTTGGCTCTGTTTACAA

and

5'-

CACAGACTGG-3’;

GGTTATGCATGGACCATCGCACAGTGTAAAATTTGTGC-3'

5'and

5'-

GCACAAATTTTACACTGTGCGATGGTCCATGCATAAC-3',
CGTCCGAGCACCGAAGCAAG

5'-

CTGGTTTCCGGGTTATGC-3'

GCATAACCCGGAAACCAGCTTGCTTCGGTGCTCGGAC

G-3';

CGAGCACCGAACATAGCGCGTTTCCGGGTTATGCATGG-3'

and

CCCGGAAACGCGCTATGTTCGGTGCTCG-3', respectively.
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and

5'-

and

5'-

5'-CCATGCATAA

3.7.2 Supplementary Figures

Figure 33. Sequence conservation of CRBN thalidomide binding site. (A) Diagrammatic
representation of the CRBN’s ubiquitin targeting complex containing DDB1, Cul4A, Roc1,
Rbx1. The region of the thalidomide-binding domain (TBD) indicated (red) interacts with the
glutarimide ring of the IMiDs, whilst the second ring (phthalimide, isoindolinone and
quinazolinone) interacts with the CRBN TBD and its substrates (Ikaros, Aiolos, CK1α, and
unknown proteins), respectively. Also shown is the structure of dBET1 that recruits BRD4 and
other BET-domain containing proteins and molecules that interact with the JQ1-like BET
targeting group. (B) The CRBN protein sequences from diverse vertebrate species that
correspond to the human thalidomide binding site were aligned using Clustal Omega (Sievers
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and Higgins 2014). Positions that are at least 90% identical are shaded in black and similar
residues are shaded in gray. Shading in other colors highlight sequence diversity at three
positions: Cys366, Glu377 and Val388 in human (above) and Ser369, Val380 and Ile391 in
mouse (below). Arrows indicate cysteines involved in forming disulfide bridges. Sequences
include: thirteen primates (human, NP_001166953.1, common chimpanzee, XP_001140433.1;
western lowland gorilla, XP_004033566.1; Sumatran orangutan, NP_001127555.1; northern
white-cheeked gibbon, XP_012357648.1; rhesus macaque, NP_001182576.1; olive baboon,
XP_003894216.1; green monkey, XP_007983240.1; squirrel monkey, XP_010336170.1;
common marmoset, XP_008980298.1; Philippine tarsier, XP_021562663.1 ; gray mouse lemur,
XP_020139859.1 ; Sunda flying lemur, XP_008581608.1), five non-primate mammals (mouse,
NP_067424.2; rat, NP_001015003.1; domestic dog, XP_005632293.1; cow, NP_001068995.1;
Florida manatee, XP_012409572.1), one marsupial (gray short-tailed opossum,
XP_001374178.2), one reptile (American alligator, XP_006263115.1), two birds (chicken,
XP_004944767.1; zebra finch, XP_012429169.1), one amphibian (Xenopus, NP_001008192.1),
one lobe-finned fish (West Indian Ocean coelacanth, XP_006001868.1), two rayfinned fish
(Spotted gar, XP_006630756.1; zebrafish, NP_001003996.1) and one cartilaginous fish (whale
shark, XP_020385559.1).
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Figure 34. Dose of anti-CD3 and lenalidomide to induce IL-2 and proliferation by T cells. (A)
Relative IL-2 mRNA production with increasing concentrations anti-CD3 (0.01 – 10 μg/mL)
stimulation. (B) IL-2 secretion by ELISA in unstimulated cells and after treatment with anti-CD3
(5μg/mL) and anti-CD28 (1 µg/ml) with increasing concentrations of lenalidomide. (C)
Proliferation in human T cells and (D) mouse T cells treated with DMSO (vehicle) or
lenalidomide (10 μM) measured by S-phase transition as indicated by incorporation of
bromodeoxyuridine (BrdU) with detection by flow-cytometry in cells stained for CD8 + surface
expression.
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Table 11. IC50 (μM) of Multiple Myeloma Cell Lines
Drug

H929

U266

MM1.S

5TGM1

Lenalidomide (Len)

5.13

10.0

1.48

>>100

Pomalidomide (Pom)

0.046

0.51

0.099

>>100

H929, U266 and MM1.S are human multiple myeloma cell lines while 5TGM1 is a mouse
multiple myeloma cell line. IC50 (μM) calculated as follows: log(inhibitor) vs response based on
variable slope (four parameters), Y=bottom (best fit value) + (100-Bottom)/1+10^((LogEC50X)*n)).

Figure 35. RMSD profiles of hCRBN, mCRBN, gCRBN, and hmCRBN. (A) RMSD profiles of
hCRBN. Profiles were created using backbone atoms and were calculated with hCRBN-DDB1
complex (Bottom Graph), hCRBN alone (Middle Graph), and binding site residues N335 to
A421 (Top Graph). (B) RMSD profiles of mCRBN. Profiles were created using backbone atoms
and were calculated with all hCRBN residues (Bottom Graph), binding site residues N335 to
A421 (Middle Graph), and residues (357, 377, 379-383, 388-390, 401, 402, 404) located 6 Å
away from the ligand (Top Graph). (C) RMSD profiles of gCRBN. Profiles were created using
backbone atoms and were calculated with hCRBN-DDB1 complex (Bottom Graph), gCRBN
alone (Middle Graph), and binding site residues N337 to A423 (Top Graph). (D) RMSD profiles
of hmCRBN. Profiles were created using backbone atoms and were calculated with hmCRBNDDB1 complex (Bottom Graph), hmCRBN alone (Middle Graph), and binding site residues
N335 to A421 (Top Graph). (E) Rg Profiles of hCRBN. Profiles were created from all atoms and
were calculated with hCRBN-DDB1 complex (Bottom Graph) and hCRBN alone (Top Graph).
(F) Rg Profiles of mCRBN. Profiles were created from all atoms. (G) Rg Profiles of gCRBN.
Profiles were created from all atoms and were calculated with gCRBN-DDB1 complex (Bottom
Graph) and hCRBN alone (Top Graph). (H) Rg Profiles of hmCRBN. Profiles were created from
all atoms and were calculated with hmCRBN-DDB1 complex (Bottom Graph) and hmCRBN
alone (Top Graph). All measurement units are in Angstroms.
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Figure 36. RMSF profiles of hCRBN, mCRBN, gCRBN, and hmCRBN. (I) RMSF profile of
hCRBN. Profiles were created using backbone atoms and were calculated with hCRBN alone
(DDB1 RMSF available upon request). Binding site residues N335 to A421 displayed as dashed
line. (J) RMSF Profile of mCRBN. Profiles were created using backbone atoms of mCRBN.
Binding site residues N335 to A421 displayed as dashed line. (K) RMSF Profile of gCRBN.
Profiles were created using backbone atoms and were calculated with gCRBN alone (DDB1
RMSF available upon request). Binding site residues N337 to A423 displayed as dashed line. (L)
RMSF Profile of hmCRBN. Profiles were created using backbone atoms and were calculated
with hmCRBN alone (DDB1 RMSF available upon request). Binding site residues N335 to A421
displayed as dashed line. All measurement units are in Angstroms.

Figure 37. Potential energy profiles of hCRBN, mCRBN, gCRBN, and hmCRBN (M) Potential
energy profile of hCRBN simulation, (N) mCRBN simulation, (O) gCRBN simulation, and (P)
hmCRBN simulation. Multiple linear fits were characterized to determine asymptotic behavior
by minimizing slope.
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Figure 38. Hydrogen bonding analysis of Len isoindolinone amine and E377 carboxyl group.
Top two graphs show inter-atomic distance between ligand nitrogen and glutamate side chain
oxygens with line denoting maximum hydrogen bond cutoff of 3.5 Å. Bottom graph indicates
programmatic detection of hydrogen bonding incorporating maximum NHO angle cutoff of 90°.
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Table 12. Pose RMSD Calculations and Docking Scores.
hmCRBN hCRBN
Post MD Post MD
Glide
Score

hCRBN
Crystal

gCRBN
Post MD

gCRBN
Crystal

mCRBN
Post MD

mCRBN
Crystal

-11.040

-11.049

-10.789

-11.408

-10.724

-10.082

-9.344

-81.796

-83.437

-78.630

-77.239

-79.853

-63.197

-63.881

Pose
RMSD

-

-

-

1.6615a

1.1036a

7.1958b

7.0379b

Glide
Score

-11.279

-11.574

-10.965

-10.976

-10.494

-8.0373

-9.544

-85.454

-87.014

-79.857

-78.197

-77.976

-52.240

-57.118

Pose
RMSD

0.5944c

0.7384c

1.7233c

1.5859d

1.0053d

-

-

Glide
Score

-11.200

-10.996

-10.800

-10.256

-11.634

-7.760

-8.339

-89.915

-86.330

-81.008

-80.357

-84.483

-51.789

-58.872

-

-

-

1.7592e

0.9482e

4.6167f

2.8715f

Emodel
Thalidomide

Emodel
Lenalidomide

Emodel
Pomalidomide

Pose
RMSD
a

Pose RMSD calculated using PDB 4CI1 for comparison.
Pose RMSD calculated using PDB 4TZC for comparison.
c
Pose RMSD calculated using PDB 4TZ4 for comparison.
d
Pose RMSD calculated using PDB 4CI2 for comparison.
e
Pose RMSD calculated using PDB 4CI3 for comparison.
f
Pose RMSD calculated using PDB 4TZU for comparison.
b
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Figure 39. Recombinant TBD protein expression and purification and zinc binding domain
analysis using the zincon assay. (A) SDS-PAGE gel showing purification steps: A: total lysate, L:
ladder, B: cleavage product, C: after 2nd GST purification, D: material loaded from size
exclusion chromatography (SEC) with gel showing impurities, E-G: final samples after SEC. (B)
Expression of recombinant TBD with Cys to Ser mutations. T is the total lysate and S is the
soluble protein extract. (C) Structure of human TBD (PDB 4TZ4) in green, showing
coordination of the zinc ion (red sphere) to the four cysteine residues. (D) Schematic of the
zincon assay: zincon dye absorbs at 480 nm and upon chelation with zinc absorbs at 620-630
nm). (E) Wavelength scans showing a decrease at 480 nm and concomitant increase at 630 nm
upon incremental addition of zinc. (F) Linear regression curve obtained from (E).
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Figure 40. Binding affinity of IMiDs to TBD variants by ITC. ITC binding curves of
pomalidomide (A-D), thalidomide (E-H), phthalimide (I-L) with wild-type and mutant CRBN
TBD protein.
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Figure 41. Binding pocket with N-methyl-lenalidomide
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Figure 42. Drug Treatment of human and mouse T cells and multiple myeloma cell lines.
MM1.S and 5TGM1 cells were treated with increasing concentrations of dBET1 for 24 hours.
Protein expression levels of BRD4, c-Myc, CRBN, β-actin were determined by western blot.
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Table 13. Statistical analysis of human T cells treated with IMiDs, JQ1, and dBET (for results in
Figure 29).
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Table 14. Statistical analysis of CRBN+/+ and CRBN-/- mouse T cells treated with IMiDs, JQ1,
and dBET (for results in Figure 30).
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3.8 Chapter Appendix

3.8.1 Supplementary Computational Results
An in-depth theoretical investigation of the molecular binding mechanics of the immunemodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide (Figure 43A-C) in
complex with the protein cereblon (CRBN) was conducted to explore and understand possible
differences in drug interactions between murine and human CRBN. Analysis of the published
crystal structures for hCRBN, mCRBN, and gCRBN show negligible variation of RMSD
between observed binding poses (Figure 43D and Figure 44F and G). To further test the
structures for possible induced fit effects, protein flexibility, or crystal artifacts, MD simulations
were performed to expand structural understanding of CRBN.

3.8.2 Determination of Equilibration for MD systems
Final system equilibration was determined by the observation of asymptotic behavior of
the potential energy, RMSD, and Rg profiles and visual inspection of trajectories guided by
RMSF profiles.

3.8.2.1 Equilibration of hCRBN model system. RMSD profiles of hCRBN in complex with
DDB1 appear to show equilibration after approximately 25 ns with an average RMSD (Figure
35A) of 3.21 Å for the equilibrated region. Compared to the crystallographic structure resolution
of 3.01 Å, the system RMSD is slightly outside the error of the reported PDB X-ray diffraction
resolution. However, the RMSD profile of hCRBN residues associated with the known binding
site (i.e. residues N335 to A421 and excluding DDB1) displays significant rigidity despite
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minimal asymptotic behavior portrayed by the RMSD graphs of the whole hCRBN chain.
Further investigation using RMSF profiles (Figure 36I) finds that much of the displacement can
be attributed to the solvent exposed N terminus tail region and from the DDB1 chain. RMSD
profiles without the tail regions do show asymptotic behavior and the binding site structure is
believed to be valid for the length of simulation. In a similar trend, Rg profiles (Figure 35E) do
not appear to show equilibrated behavior for the hCRBN/DDB1 complex but do display clear
asymptotic behavior after approximately 17 ns for hCRBN alone. The potential energy graphs
(Figure 37M) also show asymptotic behavior after approximately 30 ns. From this data, all
structures, analyses, and statistics for hCRBN are performed using the last 70 ns of the
simulation and the stability and accuracy of the protein model of hCRBN are considered
comparative to the original crystal structure (PDB 4TZ4) for the purposes of this study.
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Figure 43. 3D chemical structures of IMiDs and CBN ribbon overlays. 3D chemical structures
of thalidomide (A), lenalidomide (B), and pomalidomide (C). The S enantiomer was used for
each compound. Ribbon overlays (D) of human (purple; PDB code 4TZ4) and chicken (blue;
PDB code 4CI2) X-ray crystal structures and post-MD structure of mouse (yellow; PDB code
4TZ4) cereblon. Human immunomodulatory drug–binding site residues His-378, Trp-380, Trp386, and Phe-402 and ligands thalidomide (yellow), lenalidomide (green) and pomalidomide
(blue) are shown for reference. Ribbon representations of the alanine mutation study (E) shown
with the mutated residues H378A and W380A (green) of the post-MD haCRBN system (grey)
juxtaposed with the WT residues of the original hCRBN system (purple).
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Figure 44. Overlays with concentered view of the CRBN thalidomide binding site. Images
depict a superposition of backbones, represented as ribbons (F), and a superposition of cocrystallized ligands (H) of hCRBN (purple, PDB 4TZ4), gCRBN (blue, PDB 4CI2), and
mCRBN (yellow, PDB 4TZ4) with residues H378, W380, W386, W400, F402, and the ligands
thalidomide (yellow), lenalidomide (green), and pomalidomide (blue) shown for reference. PostMD equilibrated systems of the CRBN thalidomide binding site after IFD displayed as a ribbon
overlay (G) of hCRBN (red), hmCRBN (green), and gCRBN (orange), using the original crystal
structure of hCRBN (purple, PDB 4TZ4) and lenalidomide (green) for reference. Superpositions
of ligand poses (I) of lenalidomide (green) for the post-MD equilibrated systems of the CRBN
thalidomide binding site after IFD for hCRBN (red), hmCRBN (green), gCRBN (orange), and
the original crystal pose for hCRBN (purple) are also shown with the post-MD equilibrated
protein structure of hCRBN (red) shown for reference.

187

Figure 45. SiteMap binding site characterization and overlays of human and mouse CRBN.
SiteMap binding site characterization of CRBN (J) portrays regions of preferential hydrophobic
interactions (yellow) and hydrogen bond donor (blue) and acceptor (red) regions as transparent
surfaces with overlays of the crystal ligand poses of thalidomide (yellow), lenalidomide (green),
and pomalidomide (blue). Overlays of residues 377 and 388 (V377 and I388 for mCRBN. E377
and V388 for hCRBN), demarcated as thin tubes, (K) of the post-MD equilibrated hCRBN (red)
and hmCRBN (green) systems with the original hCRBN crystal pose of lenalidomide (purple)
shown for reference.

3.8.2.2 Equilibration of mCRBN model system. The mCRBN system does not appear
to be able to reach equilibrium. The average RMSD (Figure 35B) of approximately 3.27 Å is
well outside the reported crystallographic structure resolution of 1.88 Å. The Rg profile (Figure
35F) and potential energy graph (Figure 37N) of the mCRBN simulation do no display
asymptotic behavior. The RMSF profile (Figure 36J) and visual inspection reveals unfolding
events of residues near the truncated regions of the protein which are the primary contributions
to the average RMSD. However, the proximal residues 6 Å away from the ligand appear stable
after 38 ns and may be able to be used for limited qualitative analysis. However, given the
evidence provided, this model is not adequate for further modeling and analyses should be
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viewed ephectically. All structures, analyses, and statistics for mCRBN are performed using the
last 62 ns of the simulation.

3.8.2.3 Equilibration of gCRBN model system. RMSD profiles of gCRBN in complex
with DDB1 appear to show equilibration after approximately 32 ns with an average RMSD
(Figure 35C) of 3.82 Å for the equilibrated region. Compared to the crystallographic structure
resolution of 2.98 Å, the system RMSD is outside the error of the reported PDB X-ray diffraction
resolution. However, in a similar trend to hCRBN, the RMSD profile of gCRBN residues
associated with the known binding site (i.e. residues N335 to A421 and excluding DDB1)
displays significant rigidity despite minimal asymptotic behavior portrayed by the RMSD graphs
of the whole gCRBN chain. Further investigation using RMSF profiles (Figure 36K) finds that,
again comparable to hCRBN, much of the displacement can be attributed to the solvent exposed
N terminus tail region and from the DDB1 chain. RMSD profiles without the tail regions do
show asymptotic behavior and the binding site structure is believed to be valid for the length of
simulation. Rg profiles (Figure 35G) do not appear to show equilibrated behavior for the
gCRBN/DDB1 complex but do display clear asymptotic behavior after approximately 22 ns for
gCRBN alone. Despite potential energy graphs (Figure 37O) showing some continued
declination, the error of the minimized fitted slope does encompass zero gradient after 7 ns.
From this data, all structures, analyses, and statistics for gCRBN are performed using the last 27
ns of the simulation and the stability and accuracy of the protein model for the residues
associated with the known binding site of gCRBN are considered comparative to the original
crystal structure (PDB 4CI2) for the purposes of this study.
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3.8.2.4 Equilibration of hmCRBN model system. Equilibration can be safely assumed
after 40 ns from the RMSD profiles of hmCRBN in complex with DDB1 with an average RMSD
(Figure 35D) of 2.82 Å for the equilibrated region. Compared to the crystallographic structure
resolution of 3.01 Å and the average RMSD calculated for the progenitor hCRBN system of 3.21
Å, the hmCRBN average system RMSD is well within error. Moreover, the RMSD profile of
hmCRBN residues associated with the known binding site (i.e. residues N335 to A421 and
excluding DDB1) also displays significant rigidity in confluence with the original hCRBN
system. Further investigation of RMSF profiles (Figure 36L) finds, once again similar to the
hCRBN system, that much of the displacement can be attributed to the solvent exposed N
terminus tail region and from the DDB1 chain. Rg profiles (Figure 35H) do not appear to
advance any evidence against equilibration and purport fluctuations directly analogous to the
hCRBN system. The potential energy graphs (Figure 37P) also show asymptotic behavior after
approximately 30 ns. From this data, all structures, analyses, and statistics for hCRBN are
performed using the last 60 ns of the simulation and the stability and accuracy of the protein
model of hCRBN are considered comparative to the original crystal structure (PDB 4CI2) for the
purposes of this study.

3.8.2.5 Equilibration of haCRBN model system. The RMSD (Figure 46A) and Rg
(Figure 46B) plots for haCRBN do not show any asymptotic trend over the length of the
simulation. Multiple distinct structural transitions are evident with the most pronounced
conformational shift occurring after 8 ns when the binding site is observed to collapse,
apparently due to the smaller occupied volume of the alanine mutation of residue 380 compared
to tryptophan. The RMSD profiles also show a large degree of structural fluctuation through the
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duration of the simulation. RMSF (Figure 46C) profiles also confirm this increased motion of
binding site residues compared to WT hCRBN (See graphical inlay of Figure 46C). Potential
energy graphs (Figure 46D) do display a negative slope, however, the error of the minimized
fitted slope does prelimit possible convergence after 12 ns. From the supplied evidence, this
model does not appear to converge toward equilibrium within the timespan of the simulation.
Even so, the simulation does provide some insights into the structural dependence of the CRBN
active site on the W380 residue and are discussed in the results section of the main text (Section
3.2.3 Immunomodulatory compound binding is conserved in CRBN sequence variants). All
structures, analyses, and statistics for haCRBN are performed using the last 82 ns of the
simulation with four explicit representative structures produced from hierarchical clustering. It
should also be noted that SiteMap did not find any suitable cavities near the original binding site
for any of these structures.
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Figure 46. Equilibration profiles for haCRBN model system. (A) RMSD profiles of hCRBN.
Profiles were created using backbone atoms and were calculated with hCRBN-DDB1 complex
(Bottom Graph), hCRBN alone (Middle Graph), and binding site residues N335 to A421 (Top
Graph). All measurement units are in Angstroms. (B) Rg Profiles of hCRBN. Profiles were
created from all atoms and were calculated with hCRBN-DDB1 complex (Bottom Graph) and
hCRBN alone (Top Graph). All measurement units are in Angstroms. (C) RMSF Profile of
hCRBN. Profiles were created using backbone atoms and were calculated with hCRBN alone
(DDB1 RMSF available upon request). Binding site residues N335 to A421 displayed as dashed
line. All measurement units are in Angstroms. (D) Potential energy profile of hCRBN simulation.
Multiple linear fits were characterized to determine asymptotic behavior by minimizing slope.

3.8.3 Determination of H378 protonation states
Determination of protonation states for protein side chains is an inherently difficult
process. Crystallographic resolutions are rarely sufficient to resolve individual hydrogen atoms
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and current methods for determining NMR coupling constants are not applicable to large proteins
(330). This results in the need for indirect evidence to statistically characterize the ionization
states for certain side chains. Hydrogen bonding analysis is a common practice of inferring
protonation states (329). The determination of a hydrogen bond, however, is not a well defined
parameter that largely succumbs to best practices. For this study, we use the metrics of a donoracceptor distance of less than 3.5 Å and three point angle of greater than 90 degrees to quantify a
hydrogen bond (327). For this study, careful attention must be made the residue H378 due to its
involvement in the suspected binding motif of thalidomide. The six crystallographic structures of
CRBN used in this study all appeared to show the H378 Nδ coordinated with the carbonyl
oxygen of the ligand. This posits the assumption of a hydrogen bond and that the H378 Nδ must
therefore be protonated. Unfortunately, studies have shown that reported structures do not
necessarily portray the most stable isomer or statistically weight tautomeric states (329,331). For
further insight into this issue, a separate system using a representative structure from the
equilibrated hCRBN system was run to query alternate protonation states of this particular
residue. PROPKA analysis before and after simulations were performed and confirm the
assumption that the H378 Nδ is protonated. As such, all MD systems were generated with the
neutral H378 δ-nitrogen as being protonated. PDB 4TZC and 4TZU (mCRBN) do not show the
same interaction, however, as previously discussed, these systems do seem to have artifacts
associated with crystal packing in which crystal mates may be interfering with the thalidomide
binding site.
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3.8.4 Computational Model Validation
All models developed through simulations, aside from mCRBN and haCRBN, are
statistically valid for reproducing physical results and support the physical relevance of the
crystal structures (See Section 3.8.2 Determination of Equilibration for MD Systems). While
the mCRBN crystal structure is valid, it is not sufficient for computational modeling (See Section
3.8.2.2 Equilibration of mCRBN Model System). This is probably due to truncation of the
protein sequence and the omission of DDB1. Crystal packing effects appear to provide surrogate
stability for the absent DDB1 cofactor, allowing for crystallization but limiting the effectiveness
of computational modeling on mCRBN alone. This artificial instability of the native structure
likely imposes a manufactured mutability of the thalidomide binding site as evidenced by poor
reproduction and comparison of IFD results shown in Table 12.
The murine CRBN analog, hmCRBN, developed from the hCRBN system appears to be
capable of reproducing the crystal ligand poses of PDB 4TZC and 4TZU (mCRBN) and the
equilibrated hmCRBN system displays minimal conformational deviation from the murine
crystals (Figure 44G and Figure 45K). The hmCRBN system can therefore be considered a
suitable substitute for mCRBN for modeling purposes. Further, the three residue distinctions
between hCRBN and mCRBN do not appear to have any observable relevance in the structure or
function of CRBN. The E377 residue for hCRBN does not appear to interact with the ligands in
any significant way. This is evidently due to backbone dihedral strain which forces the charged
carboxyl moiety away from the binding site and minimizes possible interactions with the ligands
(Figure 45K). The unexpected absence of this interaction helps to explain why the binding
modes do not appear to differ between hCRBN and mCRBN. Binding modes also do not appear
to differ between models and compounds as evidenced by negligible differences in RMSD
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calculations between crystal binding poses and post-MD models (Figure 44F-I and Figure 45J).
IFD also predicts no observable difference in binding affinity between models and compounds
(Table 12). All poses are within 1.8 Å which is the expected threshold reported by Sherman et al.
for the IFD protocol (123).

3.8.5 CP Consensus Docking Results
A CP consensus docking study was performed on hCRBN with thalidomide,
lenalidomide, and pomalidomide (S entantiomers only) as known literature controls, SG5-003,
MANT uracil, CC-122, and Glutarimide as positive project controls, and uracil, phthamimide,
NCI373535, and SG5-005 as negative controls and decoys. Docking was performed on the
prepared, MD equilibrated hCRBN model (Section 3.8.2.1 Equilibration of hCRBN model
system). The results of the analysis are shown in Table 15.
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Table 15. CP Consensus Docking on hCRBN with controls and experimental KD values.

Experimental KD values were converted to ΔG° for correlation to docking runs. Theoretical KD
ranges were directly correlated to experimental KD values.
Table 15 gives a clear breakdown of computational error and protein model
characteristics, allowing for a simple rescaling of docking results using Pearson correlations as
regression weights and confidence in relying only on XP docking for additional analog testing
(Table 16). From Table 6, we can infer several properties of the hCRBN binding site and
binding modes from CP consensus docking results. Due to low correlation to IFD and
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MM/GBSA and high correlation to XP, ligand binding to CRBN TBD does not appear to have
any induced fit effects. Since the binding site is not catalytic, binding must interfere with or
induce alternate protein-protein interactions. Further, high correlation to XP and low correlation
to SP indicate a significantly hydrophobic pocket with hydrogen bonding donor and acceptors in
the hydrophobic enclosure. Strong correlation to QPLD also suggests a complex electronic
environment in the binding site, understandable due to the aromatic cage that creates the TDB
pocket. Poor correlation to MM/GBSA also represents little dependence on solvent. This is a
reasonable assumption since there are no apparent structural waters in or near the binding site
and the pharmacophore occludes any space for solvent to intrude. From these propositions,
SiteMap analysis, and ligand structural overlays, a simple pharmacophore can be developed to
fully explain the binding mechanism of hCRBN (Figure 45J). Additionally, docking results can
now be scaled to fit the absolute binding energies from experiment, allowing predictive
computational measurement for novel analogs with optimal efficiency. The higher range of
docking scores fit better with experiment, therefore, subsequent docking scores are normalized
with a bias toward less negative energies.

3.8.6 High Accuracy Course-Grained Docking Derived from CP Consensus Docking
The complete pharmacophore coupled with high correlations of XP docking with controls
provides ample evidence that a course-grained virtual screening model using only XP docking
can reproduce physical results to a sufficient degree of accuracy compared to experiment and
high resolution modeling. Table 16 is an example of applying this course-grained model to
analogs. The drug discovery project was able to drastically reduce ITC and florescence
experiments, reducing costs and speeding up production. Positive and negative controls should
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be included to scale expected binding affinities to the controls. Table 16 employs a conservative
binary ranking of “possible” or “unlikely” estimates of a hit for analogs. The distribution of
binding affinities for the controls could reasonably allow for up to four categories of affinity
estimates.

3.8.7 Conclusions from Modeling
Due to truncation of the protein sequence and the omission of DDB1, mCRBN is not a
sufficient model for virtual study, leading to poor reproduction and comparison of IFD results.
The murine CRBN analog, hmCRBN, however, can be used as a surrogate for mCRBN. Alanine
mutations of hCRBN, haCRBN, show the significant residues forming the aromatic cage of the
CRBN-TBD. When the residues are mutated to the smaller alanine side chain, the binding site
collapses after a few nanoseconds of MD. All other models show excellent agreement with
experimental crystal structures, pose RMSD, and estimated free energies of binding. This
indicates the exceptional ability of the designed computational models to reproduce and predict
physical quantities.
Further, ITC experiments for KD determination used a racemic mixture of each IMiD
control. Docking runs on each enantiomer exhibited marginally better binding of the S
enantiomer compared to the R enantiomer (Table 16). This finding lines up well with recent
experiments able to overcome the optical inversion of IMiD enantiomers. Mori et al.
demonstrated a significant difference in enantiomer KD, 3.5 ± 0.4 μM for (S)-thalidomide and
20.0 ± 2.9 μM for (R)-thalidomide (336). Re-scaled computational results are within
experimental error and confirm the analytical and predictive power of the CP consensus docking
methodology.
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Table 16. Course-grained virtual screening model utilizing only XP docking for assessing analog
binding affinity.

Experimentally determined strong binders in green, average binders in orange, and poor binders
in red. IMiD enantiomers in yellow.
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4 Discovery of a Non-Nucleotide Potential STING Antagonist from Consensus Docking and
Dimer Identification with Novel Site-Restriction Virtual Screening

4.1 Introduction
STING (Stimulator of Interferon Genes), also known as MITA, MPYS, and ERIS,
encoded by gene TMEM173, is a facilitator of the innate immune system trough sensing cyclic
dinucleotides created by cGAS after interacting with cytosolic DNA and RNA. STING then
promotes production of cytokines and type 1 interferons, α and β, by propagating the signal by
means of interferon regulatory factor 3 (IRF3) phosphorylation (337). This is the first report on
the discovery of STING as an essential innate immune regulator (338,339). This report
demonstrates that CDNs bind to and activate STING. This invasion of aberrant cytosolic DNA
can be caused by various infectious agents including bacterial and viral infection (340). Other
sources can be from self-DNA breaching nuclear confines due to improper cell division or DNA
damage caused by oncogenic processes. Self-DNA present in cytosol may also come from some
autoimmune disorders such as systemic lupus erythematosus (SLE) or Aicardi–Goutières
syndrome (AGS) (341). This leads to a surprising number of diseases and disorders that intersect
the STING pathway and gives rise to potentially novel therapeutic options for these difficult to
treat diseases.
Recently, there has been interest in developing agonists to increase activity of the STING
pathway as a modality for cancer treatment (342). The idea is to stimulate the immune system to
target tumor cells. Most STING agonists developed to date have been cyclic di-nucleotides
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(CDNs). An exception is a recently reported amidobenzimidazole STING agonist (343). A CDN
agonist drug candidate from Aduro Biotech, Inc. has entered clinical trials (344). However, no
STING antagonists have entered clinical trials.
STING is a promising new target for systemic lupus erythematosus (SLE) therapy due to
its response to cytosolic DNA. The cytosolic enzyme cGAS (cyclic GMP-AMP synthase) is a
surveillance enzyme that detects cytosolic DNA and produces a molecule referred to as 2’3’cGAMP (cyclic [G(2’,5’)pA(3’,5’)p]). 2’3’-cGAMP activates the STING pathway through direct
binding to STING (Figure 47). This pathway has been proposed as a cause of increased
expression of IFIT3 and other type 1 interferons in SLE (345–347). STING, an endoplasmic
reticulum bound cytoplasmic protein, is key in the cellular defense when there is cytosolic DNA
or RNA. Blocking STING activation may prevent anti-DNA antibody production in SLE.
There is a dire need for new drugs to treat SLE since many drug candidates are failing in
clinical trials. In 2018, only one of the eight drug candidates in mid to late trials attained
significant efficacy and that candidate required higher doses to reach efficacy so safety issues
must be readdressed (347). Anti-DNA autoantibodies are a hallmark of SLE, occur in most SLE
patients, and can appear years prior to SLE symptoms (348). Rather than stimulating STING to
provoke an immune anti-tumor response, the objective of a STING antagonist would be to
suppress anti-DNA antibody production that might attack endogenous DNA in some autoimmune
disease models, allowing treatment options at an earlier interdiction point in the disease.
Since DNA normally resides in the mitochondria, its presence in the cytoplasm causes a
danger-associated molecular pattern (DAMP). STING works through the mechanism of nucleic
acids from bacteria or viruses inducing immune responses in cells (349). Once free-floating
exogenous DNA or RNA is identified, CGAS is the sensor that detects DNA as a DAMP, making
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cyclic dinucleotides. Cyclic dinucleotides such as cyclic di-guanine monophosphate (c-di-GMP)
and cyclic [G(2’,5’)pA(3’,5’)p] (2,3-cGAMP) are immune stimulators which regulate type I
interferon (IFN-α and β) induction (350). These special nucleotides are secondary messenger
molecules which bind to STING, a protein localized on the endoplasmic reticulum membrane.
Binding of cyclic dinucleotides induces a conformational shift in STING allowing the
recruitment of tank-binding kinase 1(TBK1) and transcription factor IRF3 to STING (Figure 47)
(351). IRF3 then localizes to the nucleus forming a transcription factor complex with NFkB, AP1, P65, P50, and CBP (352).
NF-kB and IRF3 are components of the IFN-β promoter enhanceosome that forms to
stimulate the IFN-β gene transcription. The enhanceosome (composed of ATF2 and c-JUN, IRFs,
NF-kB, and HMG-I(Y)) recruits histone acetyl transferases (HATs) to locate the transcription
start site acetylating a subset of lysine residues in the histones of the nucleosome. This ultimately
recruits the TFIID transcription complex to the IFN-β gene promoter (353). IFN-β secretion
engages the type I IFN receptor to activate JAK-STAT (signal transducer and activator of
transcription) signal transduction and tyrosine phosphorylation of STAT1 and STAT2 and the
transcription of their target genes (354). The IFN-β promoter is very weakly associated with
TNF-a in that TNF-a can activate the IFN-β promoter which leads to activation of NF-kB and
AP-1 but not IRFs (355).
Two homologous proteins, IRF3 and IRF7 are key regulators of type I IFN gene
expression induced by viruses. IRF3 resides latently in the cytosol. It is constitutively expressed
and undergoes phosphorylation, dimerization, and nuclear translocation upon viral infection
(356).
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Figure 47. STING pathway. To understand the direct binding mechanism of STING to other
protein binding partners, Sitemap surface modeling was carried out to determine the most likely
alignment between the ordered lid region of STING with TBK1. Sitemap surface analyses also
showed significant similarities between the surface of IRF3 and the ordered lid region of STING
indicating that TBK1 likely binds to both in the manner shown above. This information was
needed to determine what residues are important for binding and what protein conformations
were essential for propagating the signal downstream. From structural data using PDB 4LOH,
4IM0 and 5JEJ, a more comprehensive diagram of STING interactions with TBK1 and IRF3.
TBK1 and IRF3 facilitate IRF3 phosphorylation, leading to IRF3 dimerization and translocation
to the nucleus. Upon translocation, the IRF3 dimer activates IFN-β gene transcription. IFN-β is
responsible for antiviral, antibacterial and anticancer properties.

In 2011, Vance et al. discovered that cyclic diguanylate monophosphate (c-di-GMP)
binds to mammalian STING receptors, activating an innate immune response (339). Then, Sun et
al. found that an enzyme called cyclic GMP-AMP synthase (cGAS) binds DNA enabling two
nucleotides to covalently bond together creating a cyclic dinucleotide (CDN) (357). The prospect
of using manufactured CDNs or other compounds which modulate STING have caused many
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biopharma companies around the world to extensively study STING for the treatment of cancer,
infectious diseases as well as use in vaccines as adjuvants.
Early studies on STING focused mainly on mSTING due to its high sequence homology
(~89%). The compound DMXAA arose as a promising lead compound from these initial
experiments, even though it ultimately failed in human trials (358). Despite the lack of efficacy
in human trials, we compared the crystal structures between mSTING and hSTING and found
that, while the two forms have significant homology and structural similarities, the SiteMap
analyses of the CDN binding site show that they have completely different binding site
topologies (Figure 48). Therefore, mSTING was not deemed necessary for inclusion in this
study. This observation may also explain differences in IFN-β fold induction among compounds
between the two species.
Leticia Corrales of Aduro biotech published the groundbreaking paper that lead the field
towards its current, feverish state of intense research (344) Concerns of toxicity and an
uncontrolled “cytokine storm” lead to reevaluation of STING agonists upon revelation of the
dark side of STING upregulation (359,360). While there are many types of STING agonists,
cyclic di-nucleotides (CDNs) are the most prominent type of molecule being proposed to
upregulate the activity of STING. Examples of such molecules can be found (361). These
agonists mimic the structure and therefore activity of 2,3-cGAMP in the binding pocket of
STING. While very potent, these ubiquitous prokaryotic intracellular signaling molecules lack
efficacy due to their need for intratumoral injection (IT) which prohibits treatment of noncutaneously accessible tumors (344) as well as requiring multiple injections and concomitant
administration of immune checkpoint antibodies (362). Clinical trial NCT02675439 which
investigates IT of a CDN as monotherapy may prove to be insufficient to treat patients with
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advanced/metastatic solid tumors and lymphomas. Clinical trial NCT03010176 uses a CDN in
conjunction with a checkpoint inhibitor to treat patients with advanced/metastatic solid tumors
and lymphomas. Through biomarker evaluation of patients, a non-inflamed could become and Tcell inflamed tumor microenvironment which would presumably make patients more sensitive to
checkpoint inhibitor therapy. The current objective response rate to anti-PD-1 therapy is about
40–45% in patients with PD-L1-positive tumors (363–365) (Merck, NCT03010176)
The STING cytosolic pathway was demonstrated to be involved in cellular response to
diverse viral and bacterial infections with cytomegalovirus being one of the most widespread
viral agents among human populations. STING was implicated in sensing and controlling its
replication in vitro by means of activation of cGAS-STING-TBK1-IRF3 pathway (366,367).
Additionally, Reinert et al. demonstrated that cGAS-STING signaling pathway is extensively
involved in response to herpes simplex virus infection among microglia via activation of IFN I
through TLR3 pathway, and effects of innate immune priming. Furthermore, cytosolic DNA
sensing pathway- deficient mice experienced elevated receptiveness to herpes simplex
encephalitis (368). STING was also found to be associated with cytokine production in response
to Legionella pneumophila bacterial infection. STING or cGAS deficiency in murine model and
HAQ TMEM173/STING allele expression indicated a strong predisposition to the bacterial
infection; mice with impaired cGAS-STING pathway experienced higher bacterial loads,
compared to the control groups. Ruiz-Moreno et al. explicitly correlated HAQ allele expression
with advanced bacterial and viral infection rates (369).
On the other hand, STING agonists shown by (370) activate STING, leading to
immunostimulatory downstream effects. This study showed that CDNs injected without delivery
agents diffused away rapidly which did not appear to cause any lasting cytotoxic effects. Another
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STING agonist, ML RR-S2 CDA shows promise in clinical trial NCT02675439 due to its
efficacy in promoting the specific rejection of several types of tumors in murine models.
(AduroBiotech, NCT02675439)

Figure 48. SiteMap analysis between CDN binding sites of hSTING (B) and mSTING (A).
Hydrogen bond acceptor regions shown in blue, hydrogen bond donor regions shown in red, and
hydrophobic regions shown in yellow. Residues R238, Q266, and T267 are displayed for
reference. (C) Ribbon overlay comparing structures of mSTING (light blue) and hSTING
(orange).
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4.2 Experimental Design and Methods

4.2.1 Computational Methods

4.2.1.1 Protein Preparation. Protein model systems hSTING variants are prepared using
the Schrodinger software suite (25). Protein structure coordinates are downloaded from the
Protein Data Bank (PDB) (227,228). The hSTING models are generated from the PDB entries
(Table 17): 4LOH (REF allele co-crystallized with 2’3’-cGAMP), 4LOI (REF allele cocrystallized with 2’2’-cGAMP) (371), 4EMT (REF allele co-crystallized with c-di-GMP), 4EMU
(REF allele apo structure) (349), 4KSY (WT allele co-crystallized with 2’3’-cGAMP) (372),
4F5Y (WT allele co-crystallized with c-di-GMP) (373), and 4F5D (HAQ allele co-crystallized
with c-di-GMP) (373). An MD simulation was also performed on the hSTING WT structure with
2’3’-cGAMP bound mutated to the hSTINGHAQ isoform using PDB 4KSY to simulate 2’3’cGAMP structural effects on the HAQ variant. The apo structures for hSTING, PDB 4EMU, is
used to cross reference conformational states from MD simulations.

Table 17. List of PDB entries used for MD simulation.
PDB ID
4LOH
4LOI
4EMT
4EMU
4KSY
4F5Y
4F5D

hSTING Allele
REF
REF
REF
REF
WT
WT
HAQ

Binding Site Residue Positions
230
G
G
G
G
G
G
A

232
H
H
H
H
R
R
R
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Co-crystallized Ligand
2’3’-cGAMP
2’2’-cGAMP
c-di-GMP
2’3’-cGAMP
c-di-GMP
c-di-GMP

PDB systems are prepared with the Protein Preparation Wizard (PrepWizard) in Maestro
(231,232). Cofactors used in crystallization (such as sulfate or phosphate ions), ligands, and
additional protein dimers are deleted. Bond orders are then assigned, including disulfide bridges,
and original hydrogens are deleted and later replaced to reduce bad contacts and other crystal
artifacts before protonation and hydrogen bond optimization. All waters are retained for assisting
in the determination of side chain protonation states and initial hydrogen bond optimization.
Missing side chains are added and optimized using Prime (16). Hydrogen atoms are then added
to the protein, remaining cofactors, and to any added structural waters. The program PROPKA
(50) is used for the prediction of protein ionization states at 7.4 pH and ProtAssign is used for
hydrogen bond optimization. After automatic hydrogen assignment, visual inspection is used to
flip residues and change protonation states at protein-protein interfaces if and when appropriate.

4.2.1.2 Molecular Dynamics. MD simulations (Table 17) are performed with the GPU
accelerated Desmond MD program (233–236) on two Nvidia GeForce GTX 1080 Ti video cards.
A cubic simulation box is created extending at least 10Å from the protein with imposed periodic
boundary conditions using TIP3P waters (237) as solvent. The OPLS-3 all-atom force field (34)
is then applied to all atoms. Simulations are run at a temperature of 310 K and a constant
pressure of 1 atm. All systems are energy minimized followed by multiple restrained
minimizations to randomize systems before equilibration and final simulation. Production MD is
performed on all systems for 250 ns.
Final system equilibration is determined by the observation of asymptotic behavior of the
potential energy, Root Mean Square Deviation (RMSD), and Radius of Gyration (Rg) profiles
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and visual inspection of trajectories guided by Root Mean Square Fluctuation (RMSF) profiles
(Figure 57).

4.2.1.3 Consensus Docking. After equilibration is determined, a hierarchical average
linkage clustering method based on RMSD was utilized to determine an average representative
structure for the equilibrated hSTING systems. The program PROPKA is then implemented
again on the equilibrated structure to test consistency of side chain protonation states at 7.4 pH.
The representative structure is then used for consensus docking incorporating five diverse and
complementary docking methods, SP and XP rigid receptor docking, Induced Fit Docking,
Quantum Polarized Ligand Docking, and MM/GBSA methods. Each described in detail below.
By applying these varied energy scoring methods, the weaknesses of each method can be
identified for a particular model and error statistically minimized, yielding a more accurate
summary of ligand binding dispositions and affinities.
As a check for the placement of the grids used in the docking studies and for further
analysis of the binding cavity for the CDN binding site, Schrödinger's SiteMap program (245–
247) is employed. SiteMap searches the protein structure for likely binding sites and highlights
regions within the binding site suitable for occupancy by hydrophobic groups, hydrogen-bond
donors, acceptors, or metal-binding functionality of the ligand.

All ligands were prepared

using the program LigPrep (248) and the OPLS-3 all-atom force field (34) was applied to all
ligand atoms.

4.2.1.4 Rigid Receptor Docking (RRD). Rigid docking simulations were performed by
the docking program Glide (114,121,125,335). Glide uses a GlideScore fitness function based
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on Chemscore (249,250) for estimating binding affinity, but includes a steric-clash term, adds
buried polar terms to penalize electrostatic mismatches, and modifies other secondary terms.
Docking simulations used both the standard precision (SP) and extra precision (XP) methods. XP
mode is a refinement algorithm enforced only on good ligand poses. Sampling is based on an
anchor and refined growth strategy and the scoring function includes a more complete treatment
of some of the SP energetic terms, such as the solvation and hydrophobic terms. Docking grids
were defined by a rectangular ligand atom inclusion outer box of 22Å and ligand centroid
constraint inner box of 10Å in the x, y, and z directions originating from the binding cavity
centroid defined by SiteMap.

4.2.1.5 Induced Fit Docking (IFD). The IFD methodology (122–124,334) incorporates
both the docking program Glide to account for ligand flexibility and the Refinement module in
the Prime program to account for receptor flexibility. The Schrödinger IFD protocol attempts to
model induced-fit effects from alterations in binding site conformation due to ligand binding in
order to increase accuracy of binding affinity estimates and prediction of possible binding
modes.
Separate cubic docking grids for the CDN binding site are centered on the original cocrystallized ligand centroid and from the binding cavity centroids defined by SiteMap. A
constrained minimization of the receptor is performed preceding an initial softened potential
Glide docking of the ligand set is then implemented with the standard precision (SP) mode. The
resulting top 20 poses of the ligands are used to sample protein plasticity by conformational
searches and minimizations of binding pocket residues within 6 Å of any ligand pose for all
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complexes obtained. The new receptor conformations are then redocked using complexes within
30 kcal/mol from the best scoring structure.
The estimated binding affinity of each complex is reported in the GlideScore and used to
compare differences between each ligand while the Emodel score is used to inter-compare poses
of the ligands. Emodel places more significance on weighting force field components
(electrostatic and van der Waals energies), making it better for comparing conformers as opposed
to comparing chemically-distinct species.

4.2.1.6 Quantum Polarized Ligand Docking (QPLD). To account for ligand
polarization upon binding, Quantum Mechanics / Molecular Mechanics (QM/MM) docking is
performed by the Schrödinger QM-Polarized Ligand Docking Protocol (QPLD) (126,127). The
protocol first employs RRD using Glide in SP mode. In this step, the top five poses of each
ligand in the initial RRD are used. Potential ligand polarization induced by the protein are then
calculated with Qsite (111,251,252) at the B3LYP/6-31G* level. The ligand force fields are then
reconstructed with QM/MM modified charges, redocked, and five poses of each ligand are saved
for evaluation.

4.2.1.7 Molecular Mechanics and Generalized Born Surface Area (MM/GBSA). The
MM/GBSA method combines molecular mechanics energy terms and implicit solvation models
to calculate the binding-free energy based on docking complexes. The protocol, implemented by
the Prime MM-GBSA module, calculates optimized free energies for the free protein and free
ligand and references them with the original bound complex energy (253). Polar contributions
are calculated using the Generalized Born (GB) model (254), an implicit solvent model is based
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on a variable dielectric surface Generalized Born (VD-SGB) approach, where the variable
dielectric value for each residue was fit to a large number of side-chain and loop predictions
while the non-polar energy is estimated using the solvent accessible surface area (SASA) (255).
The simulation was performed based on receptor–ligand complex structures obtained from
induced fit docking. The obtained ligand poses were minimized using the local optimization
feature in Prime, whereas the energies of complex were calculated with the OPLS-3 force field
and Generalized-Born/Surface Area continuum solvent model (256). During the simulation
process, the ligand strain energy is also considered.

4.2.2 Experimental Methods

4.2.2.1 Surface Plasmon Resonance (SPR). Surface Plasmon Resonance (SPR) was
employed for binding measurements using His-tagged hSTINGWT CDN domain. A GE
Healthcare Biacore T200 was equipped with an Ni-NTA chip. 16,951 RU of 6X-His tagged
human STING was crosslinked via NHS chemistry following injections of 350 mM EDTA and
500 mM NiSO4. STING natural substrates and the lead compound were titrated and flowed at 60
uL/min in 1X PBS for 60 sec association time followed by a 135 sec dissociation. The
sensorgrams were analyzed using Biacore T200 Software 3.0 (GE Healthcare) and steady state
was measured at 4 sec before injection stop, exported into Graphpad, and fit vs concentration
using a one site specific binding model to calculate the apparent equilibrium dissociation
constant (KD). Where appropriate, kinetics were measured using a 1:1 Langmuir binding model
with Rmax set to local to obtain the association rate (Kon), dissociation (Koff), and the KD.
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4.2.2.2 Microscale Thermophoresis (MST). Nanotemper Monolith NT.115 labeled
thermophoresis machine was used with standard treated capillary tubes using samples comprised
of labeled protein and titrations of small molecule in 1X PBS. MST experiments were conducted
in triplicate mixing 200 nM protein with 100 nM dye and allowing to sit at room temperature for
30 minutes followed by centrifugation on Ni-NTA 488 labeled His-labeled hSTING WT. Detection
of the protein was performed using the blue detection channel with LED excitation power set to
90% and MST set to high allowing 3 s prior to MST on to check for initial fluorescence
differences, 25 s for thermophoresis, and 3 s for regeneration after MST off. Analysis was
performed using M.O. Affinity Analysis Software with difference between initial fluorescence
measured in the first 5 s as compared with thermophoresis at 15 s at 15 different analyte
concentrations ranging from 15 nM to 1 mM and exported into Graphpad Prism v.8 using a Log
inhibitor v. response 4 parameter fit.

4.2.2.3 Luciferase Assay. THP1-ISG-Lucia cells were obtained from Invivogen and
maintained in RPMI 1640 containing 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated
fetal bovine serum, 100 μg/ml Normocin™, Pen-Strep (100 μg/ml). To maintain selection
pressure, 10 μg/ml of blasticidin and 100 μg/ml of Zeocin™ was added to the growth medium
every other passage.
Reporter cells were plated at 100,000 (THP1-ISG-Lucia) cells per well in a white 300uL
sterile 96 well plate and treated with 3, 5, 10, 15, 20, 30, 40, 50μM 2’3’-cGAMP, DMSO and
NSC 335504 (Figure 53). For compounds, 10mM stock solution in 100% DMSO was diluted
1:4 with ultrapure Milli Q water. For the positive control, 1mM stock solution in 100% Milli Q
H2O was diluted 3:1 with water. 50μL of QUANTI-Luc™ luminesence assay reagent (Invivogen,
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San Diego, CA, USA) was added after 18-24h incubation period. Expression of Lucia luciferase
was quantified by measuring luminescence from duplicate treatments. Data illustrated are
average luminescence changes shown relative to DMSO-treated cells.
Using a Glowmax luminometer (Promega, Madison, WI, USA). Prepare QUANTI-Luc™
following the manufacturer’s instructions. Pipet 10 µl of THP1-Dual™ KI-hSTING-R232 cell
culture supernatant per well in a 96-well white (opaque) plate. Add 50 μl of QUANTI-Luc™ per
well. Proceed immediately with the measurement using a 4sec incubation time and integrating
over 1 sec.
THP1-Dual KI-hSTING-R232 Cells from Invivogen contain a knockin of the intronless
coding sequence of the R232 hSTING variant. This variant, which contains an arginine at
position 232 (R232), is the most prevalent variant (~45-58%) in the human population (344).
This isoform is preferentially activated by 2’5’linkage-containing cGAMP isomers (339).

4.2.2.4 Chemical Synthesis of NSC335504. NSC335504 (Clonixeril) was synthesized
by employing substituted nicotinic acid esters (or free acids) and substituted anilines. Figure 49
shows the full synthesis scheme utilized to make the compound.
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Figure 49. Clonixeril synthesis scheme.

4.3 Results & Discussion

4.3.1 Computational Agonist and Antagonist Model Construction
Initial computational studies employed extensive MD simulations to better understand
how STING interacts with ligands and other potential binding partners. Some commonalities
seem to arise from comparing trajectories between isoforms and control ligands leading to
postulation on unique and intricate binding mechanics. The main binding partners for STING in
the IFN-β pathway are IRF3 and TBK1 (351). A simple metric was devised to measure possible
activation of STING by evaluating the distance between the alpha carbons of residue H185 at the
end of the α2 helix (Figure 51). Crystal structures of known agonists present alpha carbon
distances in the range of 34 to 38 Å. Apo crystal structures have alpha carbon distances in the
range of 47 to 56 Å (Table 18). The proposed binding mechanism is that initial binding is with
the bottom of the CDN binding region near residues Q266 and T267. Then, as proposed by
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several authors (372–374), the initially disordered “lid” region comprising residues 154-244
(Figure 51, green ribbon) interacts with the bound ligand and induces a β sheet formation,
bringing the α2 helices closer together. The ligand then associates itself more with the ordered lid
region, further stabilizing the conformation.
This realization allowed the ability to form two separate ensemble docking models to
screen for agonists, compounds that have greater affinity to the holo structure and thus stabilizing
the ordered lid allowing for signaling to continue, and for antagonists or partial agonists in which
compounds would have better affinity with the disordered apo structure, limiting the lid
microfolds from occurring and thus attenuating further downstream signaling. Experimental
evidence provides solid support for these theoretical models. ITC experiments from Zhang et al.
(372) give evidence that the binding mechanism for 2’3’-cGAMP is largely entropy driven (-TΔS
= 12.199 kcal/mol; ΔH = 0.71 kcal/mol) denoting decreasing entropy from reording of the lid
region upon binding, while c-di-GMP is mostly enthalpic with a large entropy penalty (-TΔS =
-12.117 kcal/mol; ΔH = -20.19 kcal/mol). This large entropy gain when binding c-di-GMP
clearly shows that STING is more disordered when binding to this compound but still
energetically favorable due to better protein-ligand contact from induced fit effects with a more
flexible protein structure. SPR binding kinetics also lend support for these separate mechanisms.
The koff rates for 2’3’-cGAMP and c-di-GMP differ by nearly an order of magnitude, k off =
9.72x10-4 and 8.76x10-3 respectively. Since 2’3’-cGAMP does not have better enthalpic
interactions than c-di-GMP, quite the opposite from the difference in ΔH, the longer ligand
association time must, therefore, be due to significant induced folding.
Phenotypic prediction based on protein dynamics may also be possible by determining
the H185 alpha carbon distance after MD simulation with the associated ligands (Figure 58).
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Measured distances for crystal structures and 250 ns MD simulations (Table 18) showed
excellent systematic agreement for 2’3’-cGAMP (35 Å for crystal (372), 37.8 Å for MD
structure), an artificial analog 2’2’-cGAMP (38.4 Å for crystal (371), 41.9 Å for MD structure),
c-di-GMP (41.4 Å for crystal (349), 46.1 Å for MD structure), and apo structures (47.1 Å for
crystal (349), 55.5 Å for MD structure, Figure 59). RMSD profiles of MD trajectories fit well
with crystallographic B-factors overall (Figure 57) and MD models appear to better resolve
binding energetics and comparisons to literature values.

4.3.2 STING Isoform Selection
Additional complexities arise when accounting for the different STING alleles. Profiles
of RMSD per residue from MD simulations show significant contrasts between the REF, WT,
and HAQ isoforms. The lid regions for REF and WT are substantially more disordered than
HAQ (Figure 50). This may be due to increased entropy from the glycine residue at the 230
position for REF and WT, opposed to alanine for HAQ (Figure 51). This could account for some
discrepancies between experimental binding energies and model calculations as current
computational techniques cannot easily measure this.
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Figure 50. RMSF profiles between REF (green), WT (red), and HAQ (blue) isoforms of STING
bound to 2’3’-cGAMP. Residues for lid region shown as dashed lines.
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Figure 51. hSTINGREF CTD structures after MD with distance between H185 residue shown for
holo structure bound to 2’3’-cGAMP, red carbons, (left) and apo structure (right). “Lid” region
demarcated with green ribbon and α1 and α2 helix in light blue. Residues H185, G230, and H232
represented as tubes for clarity.

To account for potential differences between STING isoforms, computational models
were created using only those isoforms which had amino acid variations in the known STING
binding site, residues 230 and 232. This lead to three main models, hSTING WT (G230, R232),
hSTINGREF (G230, R232H), and hSTINGHAQ (G230A, R232). Technically, there is no difference
between AQ and HAQ structure in terms of binding site residues, but for consistency, we will
continue to reference the G230A R232 variant as the HAQ structure. No literature data was
found for ITC KD values on control compounds (2’3’-cGAMP, 2’2’-cGAMP, and c-di-GMP) for
the HAQ variant. Since these values are imperative for proper model validation, hSTING HAQ was
not used for comparing model controls with literature values. We performed ligand binding
analyses using five different binding energy estimation algorithms (SP, XP, IFD, QPLD, and
MM/GBSA) to evaluate theoretical binding energies of control compounds to the hSTING WT and
hSTINGREF isoforms to determine the optimal docking algorithm and default isoform. Statistical
models were compiled based on deviation from known values and internal variance to adjust for
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docking and simulation error. ITC, SPR, and consensus docking energetics for the hSTINGWT
native ligands 2’3’-cGAMP, 3.8 nM (372), 1.4 nM, 2.4 nM respectively, and c-di-GMP, 1.2 μM
(372), 4.8 μM, and 6.4 μM respectively (Table 18), agree with unequivocal precision, lending
substantial evidence to the validity of the hSTING WT binding models. Due to the WT allele
dominance in human populations and the accuracy of docking replication of controls, the MD
equilibrated hSTINGWT antagonist (PDB 4F5Y) and hSTINGWT agonist (PDB 4KSY)
conformation were then taken as the two generalized conformer docking models for STING.

Table 18. Model comparisons to literature and experiment.

Structure

hSTING WT

hSTING REF

Compound

H185
H185 Post-MD
Model KD
Distance
Distance
(nM)
(Angstroms) (Angstroms)

SPR KD
(nM)

ITC KD
(nM)

c-2'3'-GAMP

35.0a

37.8

2.4

1.4

3.8a

c-2'2'-GAMP

-

43.1

256

-

287a

c-di-GMP

53.0e

56.5

6377

4776

1210a

c-2'3'-GAMP

34.7b

39.3

784

-

5300b

c-2'2'-GAMP

38.4b

41.9

236

-

2500b

c-di-GMP

52.6d

54.1

1300

-

4600c
4420d

Cell EC50
(nM)
42
(IFNβ mRNA)a
16
(IFNβ mRNA)a
538
(IFNβ mRNA)a
1200
ELISAb
3400
ELISAb
ND
(IFNβ Luc)c
ND
(IFNβ Luc)d

a Zhang et al. (372), b Gao et al. (371), c Shu et al. (349), d Ouyang et al. (375), e Shang et al.
(373). ND (Not detected). Cell assay type given in parentheses.
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4.3.3 Consensus Docking Results
The consensus docking approach employed in this work attempts to apply docking
protocols that specialize in determining pose prediction and scoring from more encompassing
physical properties (e.g. polarizabilty, receptor flexibility, solvent interaction, etc.) and weighting
the output of each simulation to yield more insight into individual protein-ligand complexes.
Consensus docking performed in this manner can partition the physical characteristics of a
binding pocket to help elucidate the binding mechanisms of that site. With appropriate controls,
an optimal course-grained algorithm can also be identified for virtual screening of larger
compound libraries. Docking was performed on the prepared, MD equilibrated hSTING WT
antagonist (PDB 4F5Y) and hSTINGWT agonist (PDB 4KSY) models.
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Table 19. Consensus docking using disparate docking methodologies to partition physical
characteristics of the STING-CDN binding site.
Compound

XP

Combined Ensemble
2'3'-cGAMP
-10.802
2'2'-cGAMP
-7.121
c-di-GMP
-6.233
NSC335504 (LD)
-7.860
Pearson
0.974
0.948
R2
Agonist Model (Post-MD)
2'3'-cGAMP
-10.802
2'2'-cGAMP
-7.121
c-di-GMP
-4.682
NSC335504 (LD)
-4.840
Pearson
0.964
0.930
R2
Antagonist Model (Post-MD)
2'3'-cGAMP
-6.120
2'2'-cGAMP
-6.669
c-di-GMP
-6.233
NSC335504 (LD)
-7.860
Pearson
-0.388
0.151
R2

SP

IFD

QPLD

MM/
GBSA

Average +/-

Error Theoretical
KD (nM)
(SD)

-8.324
-9.488
-5.801
-8.782
0.327
0.107

-12.531 -12.163 -15.282
-11.594 -9.736 -7.276
-10.179 -7.439 -5.985
-10.614 -8.163 -7.127
0.922
0.961
0.994
0.851
0.924
0.988

-11.820
-9.043
-7.127
-8.509
0.984
0.967

+/+/+/+/-

2.543
1.871
1.822
1.319

2.4
256
6377
627

-8.324
-9.488
-5.012
-4.348
0.533
0.284

-12.531 -12.163 -15.282
-11.594 -9.736 -7.276
-12.190 -5.816 -2.145
-9.853 -4.315 -1.401
0.443
0.826
0.948
0.197
0.682
0.899

-11.820
-9.043
-5.969
-4.951
0.876
0.768

+/+/+/+/-

2.543
1.871
3.739
3.058

2.4
256
44569
245919

-5.358
-5.554
-5.801
-8.782
-0.369
0.136

-7.992
-8.430
-10.179
-10.614
-0.760
0.578

-6.279
-6.264
-7.127
-8.509
-0.499
0.249

+/+/+/+/-

1.402
1.891
1.822
1.319

26489
27174
6377
627

-7.351
-7.231
-7.439
-8.163
-0.293
0.086

-4.574
-3.435
-5.985
-7.127
-0.391
0.153

Experimental KD values were converted to ΔG° for R2 and Pearson correlations to docking runs.
NSC335504 docking scores are for the zero-order bond linked dimer (LD).

Table 19 gives a clear breakdown of computational error and protein model
characteristics. Docking correlations between ensembles provide further evidence of the need for
separate docking models to assess conformational stabilization of the active or inactive forms of
STING. R2 and Pearson correlations of control compounds with experimentally determined K D
values (Table 18) show poor correspondence when docked to only one conformational model.
However, when the ensembles are combined based on which model best approximates
experimental values, correlations show extremely reliable agreement to controls. From this, we
can infer several properties of the hSTINGWT binding site and binding modes. Low correlation to
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SP docking and underestimated binding affinities of XP docking coupled with higher correlations
to flexible docking methods (IFD and MM/GBSA) strongly suggest that ligand binding is
dependent on significant induced fit effects and domain conformational shifts. This is obvious
from the distinct conformational differences of the apo and holo crystal structures, though
reveals a potential binding mechanism of antagonistic molecules. Antagonistic molecules not
only search for the initial open conformation of the apo structure, but likely induce and stabilize
a disordered lid conformation while maintaining a strong affinity for the site. Additionally, high
correlation and accurate estimation of control ligand affinity through QPLD implies the site has a
complex electrostatic environment capable of repolarizing susceptible ligands. This is a
reasonable assumption owing to the presence of highly charged residues in the site, depending on
the isoform tested. It may be due to the lack of charge characteristic and increased flexibility of
the lid region that the REF isoform does not bind or produce as much of a cellular response to
control ligands. Coupling IFD and MM/GBSA methods appears to balance out affinity
estimations. IFD generally overestimates affinities, while MM/GBSA shows consistently lower
affinity values. As the site is largely exposed to solvent, dependence on solvent interactions is
presumably significant and, therefore, understandable that the Generalized Born and Surface
Area continuum solvation algorithm would correlate well with controls.
From these propositions, SiteMap analysis, simulations, and reproduction of literature
values, a general pharmacophore can be developed to explain the binding mechanism of
hSTING.

Additionally, after comparing multiple docking algorithms between each model

structure, docking results can now be scaled to fit the absolute binding energies from experiment,
allowing predictive computational measurement for novel analogs with optimal efficiency. XP
docking was found to be a sufficient coarse screen method using the hSTING WT agonist and
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antagonist models. The NCI diversity set V and ASINEX diversity sets were screened and a
coarse-grained pharmacophore model was employed to rapidly scan the ZINC database using the
ZINC Pharmer algorithm (376). Hits from ZINC Pharmer were then rescored through XP
docking. Top hits were reviewed and best candidates were chosen for experimental testing to
confirm hits.

4.3.4 Site-Restriction Virtual Screening for Identification of Possible Dimer
Complexes
The STING-CDN binding site is a relatively voluminous pocket with a complex and
symmetrical binding surface between the two protein monomers. Hence, there is significant
potential for a small molecule to form a dimeric complex inside the binding site. Current docking
programs are bounded to docking and evaluating a single molecule at a time and are, thus, unable
to effectively interpret ligand dimerization. To overcome this limitation, we developed a simple
docking method that can be used in conjunction with standard virtual screening protocols to
assist in identifying potential dimer complexes.
Following typical compound screening of the whole site (Figure 52B), an additional
screening is then performed with the ligand restricted to a monomeric half of the binding site
(Figure 52A). This procedure, as opposed to only docking to the protein monomer alone, ensures
the site electrostatics are consistent between the whole site and the restricted portion. The next
step is to implement a RMSD comparison of the ligand poses for the whole and half site docking
runs. If the RMSD between the whole and half site poses is less than the commonly accepted 2 Å
cutoff, then the docked ligand evidently prefers a specific region in the binding site and should
allow for another stoichiometric equivalent of the molecule to bind into the surplus volume.
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After review of the initial ligand poses, updated docking grids are generated with the original
docked compound and the unoccupied region subsequently screened with a duplicate ligand
(Figure 52C). Providing the postliminary screen is successful at producing a reasonable pose,
the dimer composite structure can then be linked through a zero-ordered bond connecting the two
most proximal atoms. For Glide, this type of bond only has an enforced distance constraint, angle
and dihedral terms are zero, and does not interfere with the molecular force field. Docking the
linked dimer (LD) back into the respective conformer will allow the docking algorithm to
properly calculate estimated free energies of binding for the LD-protein complex.

Figure 52. Site-restriction docking method for identifying potential dimeric ligand complexes.
Initial docking to monomer unit of binding site is performed with half of the site excluded (A).
Secondary re-docking of ligand is the performed with no restrictions (B). If ligand maintains
pose in both docking simulations, a second copy of the ligand is re-docked to a new grid with the
original ligand held in place (C). The re-docked copy is then linked to the initial pose with a
zero-order bond, connecting the most proximal atoms, and re-docked once more (D, molecular
surface shown for clarity). Lid region demarcated with green ribbons. Green boxes indicate
ligand centroid positional constraint and purple boxes represent all ligand atom positional
constraint. Antagonist model with NSC335504 shown as reference.
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From this screening protocol, the compound NSC335504 (Figure 53) was identified as a
potential hit (Figure 52D). Consensus docking was implemented on the dimer structure with a
predicted affinity range of 70 nM to 5.7 μM. Further experimental assays were performed for
verification.

Figure 53. Molecular representation of NSC335504 (left) and associated mass spectrum profile
(right). NSC335504 has a molecular weight of 336.772 g/mol and a molecular formula of
C16H17ClN2O4.

4.3.5 Direct Binding Assays
Computational modeling predicted an average binding affinity K D of 627 nM for
NSC335504. Microscale Thermophoresis (MST) was performed as a rough initial estimate of
binding affinity, yielding a KD of 260 ± 66 nM and SPR was then used to refine and confirm
results with a KD of 430 ± 140 nM (Figure 54, left and right respectively). SPR was also
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implemented on the native ligands c-di-GMP and 2’3’-cGAMP (Figure 55). Direct binding
assays are well within agreement with literature values and computational models (Table 18 and
19). Therefore, computational modeling can be heavily relied on for lead optimization for either
agonists, partial agonists, or antagonists with the NSC335504 scaffold.

Figure 54. MST (Left) and SPR (Right) binding assays for NSC335504. SPR steady state
utilized hill model yielding a Hill coefficient determined as 1.738, indicating ligand dimerization
near 2:1 binding.

Figure 55. Steady state SPR binding affinity plots for c-di-GMP and 2’3’-cGAMP controls.
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4.3.6 THP-1 Luciferace Reporter Assay
In order to determine the cellular activity of NSC335504, a luciferace reporter assay of
IRF3 expression was employed to qualitatively determine activation of the STING pathway by
NSC335504. The cell-based assay exhibited insignificant upregulation of IRF3 in comparison to
2,3-cGAMP (Figure 56).
Modeling and direct binding analysis clearly indicate NSC335504 strongly binds to the
STING receptor (Table 18 and Figure 54) but does not appear to activate the STING pathway
with any significant potency. This evidence combined with modeling data of NSC335504
favoring an inactive conformation of STING strongly suggests the potential antagonistic
behavior of NSC335504.
NSC335504 is the National Cancer Institute (NCI) accession number for clonixeril, the
glyceryl ester of clonixin. Formerly used as an NSAID for pain and inflammation, particularly in
transdermal drug delivery formulations (377), we believe the clonixeril structure has been underutilized, with possibilities for more specific targeting.
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Figure 56. 2’3’-cGAMP and NSC335504 induced IRF3 upregulation in THP-1 cells. Luciferase
assay utilizing monocytic leukemia THP-1 cells was carried out to determine the regulation of
interferon stimulated genes (ISG).

4.4 Conclusions
MD equilibrated crystal structures for human HAQ, REF, and WT alleles were clustered
to find optimal conformations for diverse chemical library screening. Novel consensus docking
protocols utilizing rigid receptor, induced fit, and quantum polarized ligand docking were
applied for quantifying and refining proposed binding mechanisms of STING isoforms. Models
for STING agonists and antagonists were developed and rigorously tested against literature and
experimental biochemical and cellular studies.
From directed virtual screening, a novel low-molecular-weight organic molecule, NSC
335504, not based on a cyclic dinucleotide was found as a potential STING deactivator and is
currently under investigation. Our hypothesis is that NSC335504 acts as an antagonist,
potentially competing with 2,3-cGAMP. SPR and MST characterize strong binding, while a
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luciferase assay displays negligible STING activation compared to the native ligand suggesting
an antagonistic mechanism.
Small molecule antagonists described in (378,379) demonstrate that our approach to
inhibiting STING is viable. The study provides support for the efficacy of STING antagonists in
the treatment of autoinflammatory disease. The progress of this compound will depend on
multiple validation studies and the modifications of the compound to create a more bioavailable
compound. Future projects will focus on developing a competition assay to confirm NSC335504
as an antagonist and synthesizing analogs from the NSC335504 scaffold guided through rational
drug design.
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4.5 Supplementary Material

4.5.1 Supplemental Figures

231

Figure 57. RMSD and Radius of Gyration plots for MD systems. RMSD and R g profiles of
hSTINGREF are as follows: 4LOH (A), 4LOI (B), 4EMT (C), and 4EMU (D). RMSD and Rg
profiles of hSTINGWT are as follows: 4KSY (E) and 4F5Y (F). RMSD and Rg profiles of
hSTINGHAQ are as follows: 4F5D (G) and 4KSY G230A mutation (H). Profiles were created
using backbone atoms and all measurement units are in Angstroms.

Figure 58. H185 Cα distances for MD systems. Structures for hSTING WT are as follows (Solid
lines): Dark Red – 2’3’-cGAMP, Dark Blue – 2’2’-cGAMP, Dark Green – c-di-GMP. Structures
for hSTINGREF are as follows (dashed lines): Light Red – 2’3’-cGAMP, Light Blue – 2’2’cGAMP, Light Green – c-di-GMP.
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Figure 59. H185 Cα distance for STINGREF apo structure MD system.
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